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SUMMARY 
 
This dissertation is a compilation of research on various topics encountered in real life 
Andrology clinical practice and research.  Current day clinical consultation involves a spectrum 
of challenges from interpreting laboratory steroid hormones assays, infertility, 
hypogonadism, fertility preservation to complex genetic tests to diagnose and manage 
disorders of sexual differentiation and congenital hypogonadotropic hypogonadism. This 
thesis is an attempt to cover the broader aspects of Andrology, as encountered in daily 
practice, covering topics outlined below. 
 
The first chapter is on the reversibility of testicular function in men using non-prescribed 
androgens for body building. This study was an investigator-initiated cross-sectional study. 
Androgen abuse which was once an epidemic in the elite athletes has now become an 
endemic in affluent societies with the ease of access to buy such products mainly on the 
internet supplied by low-cost chemical manufacturing plants. The growing prevalence of 
androgen abuse among youth is a public health concern. Androgen abuse is associated with 
higher incidence of violence, criminality, psychiatric disorders including habituation or 
dependence, excess cardiovascular risk and premature death. There is transient 
hypogonadism on cessation of use which can last for many months. The symptoms of 
hypogonadism/ androgen deficiency symptoms vary between individuals from lethargy, 
sexual dysfunction and loss of muscle mass and strength. This leads to a cycle of habituation 
and dependence which encourages continued use and discourages cessation.  
 It is known that supraphysiological androgen administration suppresses testicular functions 
causing reduced sperm output and testosterone secretion. The rate and extent of testicular 
function recovery after cessation is not known beyond anecdotal reports.  
This chapter describes a cross-sectional study comprising age-matched (mean 34 years) 
participants recruited through social media and needle exchange centres comprising 41 
current users, 31 past users (≥3 months (median 300 days) since last use) and 21 healthy 
eugonadal controls providing comprehensive medical history, examination, hormonal data 
and semen analysis results. Current users, compared with past and non-users, had significant 
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suppression of mean testicular volume, sperm output and mean serum LH, FSH, SHBG and 
had significant increases in serum testosterone, DHT and oestradiol.   
This study found that suppressed testicular function due to androgen abuse is mostly 
reversible [apart from persistent testicular volume (TV) reduction] with recovery taking 
between 9 to 18 months or longer after ceasing androgen intake. Suppressed serum LH and 
FSH represent convenient, useful and underutilized markers of androgen abuse and recovery. 
 The study has been presented at US Endo 2019 as a late breaking abstract.  
 
Carrying on the theme of male fertility, the second chapter is on fertility preservation – a 
review of a sperm cryostorage database in a tertiary teaching hospital over 4 decades. For 
men undergoing gonadotoxic therapy or gamete loss, this study describes the pre-freeze 
semen parameters, hormone levels, disease types, accessibility in regional and rural areas, 
feasibility of cryostorage in young adults and ultimately the disposal of stored samples – 
reasons and time taken for use in ART or disposal.  
Sperm cryopreservation is an established technique to preserve male fertility prior to 
gonadotoxic treatment. It is well known that gonadotoxic treatment for cancer or non-cancer 
diseases damages spermatogenesis and impairs male fertility. The study described clinical, 
anthropometric, semen analysis and hormonal data between 1978-2017 in 2717 men 
comprising 2085 men with cancer, 234 non-cancer disease requiring gonadotoxic treatment 
and 398 healthy controls.  
There were 2085 men with cancer, 904 (43%) had haematological malignancies, 680 (33%) 
testicular cancers and 136 (6.5%) were adolescents. Most men (89%) and adolescents (80%) 
could collect sperm. Sperm output for all cancers and non-cancer diseases was lower than 
controls. Sperm output correlated positively with total testicular volume and negatively with 
serum FSH and LH but not testosterone. For all stored samples, the median time in 
cryostorage was 8.5 years, 7% were transferred for use to induce pregnancy at a median time 
of 2.5 years and 62.2% were discarded as no longer needed, the high disposal rate reflecting 
regular annual follow-up to establish ongoing need for continued cryostorage. Cryostorage 
facilities are less available in remote and rural areas of the State and the proportion of outer 
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regional and remote area residents cryostoring sperm was only about half that compared 
with urban residents. 
The conclusion from the study was that sperm cryostorage was feasible for virtually all men, 
including sufficiently mature adolescents, who could collect semen to insure future paternity 
as well as making positive psychological preparation for the patient’s survival. Disposal of 
cryostored material when no longer required is efficient with regular follow-up. Sperm 
cryopreservation should be an integral part of comprehensive treatment plan in men 
receiving gonadotoxic treatment but remains underutilised. 
 This paper has been published in Human Reproduction as an editor’s highlight article. 
 
After describing fertility preservation and pre-freeze semen and sperm parameters in men 
undergoing gonadotoxic treatment, an effort was made to understand the hormonal and 
genetic mechanisms of sexual differentiation and gonadal development. The third chapter is 
a case report of 17-year-old 46XX phenotypic male presenting with testicular pain due to 
ovulation into an ovotestis. He was diagnosed to have a SOX9 duplication resulting in ovo-
testicular disorder of sexual differentiation (DSD). The case report is followed by a literature 
review of 46XX DSDs. This paper highlights the importance of understanding the complex 
genetic pathway involved in gonadal development in sexual differentiation to diagnose and 
manage such cases. 
In mammals, the early gonad is bipotential and can differentiate into either a testis or an 
ovary. SRY is the master switch in testis determination having evolved from the ancestral 
SOX3 (SRY type High Mobility Group box gene) gene. SRY (sex determining region on the Y 
chromosome) is specific to mammals. SRY induces upregulation of SOX9 which promotes 
differentiation of the bipotential gonad into a testis and, in its absence, the genital ridge 
develops by default into ovaries. The only known function of SRY is to upregulate the 
evolutionarily more conserved SOX9. SOX9 is an autosomal gene, present on chromosome 
17. SRY-induced SOX9 activation drives Sertoli cell differentiation and proliferation, a decisive 
step in testis development. SRY is sufficient but not necessary for testis development, as 
increased SOX9 expression, like in this case is sufficient to induce testis formation, thus 
substituting for SRY function. 
 13 
 
The case report described is a 46,XX SRY-ve patient had a novel duplication in the regulatory 
region upstream of SOX9, leading to a male phenotype. He had at least one ovo-testis that 
produced sufficient testosterone to almost complete a phenotypically normal male puberty 
but not sufficient to suppress ovulation on more than one occasion, as shown by the apparent 
recent ovulation as indicated by a hemorrhagic corpus luteum as well as a corpus albicans on 
histology, indicating prior ovulation. 
 With the advances in genetic testing and the improvement in the ease of access to genetic 
tests it is prudent to endocrinologists/andrologists/paediatricians managing these conditions 
to have a through stepwise approach to diagnosis and management.  
There were 2 publications from this case report- one paper focussing on the choice of genetic 
investigations in Clinical Genetics and a full case report and literature review in Endocrinology, 
Diabetes and Metabolism Case reports. 
 
Following on the genetics laboratory investigations, the fourth chapter is a laboratory-based 
paper comparing progesterone levels measured by radio immunoassay vs LC-MS in women 
attending an IVF facility. As endocrinologists frequently encounter couples with infertility, it 
is vital for them understand interpretation of the lab results with regard to the assay 
platforms used to measure, especially steroid hormones. Beyond the established role of 
serum progesterone measurement in the luteal phase of menstrual cycle to confirm recent 
ovulation, it is also increasingly used to detect premature luteinisation during IVF 
hyperstimulation where late follicular phase increase in serum progesterone is reportedly 
associated with adverse pregnancy outcomes. Virtually all serum progesterone 
measurements in clinical and IVF practice use direct, non-extraction immunoassays often in 
multiplex, high throughput platform assays optimised for high, post-ovulatory, mid-luteal 
phase serum progesterone concentrations. However, the performance of direct progesterone 
immunoassays for smaller increases is not established. This study compared serum 
progesterone around the time of hCG administration measured in each sample by a direct 
progesterone immunoassay (Beckman Coulter Access) and by LC-MS in 254 women 
undergoing IVF hyperstimulation. Immunoassay consistently overestimated serum 
progesterone levels so that low measurements (IA<5 nM) were too inaccurate to be used 
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quantitatively. Clinical diagnosis of premature luteinisation based on increased late follicular 
phase serum progesterone measurements using direct progesterone immunoassay that 
consistently overestimates low serum progesterone concentrations should be done 
cautiously. 
This paper has been published in the Journal of Applied Laboratory Medicine. 
 
The last chapter carries on the theme of IVF. It is on an investigator-initiated study to improve 
IVF outcomes in women with poor ovarian response using transdermal dihydrotestosterone 
(DHT) gel, describing the research hypothesis, literature review and protocol.  
Poor ovarian response (POR) to ovarian stimulation is defined by the first international 
consensus in the ESHRE Bologna criteria. These require that at least two of the following three 
features must be present: (i) advanced maternal age(>40 years) or any other risk factor for 
POR; (ii) a previous POR(<3 oocytes on a conventional stimulation protocol); and (iii) an 
abnormal ovarian reserve test (ORT ie. Antral follicle count <5-7 follicles (ultrasound) or serum 
AMH 0.5-1.1 ng/ml). Two episodes of POR after maximal stimulation are sufficient to define 
a patient as a poor responder in the absence of advanced maternal age or abnormal ORT.   
Recent research, including from our lab has proven a physiological role of androgens acting 
via the androgen receptor (AR) in optimising female fertility. Over recent years some IVF 
clinics have adopted the unproven use of various off-label treatments that increase androgen 
exposure aiming to enhance poor ovarian responses in IVF These treatments include 
testosterone, the pro-androgen DHEA or an aromatase inhibitor (letrozole) which increases 
serum testosterone in women. However, each acts via additional pharmacological 
mechanisms (including via estrogen receptors(ER)) as well as the androgen receptor (AR), 
making it difficult to interpret the mechanism of action in previous or future clinical trials. 
Instead, this study proposes to use DHT treatment, a pure, non-aromatisable androgen, which 
acts solely via the AR. This would test whether any potential beneficial effects (eg improved 
live birth/pregnancy rates, reduced FSH dose and duration, minimising OHSS risk and cost) 
are due to AR-mediated mechanisms. This new mechanism-based information would 
facilitate development of novel, more specific and effective fertility treatments for women 
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with poor ovarian responses in IVF, as well as for subfertile women prior to seeking IVF 
treatment.  
This study design is followed by a literature review on safety of androgen use in women. The 
literature review was undertaken to establish the dose and pharmacokinetics of the study 
drug DHT, adverse events encountered in therapeutic use of androgens in women in various 
conditions. The literature review also highlights the effects of androgens on female 
reproductive organs especially on the ovaries as evidenced in pathological hyperandrogenic 
states such as congenital adrenal hyperplasia, maternal virilising tumours and iatrogenic use 
of testosterone in male to female transgender population. These models provide valuable 
insight into the serum levels of androgens in women or transmen, duration of exposure, 
clinical signs and symptoms (virilization) and histology where available. The study received 
ethics approval but did not commence due to unavailability of the DHT gel product in 
Australia, hence only the study design and literature review is presented. 
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THESIS PLAN (MATERIALS AND METHODS) 
Chapter 1: Impact and Reversibility of Non-Prescribed Androgen Use on Male 
Reproductive Function  
Background: Supraphysiological androgen administration suppresses testicular functions 
causing reduced sperm output and testosterone secretion. The rate and extent of testicular 
function recovery after cessation is not known beyond anecdotal reports.  
Objective: To determine the reproductive function of men who participate in regular exercise 
(e.g. 3 sessions a week of gym-based weight training, body building regular running, rowing 
or cycling) who are current or past androgen abusers as well as a group who have never used 
androgens  
Methods: The study recruited volunteers through advertising in social media, noticeboard 
advertising in gyms and word-of-mouth. The recruitment will aim to attract young men who 
are regularly exercising including participating in gym-based weight training for body building 
or regular recreational cycling, running or rowing whether or not they have ever or are 
currently abusing androgens. Eligible volunteers who provide written informed consent will 
be separated into three groups consisting of  
(a) group 1: those who are currently using androgens,  
(b) group 2:  those who have ceased using androgens for at least 3 months and  
(c) group 3: those who have never used androgens.  
All participants were healthy men aged between 18 years and 55 years and were regularly 
involved in recreational exercising including gym and/or weight training for body building or 
other regular exercise (cycling, running, rowing) 3 sessions a week. 
Those with known serious chronic medical illness including HIV or viral hepatitis and/or 
requiring regular prescribed medication or with history of major psychiatric disease were 
excluded. 
The study  involved participants who are eligible and provided written informed consent to 
visit the Andrology department to provide (a) a 20 ml blood sample for hormones and 
biochemistry (c) testicular ultrasound and (d) a semen analysis at a single booked clinic visit 
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and (e) DEXA scan (Endocrinology department). They were also be required to complete 
questionnaires. All participants provided medical history and underwent clinical examination.  
Steroid analyses of serum and was performed in a batch at the end of the whole study and 
these results were not be provided to the participants. Semen analysis was performed 
according to contemporaneous WHO methods. 
Chapter 2: Sperm Cryopreservation Prior To Gonadotoxic Treatment: 
Experience of a Single Academic Centre Over 4 Decades 
Background: Gonadotoxic treatment for cancer or non-cancer diseases damages 
spermatogenesis and impairs male fertility. The most frequent cancers affecting young men 
are testicular cancer and hematological diseases including lymphomas, leukaemia and bone 
marrow transplantation. However, many other cancers and non-cancer disease requiring 
gonadotoxic treatment may require sperm cryostorage to protect against lack of timely 
recovery of male fertility following iatrogenic spermatogenic damage. Sperm 
cryopreservation is an established technique to preserve male fertility prior to gonadotoxic 
treatment. 
Objective:  What is the natural history of outcomes of sperm cryostorage at an Australian 
tertiary academic centre? Is sperm cryostorage feasible in all men including adolescents? 
What is the accessibility to sperm cryostorage in rural and remote NSW? 
Methods: A retrospective review of clinical, anthropometric, semen analysis and hormonal 
data from 1978-2017 involving 2717 men comprising 2085 men with cancer, 234 non-cancer 
disease and 398 healthy controls, in a single tertiary academic centre. Sperm output was 
analysed according to diseases, the feasibility of sperm cryostorage notably for adolescents, 
regional access to an urban cryostorage facility, the determinants of sperm output and time-
dependent disposal of cryostored sperm. Semen samples were assessed by 
contemporaneous WHO methods. 
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Chapter 3: Painful Ovulation in a 46,XX Sry-ve Adult Male with SOX9 
Duplication: Case Report & Literature Review 
Background: In mammals, the early gonad is bipotent and can differentiate into either a testis 
or an ovary. SRY is the master switch in testis determination, responsible for differentiation 
of the bipotent gonad into testis. SRY activates SOX9 gene, SOX9 as a transcription factor is 
the second major gene involved in male sex determination. SOX9 drives the proliferation of 
Sertoli cells and activates AMH/MIS repressing the ovary. SOX9 is sufficient to induce testis 
formation and can substitute for SRY function.  Assessing karyotype and then determination 
of the presence or absence of Mullerian structures are necessary serial investigations in any 
case of DSD, except for mixed gonadal dysgenesis identified by karyotype alone. 
Objective: To understand the genetics of sexual differentiation and gonadal development 
Method: Literature review of 46XX DSD based on a case report of a boy presenting with a 
testicular mass found to be 46XX karyotype with SOX9 duplication and ovulation into 
ovotestis.  The summary also includes the previously reported SOX9 upstream duplications. 
 
Chapter 4: Accuracy of a Direct Progesterone Immunoassay 
Background: Beyond the established role of serum progesterone measurement in the luteal 
phase of menstrual cycle to confirm recent ovulation, it is also increasingly used to detect 
premature luteinisation during IVF hyperstimulation where late follicular phase increase in 
serum progesterone is reportedly associated with adverse pregnancy outcomes. Virtually all 
serum progesterone measurements in clinical and IVF practice use direct, non-extraction 
immunoassays often in multiplex, high throughput platform assays optimised for high, post-
ovulatory, mid-luteal phase serum progesterone concentrations. However, the performance 
of direct progesterone immunoassays for smaller increases is not established. 
Objective: To measure performance of direct progesterone against LC-MS especially for 
smaller increases  
Methods: In a single-centre, observational study, serum samples were provided from 254 
women undergoing IVF hyperstimulation in a single private IVF clinic. Blood samples taken 
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routinely around the time of hCG administration had serum progesterone measured in both 
a direct progesterone immunoassay (Beckman Coulter Access) and by LC-MS. Serum 
progesterone measurements were compared by Bland-Altman deviance plot and Passing-
Bablok regression methods (MedCal version 16, Belgium). 
 
Chapter 5: Randomized, Placebo-Controlled Clinical Trial of Transdermal DHT 
Gel to Improve IVF Outcomes in Women with Poor Ovarian Response 
Background: As women increasingly delay childbearing, the proportion of older women 
seeking IVF treatment is rising resulting in suboptimal outcomes, mainly due to Poor Ovarian 
Responses (POR) to controlled ovarian stimulation. Physiological role of androgens acting via 
the androgen receptor (AR) in optimising female fertility is now well established in animal 
models. Some IVF clinics have adopted the unproven use of various off-label treatments that 
increase androgen exposure aiming to enhance poor ovarian responses in IVF. These 
treatments include testosterone, the pro-androgen DHEA or an aromatase inhibitors which 
increase endogenous serum testosterone. However, these products also act via estrogen 
receptors (ER) as well as the AR, making it difficult to interpret the mechanism of action in 
previous trials. Instead, we propose to use Di-hydro Testosterone (DHT) treatment, a pure, 
non-aromatisable androgen, which acts solely via the AR. This would test definitively whether 
potential beneficial effects are due to AR-mediated mechanisms. 
 
Objective: To undertake a randomized placebo-controlled clinical trial to investigate the 
efficacy of transdermal DHT gel pre-treatment prior to IVF FSH stimulation in women with 
poor ovarian response. 
The primary end point will be the clinical pregnancy rate per cycle. Secondary endpoints the 
numbers of fertilised oocytes, fertilisation and clinical pregnancy rates, dose and duration of 
gonadotrophin treatment, cancellation rate due to poor response, sexual function and 
adverse effects.  
 
Methods: Eligible, consenting participants will, on enrolment, will be randomised to treatment 
(DHT or placebo) in a 1:1 ratio.  
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Inclusion criteria: Age >18 years, regular menstrual cycle and modified Bologna criteria 
stratified by age- for women ≥40 years, no additional inclusion criteria; for women <40 years, 
at least one additional inclusion criterion either previous IVF cycle with POR (≤3 oocytes with 
conventional stimulation) and/or impaired ovarian reserve (ultrasonic antral follicle count <7 
follicles or serum AMH <1.1 ng/ml)  
Exclusion criteria: Use of androgen or pro-androgens in previous 2 months, Perimenopausal 
(no regular cycle, high serum FSH), Major uterine abnormalities, Major medical disorders (eg 
impaired cardiac, respiratory, hepatic, or renal function). 
The dose of DHT will be 5mg DHT daily provided by 0.2 ml of 2.5% Andractim gel applied to 
the abdominal skin every day for 21days prior to the start of an IVF ovarian hyperstimulation 
cycle. Participating women will be given a supply of 5 syringes at the enrolment visit (sufficient 
to cover more than 21 days of treatment). They will return the syringes at the end of the DHT 
treatment period (Day 21 of this study) which coincides with the day the IVF hyperstimulation 
commences. Study staff and participants will be blinded to the treatment allocation 
throughout the study. This design ensures that the women are only required to make one 
extra visit to participate in this study.  
Participants will self-administer either the DHT or placebo gel daily for 21 days prior to starting 
IVF stimulation on a parallel 1:1 allocation. The enrolled patients will proceed with their usual 
ovarian stimulation and IVF treatment as per the referring clinician and data will be collected 
through medical records looking for the specific endpoints listed. 
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1. CHAPTER: IMPACT AND REVERSIBILITY OF NON-PRESCRIBED 
ANDROGEN USE ON MALE REPRODUCTIVE FUNCTION 
 
1.1. BACKGROUND  
 
Androgen abuse1 originated as an epidemic among elite competitive athletes in the post-
World War II decades. As a facet of Cold War rivalry, sport was a stage upon which the 
opposing socio-political systems could compete in symbolic rather than military terms, a 
surrogate contest on the field of sports instead of the field of battle. This epidemic coincided 
with and flourished during the Golden Age of Steroid Pharmacology, the post-war decades 
during which synthetic glucocorticoids and hormonal contraceptives were developed into 
highly successful commercial products that still occupy a major share of the pharmaceutical 
market. During that epoch there was a third major quest in pharmaceutical steroid 
development, the efforts to develop a pure anabolic steroid devoid of virilizing androgen 
properties so that it could be used freely in women and children. Unlike the other two 
successful campaigns to commercialize synthetic steroids, by the mid 1970’s it was apparent 
that, despite decades of effort, this quest failed comprehensively (Handelsman, 2011). That 
failed quest left several legacies including thousands of never-marketed synthetic androgens 
recorded in expired patent databases which have eventually after some decades formed the 
basis of a flourishing illicit trade in synthetic androgens. The illicit marketing of androgens has 
grown exponentially over recent decades with the availability of chemical manufacturing 
plants, mainly in China, providing low cost steroids and using the vast echo chamber of the 
internet as a free, ubiquitous marketing tool for illicit sales. Curiously, the goal of inventing a 
pure anabolic steroid was revived in the 1990’s under the guise of developing SARMs (specific 
androgen receptor modulators), a marketing term for the clumsy but more pharmacologically 
accurate term “mixed partial agonist/antagonists”, this was derived from the term SERM 
(selective estrogen receptor modulator) for analogous mixed partial estrogen 
agonists/antagonists the mechanism of which remains to be checked. While this 
 
1 The term androgen abuse is used exclusively herein when referring to abuse of testosterone and/or its 
synthetic analog derivatives. This is more accurate terminology for steroids which are often misnamed as 
“anabolic steroids” or “androgenic-anabolic steroids”. For more explanation see Handelsman DJ. Commentary: 
androgens and "anabolic steroids": the one-headed Janus. Endocrinology 152:1752-4, 2011 
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pharmaceutical drive led to the development of the first non-steroidal androgen in 1998 
(Dalton et al., 1998), no SARMs with the idealized properties have yet been marketed (A. S. 
Dobs et al., 2013).   
Over recent decades the epidemic of androgen abuse has spread and settled into becoming 
more prevalent  in countries like Australia with sufficient affluence to sustain an illicit 
underground drug market. Few studies in Australia and elsewhere have systematically studied 
this relatively recent and growing form of drug abuse. A monumental global meta-analysis of 
271 studies involving 2.8 million participants showed that the prevalence was highest in men 
(6.4% vs 1.6% in females), recreational sports (18.4%), athletes (13.4%), prisoners (12.4%), 
drug users (8.0%), high school students (2.3%) compared with the general non-athlete 
community (1.0%) (Sagoe et al., 2014). Using the captive population of secondary schools, the 
prevalence of androgen abuse among Australian male secondary students have remained at 
2-3% for over the last two decades (Dunn et al., 2011; Handelsman et al., 1997) whereas the 
prevalence in the general population is reportedly <1% (based on a 2007 household survey) 
(Dunn, 2010). Given the higher incidence of violence (Lundholm et al., 2015), criminality (Klotz 
et al., 2006; Lundholm et al., 2010) and psychiatric disorders (Hall et al., 2005; Kanayama et 
al., 2009; Kanayama et al., 2008) as well as medical problems (Pope et al., 2014) including 
habituation or dependence (Kanayama et al., 2009), excess cardiovascular risk and premature 
death (Darke et al., 2014; Thiblin et al., 2015; Thiblin et al., 2000), mood, behavioural and 
cognitive disorders (Kanayama et al., 2013) possibly related to neurotoxicity, endocrine 
disorders including suppression of testicular function leading to sexual dysfunction and 
subfertility (Nieschlag et al., 2015) associated with androgen abuse, the growing prevalence 
of androgen abuse among youth is a public health concern.  
 
1.1.1. REPRODUCTIVE HEALTH CONSEQUENCES OF ANDROGEN ABUSE 
 
Normal testicular function depends on an intact hypothalamic-pituitary-testicular axis 
through secretion of follicle stimulating hormone (FSH) and luteinising hormone (LH) by the 
pituitary and gonadotropin releasing hormone (GnRH) by the hypothalamus. Androgen abuse 
causes dose dependent suppression of the gonadotropin release either by directly 
suppression of FSH and LH at the pituitary or by hypothalamic suppression of GnRH release. 
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 Among the medical consequences of androgen abuse, hypogonadism due to negative 
steroidal (androgenic) feedback effects on the hypothalamus is the most consistent and an 
almost universal endocrine consequence (Nieschlag et al., 2015). The usually profound 
suppression of testicular endocrine (steroidogenesis) and exocrine (spermatogenesis) 
functions with supra-physiological doses of exogenous androgens leads to impaired 
spermatogenesis with testicular atrophy and reduced sperm output causing male subfertility. 
When exogenous androgen abuse is stopped after hypothalamic suppression is established, 
androgen deficiency symptoms experienced vary between individuals (Kelleher et al., 2004) 
but often include lethargy, loss of vitality and/or easy fatigue and sexual dysfunction. In 
concert, these symptoms plus the loss of acquired muscle mass and strength, often a major 
objective of the androgen abuse, lead to a cycle of habituation and dependence which 
discourage cessation. Nevertheless, based on the reversible mechanisms of steroidal negative 
feedback on the hypothalamus, it is generally believed, and supported by limited anecdotal 
information (de Souza et al., 2011; Nieschlag et al., 2015; Rahnema et al., 2014), that such 
hypothalamic suppression of male reproductive function may ultimately be reversible after 
cessation of the androgen abuse. However, no systematic studies of the extent and time-
course of such reversibility have been reported. The goal of this study is to obtain cross-
sectional observational evidence which may help infer the extent and time-course of recovery 
of reproductive function suppression from androgen abuse.  
 
1.1.2. CARDIAC CONSEQUENCES OF ANDROGEN ABUSE 
 
It has long been known that men have earlier onset and more severe atherosclerosis than 
women (Kalin et al., 1990) so that a priori testosterone is a risk factor for atherosclerotic 
disease (Liu et al., 2003). More recently numerous observational studies have shown an 
association between advanced cardiovascular disease and lowered circulating testosterone. 
Although such observational studies cannot ascribe causality, this has been interpreted by 
some as testosterone being protective (Corona et al., 2014; Morgentaler et al., 2015) but as 
detrimental by others (Albert et al., 2016; L. Xu et al., 2013) and it likely that, in concert, these 
studies remain still underpowered (Onasanya et al., 2016). 
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Although androgens at a physiological level interact with the androgen receptor in coronary 
arteries leading to nitric oxide-mediated vasodilation via inhibition of vascular smooth muscle 
tone (Achar et al., 2010), animal and human in vitro studies show that supraphysiological 
androgen dosage reverse these effects (Ferrer et al., 1994) to cause growth promoting effects 
such as cardiac hypertrophy (Marsh et al., 1998) followed by apoptosis (Zaugg et al., 2001), 
which may lead to cardiomyopathy and  sudden cardiac death. 
 
The effects of androgen abuse on the cardiovascular system have been reviewed in detail 
elsewhere (Achar et al., 2010; Angell et al., 2012; Kaushik et al., 2010; Pope et al., 2014; 
Vanberg et al., 2010). Small cross-sectional observational studies indicating that excessive 
androgen dosage causes left ventricular hypertrophy (Angell et al., 2014) with associated 
reduced left ventricular diastolic and systolic function (Baggish et al., 2010; Nottin et al., 
2006); however placebo-controlled studies of high dose testosterone or nandrolone for 4-8 
weeks showed no detrimental effects (Chung et al., 2007; Hartgens et al., 2003). However, 
definitive studies documenting the impact of non-prescribed androgen use on cardiac 
structure, function and its reversibility are lacking. The mechanism of the detrimental 
androgen effects, if any, on cardiac function are not well understood but appear to be dose 
dependent (T. A. Karila et al., 2003), consistent with the in vitro experimental data (Zaugg et 
al., 2001). It has been proposed that androgen-induced growth effects are mediated by 
membrane receptor–second messenger cascades although the molecular mechanisms of 
non-genomic androgen effects remain to be fully established. This mechanism proposes that 
androgens induce increased intracellular Ca2+ influx and mobilization from the sarcoplasmic 
reticulum (Lieberherr et al., 1994) which in turn alters mitochondrial membrane permeability. 
This produces mitochondrial dysfunction via release of apoptogenic factors such as 
cytochrome c and the apoptogenic proteases (caspases) in addition to excessive superoxide 
anion production (Kroemer et al., 1998).  Correspondingly, there are case reports and small 
studies of androgen abuse associated with cardiomyopathy and heart failure (Ahlgrim et al., 
2009; Han et al., 2015). There is conflicting evidence about the reversibility of the overt heart 
failure (Ahlgrim et al., 2009; Sondergaard et al., 2014) and of left ventricular hypertrophy 
(Urhausen et al., 2004).  
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Excessive exposure to androgens may also accelerate atherosclerotic disease (Nieschlag et 
al., 2015) via mechanisms such as reduced high-density and reduced low density lipoprotein 
fraction of cholesterol (Hartgens et al., 2004) with reversal taking several months after 
cessation of androgen abuse (Garevik et al., 2011). Recent studies indicate that increasing 
testosterone in older men increases coronary atherosclerotic plaque size (Budoff et al., 2017). 
This accelerated atherosclerotic disease may explain sudden cardiac death or increased 
prevalence of myocardial infarction amongst androgen abusers (Darke et al., 2014). However, 
in a case series of androgen-induced cardiomyopathy normal coronary angiograms were 
found suggesting a major non-ischaemic component to this detrimental cardiac effects of 
androgen over-dosage (Baumann et al., 2014; Sondergaard et al., 2014).  Autopsy and cardiac 
magnetic resonance imaging studies also report myocardial fibrosis with left ventricular 
hypertrophy (Baumann et al., 2014; Darke et al., 2014). The fibrosis and left ventricular 
hypertrophy maybe the consequence of the apoptotic effect of supra-physiological androgen 
exposure (do Nascimento et al., 2015). Preliminary reports suggests that androgen abuse may 
be associated with premature coronary artery calcification (Santora et al., 2006). The effects 
of androgens on cholesterol efflux capacity, a measure of HDL function, have not been 
evaluated (Anastasius et al., 2016) and will be investigated in this study.  
 
Sudden cardiac death is another association of androgen abuse (Fineschi et al., 2001). 
Mitochondrial dysfunction may contribute to aberrant myocardial electrophysiology with 
post-exercise electrocardiograms (ECG) of long term androgen abusers demonstrating a 
significantly higher rate of arrhythmias, including QRS prolongation, ventricular fibrillation 
and ventricular tachycardia compared with controls (Sculthorpe et al., 2010). Furthermore, 
androgen abusers with normal left ventricular function and without ECG voltage criteria for 
left ventricular hypertrophy have increased Tp-e interval, Tp-e/QT ratio, and Tp-e/QTc ratio 
on ECG (Alizade et al., 2015), which are associated with potentially fatal malignant ventricular 
arrhythmias. 
 
Hence the goal of this study is to obtain cross-sectional observational evidence which may 
help infer the extent and time-course of recovery of left ventricular function, hypertrophy 
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through cardiac echocardiogram and the extent of atherosclerotic disease identified on 
computer tomography calcium score. One recent study with 100 participants (37 current, 33 
past and 30 non-user controls) has reported persistent hypogonadal features and reduced 
circulating testosterone in past users for a median 2.5 years since cessation of androgen abuse 
(Rasmussen et al., 2016). Another recent study has reported that among 86 androgen abusers 
and 54 non-using controls (but no past users) there was persistent cardiac dysfunction among 
users (Baggish et al., 2017).  
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1.2. STUDY SYNOPSIS 
 
Study Title 
Impact and Reversibility of Non-Prescribed Androgen Use on Cardiac and Male 
Reproductive Function  
Objectives 
To determine cardiac and reproductive function in present and past users of 
non-prescribed androgens and healthy male controls engaged in regular 
recreational exercise (3 sessions a week of running or cycling or weights) 
Study design  Exploratory cross-sectional study 
Endpoints 
Serum LH, FSH, inhibin B, AMH, SHBG, testosterone, dihydrotestosterone, 
estradiol, estrone, DHEA, 3α and 3β androstanediol  
Clinical biochemistry (liver and renal function tests) and hematological 
(hemoglobin, leukocytes, platelets) profile 
Serum lipoproteins and cholestrol efflux capacity (CEC) 
Body composition and bone densitometry by Dual Excitation X-ray 
Absorptiometry (DEXA) 
Skin-fold thickness 
Handgrip strength and upper arm ( mid-biceps) circumference. 
Testicular ultrasound 
Semen analysis 
Questionnaires for health status (PDQ, IIEF, SF36) and drug use 
Sample size 
50 current androgen abusers (group 1) 
50 past androgen abusers (group 2) 
20 healthy male controls (group 3) 
Entry Criteria Inclusion:  
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• Aged ≥18 and ≤55 years  
• Provides written, informed consent & willing to comply with study 
requirements to provide urine and serum samples 
• Regularly involved in regular recreational exercise such as gym training for body 
building or regular running, rowing or cycling (3 sessions a week) 
Exclusion:  
• Serious chronic medical illness including HIV or viral hepatitis and/ or requiring 
regular prescribed medication  
• History of major psychiatric disease or psychological condition that may limit 
understanding and compliance with study requirements 
Study procedure 
Each participant will provide one set of serum, semen and urine sample at a 
single visit and undergo one set of cardiac function tests (ECG, 
echocardiography, CT calcium score) testing.  
In some instances where the participant is willing, a second set of the serum, 
semen and urine samples may be collected on another day.  
Statistical Analysis 
Analysis of variance and covariance between the 3 groups with group as main 
effect and covariables including age, BMI, weight and smoking. Categorical 
variables will be compared by contingency tables using an extended form of 
Fisher’s exact test  
Study administration ANZAC Research Institute 
Clinical Study sites  Andrology, Cardiology, Radiology & Endocrinology Departments, CRGH 
Ethics Jurisdiction  
Human Research Ethics Committee, Sydney Local Health District (Concord)  
Investigator-initiated clinical study 
Study Sponsor SLHD 
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1.3. OBJECTIVES 
 
To determine the reproductive function of men who participate in regular exercise (e.g. 3 
sessions a week of gym-based weight training, body building regular running, rowing or 
cycling) who are current or past androgen abusers as well as a group who have never used 
androgens  
 
1.4. STUDY DESIGN 
 
Exploratory cross-sectional study  
 
1.5. STUDY POPULATION 
 
The study recruited volunteers through advertising in social media, noticeboard advertising 
in gyms and word-of-mouth. The recruitment will aim to attract young men who are regularly 
exercising including participating in gym-based weight training for body building or regular 
recreational cycling, running or rowing whether or not they have ever or are currently abusing 
androgens. 
Eligible volunteers who provide written informed consent will be separated into three groups 
consisting of  
(a) group 1: those who are currently using androgens,  
(b) group 2:  those who have ceased using androgens for at least 3 months and  
(c) group 3: those who have never used androgens.  
 
1.5.1. RECRUITMENT  
 
Recruitment was written advertising through social media mainly Facebook and Instagram, 
needle syringe program centres, noticeboard advertisement in gyms and by word-of-mouth. 
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The needle syringe program centres dispatched the study ad on a small business card along 
with new set of syringes. The advertisement read  
“We are recruiting young men between the ages of 18 and 55 years who are involved in 
recreational strength training, weight lifting, body-building based in gyms or other regular 
exercise (eg running, cycling, rowing) for a research study of their reproductive (including body 
composition) and cardiac function. You may or may not have ever used, or are currently using, 
anabolic steroids – all are eligible for this research study.  
You will be required to provide one set of blood, urine and semen samples, to undergo heart 
function testing, a body composition (DEXA) scan and to complete some health-related 
questionnaires. This will involve a single visit of about 2 hours at Concord Hospital or booked 
as two visits. Bookings will be arranged by ringing 9767-7222.  
You will not be paid but may receive a copy of some of your results, which you may take to 
your own doctor, at the end of the study.  
The research study centre will not prescribe testosterone to participants in this research study 
nor will the department provide further health monitoring of participants outside the research 
study” 
1.6. ENTRY CRITERIA  
 
Inclusion criteria 
• Healthy men aged between 18 years and 55 years 
• Provides written, informed consent & willing to comply with study requirements 
• Regularly involved in, recreational exercising including gym and/or weight training for 
body building or other regular exercise (cycling, running, rowing) 3 sessions a week. 
 
Exclusion criteria 
• Serious chronic medical illness including HIV or viral hepatitis and/or requiring regular 
prescribed medication  
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• History of major psychiatric disease or psychological condition that may limit 
understanding and compliance with study requirements 
 
1.7. STUDY ENDPOINTS - REPRODUCTIVE FUNCTION 
 
• Serum LH, FSH, inhibin B, AMH, SHBG, testosterone, dihydrotestosterone, estradiol, 
estrone, DHEA, 3α & 3β androstanediols 
• Semen analysis 
• Testicular ultrasound 
• Clinical biochemistry (liver and renal function tests) and haematological profile 
(haemoglobin, leukocytes, platelets)  
• Quality of Life questionnaires – PDQ9, IIEF, SF-36  
• Standardized medical history, physical examination including survey of drug use 
• Body composition (muscle and fat mass), skin-fold thickness, upper arm (mid-biceps) 
circumference and hand-grip strength. 
 
1.8. STUDY PROCEDURES  
 
The study  involved participants who are eligible and provide written informed consent to 
visit the Andrology department to provide (a) a 20 ml blood sample for hormones and 
biochemistry (c) testicular ultrasound and (d) a semen analysis at a single booked clinic visit 
and (e) DEXA scan (Endocrinology department). They will also be required to complete 
questionnaires.  
 
Participants were not be paid but were provided with some of their own results (those 
performed in hospital laboratories – biochemistry, haematology, semen analysis – when the 
study was completed.  
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Steroid analyses of serum and was performed in a batch at the end of the whole study and 
these results were not be provided to the participants.  
 
Participants were not prescribed either testosterone or other drugs commonly abused 
together with androgen (eg hCG, anti-estrogens or aromatase inhibitors).  Nor were the 
participants provided with additional health monitoring outside the research study.  
 
1.9. SAMPLE PROCESSING AND DATA MANAGEMENT  
 
Frozen serum samples were stored in de-identified form till run in a single batch.  
Serum steroid measurements using validated LC-MS methods (Harwood et al., 2009; Keski-
Rahkonen et al., 2015) established in the Andrology laboratory, ANZAC Research Institute.  
Hematological and biochemical profiles were measured in the Hospital’s biochemistry 
department. Serum inhibin B and AMH were measured in a collaborating lab.  
Body composition was measured by DEXA scan, a routine test in the Endocrinology  
 department. Semen analysis was performed in the Clinical Andrology laboratory.  
 
1.10. DATA ANALYSIS 
 
 As an exploratory cross-sectional investigation with reproductive function substudies, the 
primary endpoint was the reversibility of the reproductive function, measured by a series of 
measures, consisting of serum steroids (testosterone, dihydrotestosterone, estradiol, 
estrone, DHEA, 3α and 3β androstanediol), LH, FSH, inhibin B, AMH and SHBG; testicular 
ultrasound; semen analysis; body composition. Analysis of variance and covariance were used 
between the 3 groups with group as main effect and covariables including age, BMI, weight 
and smoking. Categorical variables were compared by contingency tables using an extended 
form of Fisher’s exact test. Statistical analysis was done using SPSS 21 and NCSS software. 
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Time for recovery for sperm output and serum gonadotrophins was calculated as the time 
taken to reach the mean value of the control group. 
Other endpoints were: General health and quality of life: Clinical biochemistry (liver and renal 
function tests) and hematological (hemoglobin, leukocytes, platelets) profile; health status, 
quality of life and sexual function questionnaires (PDQ, IIEF, SF36) and for drug use. 
 
1.11. SAFETY ASSESSMENT 
 
This non-interventional study has a very low risk, relating solely to providing blood, semen, 
urine samples and radiological procedures for the study.  
 
There is a possible risk of bruising or skin infection from venesection for blood collection; 
however, this is considered minimal as the blood collection is undertaken by highly 
experienced nurses who have extensive experience in blood collection.  
 
1.12. ADVERSE EFFECTS 
 
Adverse effects directly related to participation in an observational study involving blood and 
semen sampling are unexpected. In the unlikely event that it occurred, it would be reported 
to the Ethics Committee.  
 
It is known that the suppression of reproductive function is slowly reversible with time but 
the time course is not well established. One goal of the study is to determine from 
observational data of ex-users how long reproductive suppression appears to persist after 
cessation of androgen abuse.  
 
Other than supportive management while waiting for the suppressive effects of exogenous 
androgens to wear off, there is no specific treatment for persistent androgen abuse-induced 
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reproductive function suppression. Among androgen abusers, there are beliefs that some 
other hormonal drugs such as hCG, anti-estrogens or aromatase inhibitors can reverse 
androgen abuse–induced suppression of the reproductive system; however, there are 
reasons to believe this may not be effective as they prolong pituitary suppression and such 
adjunctive treatments are not approved nor have been tested for their efficacy or safety so 
are not routinely available.  
 
Other known or potential adverse effects of androgen abuse such as cardiac or hepatic 
dysfunction or polycythemia could also be revealed. Similarly, for these adverse effects the 
recommendation is to cease androgen abuse and any health consequences would depend on 
cessation of the androgen abuse rather than on study participation or any further specific 
treatment. Where such adverse non-reproductive findings are observed, the participant 
would be referred to their own GP and/or specialists for further medical advice and follow-
up.  
 
1.13. ETHICS AND GOVERNANCE 
 
The study had approval from the Sydney Local Health District Human Ethics Committee 
(Concord Hospital) within NHMRC/Australian Health Ethics Committee guidelines for human 
experimentation (Australian Code for the Responsible Conduct of Research) which are 
consistent with the Declaration of Helsinki.  
 
1.14. RESULTS          
                                                                
 Participants were recruited from social media, needle syringe programs, local gym and word 
of mouth. There were 41 current users, 31 past users (last use ≥3 months) and 21 non-user 
eugonadal healthy controls. Each participant gave a comprehensive medical history including 
drug history, underwent physical examination, provided serum and urine samples. 
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Mean age was similar in all the 3 groups: 35 years in current users, 34 years in past users and 
33 years in controls (Table 2). Current users had a significant reduction in mean testicular 
volume, sperm output, serum gonadotropins and SHBG.  
Median age at first use was 23 years (range 14- 45 years), with 12 participants starting to use 
≤ 18 years of age. Most current and past users had a cyclical pattern of use (64%), mostly 12 
weeks on androgens and 12 weeks off and 36% were continuous users. There was 
concomitant use of other drugs use such as cocaine, amphetamines and stimulants. Cocaine 
was the most commonly used recreational drug, with one third of current and past users 
having history of ever use of cocaine. 
Androgens were mostly used in injectable form with 30 current users injecting, 3 taking orally 
and 8 using both forms. 34 of the 41 current users and 25 of the 31 past users had used oral 
androgens at some point. Some participants use aromatase inhibitors to decrease chances of 
developing gynaecomastia, hCG to stimulate spermatogenesis. Other hormones used 
included thyroxine for weight loss, IGF-1 and insulin for anabolic effects.  Many participants 
took food supplements including multivitamins, fat burners, protein supplements (Table 1).  
Table 1: Supplement and drugs used by current and past androgen abusers 
Supplements/ other drug use N= 
Proteins 59 
Tamoxifen 51 
Sympathomimetics including amphetamine 45 
Multivitamins 38 
Aromatase Inhibitors 37 
Clomiphene  37 
Creatine 33 
hCG 32 
Viagra/Cialis 31 
GH 25 
Cocaine 24 
Thyroxine 20 
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Diuretics 16 
Fish oil 16 
Insulin 11 
Liver Detox over the counter supplements 11 
 
Amongst the current and past users, at least half of them had used aromatase inhibitors (51%) 
and clomiphene (51%); nearly three quarters used Tamoxifen (71%); hCG was used for 
spermatogenesis in about 44% and Viagra or Cialis was used for erectile dysfunction in 43%. 
Growth hormone was used for anabolic effect in about one third (35%) and insulin was used 
for similar reason in 15%. There was also tendency to use fat burners and to increase 
metabolic rate with thyroxine (28%), sympathomimetics (62%). One fifth them used diuretics 
in order to weigh less by loss of body fluid (22%), especially on competitive sports days. 
The current and past users had higher rates of protein (82% vs 52%) and creatine use (46% vs 
14%).  
Gynaecomastia was present in 12 of the 41 current users (29.3%), 7 of the 31 past users 
(22.6%) and none of the controls. 18 current users had acne on the trunk (44%), 5 past users 
had acne 16% of which 4 had acne on the trunk and only one had facial acne. Temporal hair 
loss was noted in 13 the current users (31.7%), 10 past users (32%) and 2 controls (1%). 
Mean testicular volume, sperm output, mean serum LH, FSH, SHBG, steroid hormones, are 
described in table 2.  6 men had undergone vasectomy and they were excluded for sperm 
output analysis.  All but TV and SHBG were not significantly different between past and non-
users consistent with full recovery.  
Suppressed variables from androgen abuse such as serum gonadotrophins and sperm output 
were completely reversible. Rate of recovery for androgen-suppressed variables was 
estimated as the time taken to reach the mean for non-users and was 9 months for serum LH, 
14.2 months for sperm output and 18.7 months for serum FSH (figure 1, 2, 3 and 4) after 
cessation of use. 
On the body composition scan, current users displayed higher body weight, BMI, BSA and lean mass 
(Table 2).Other end points apart from reproductive function were not presented as the data 
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is still being analysed. Cardiac end points are being analysed by cardiology collaborators. The 
remaining results will follow on a paper (manuscript under review). 
Table 2: Descriptive features, history, examination, serum gonadotrophins, steroid 
hormones, haematology and biochemistry and DEXA results in the 3 groups. 
 of the 3 groups 
Variable Current 
Users 
Past     Users Non-User 
Controls 
P1 P2 
n 41 31 21   
Age at study (years) 34 ± 2 29 ± 3 32 ± 3   
Age at first use (years) 27 ± 1 23 ± 1 -- 0.014 -- 
Total use (weeks) 265 ± 40 183 ± 46 -- <0.001 -- 
Height (cm) 179 ± 1 176 ± 1 180 ± 1   
Weight (kg) 95.3 ± 2.3 87.0 ± 2.6 83.8 ± 3.2 0.004 0.49 
Body mass index (cm/kg2) 29.5 ± 0.6 28.0 ± 0.7 25.9 ± 0.9 0.001 0.07 
Body surface area (m2) 2.19 ± 0.03 2.07 ± 0.03 2.05 ± 0.04 0.01 0.83 
Heart rate (beats/minute) 75 ± 2 67 ± 2 66 ± 3 0.016 0.85 
Systolic blood pressure (mm) 130 ± 3 121 ± 3 120 ± 4 0.041 0.78 
Diastolic blood pressure (mm) 77 ± 1 73 ± 1 70 ± 2 0.006 0.29 
History of infertility 8 0 0 0.008 1.00 
Acne 18 5 0 <0.001 <0.001 
Gynecomastia 12 7 0 <0.001 0.016 
Temporal hair loss 13 10 2 0.007 0.039 
Testicular volume (ml) 14 ± 2 19 ± 2 28 ± 2 <0.001 0.005 
Semen volume (ml) 3.0 ± 0.2 3.4 ± 0.3 3.7 ± 0.3   
Sperm output  
(million/ejaculate)# 
4 (0, 39) 210 (80, 
359) 
203 (92, 
340) 
<0.001 0.78 
Motility (%) 29 ± 4 50 ± 4 57 ± 5 <0.001 0.27 
Serum LH (IU/L) 0.5 ± 0.3 5.5 ± 0.3 5.2 ± 0.4 <0.001 0.65 
Serum FSH (IU/L) 0.5 ± 0.3 4.7 ± 0.4 4.9 ± 0.4 <0.001 0.71 
Serum SHBG (IU/L) 17 ± 2 34 ± 2 42 ± 3 <0.001 0.034 
Serum testosterone (ng/ml) 36.5 ± 3.3 6.2 ± 3.8 8.7 ± 4.6 <0.001 0.69 
Serum DHT (ng/ml) 1.5 ± 0.1 0.5 ± 0.1 0.7 ± 0.2 <0.001 0.41 
Serum estradiol (pg/ml) 146 ± 17 41 ± 19 48 ± 23 <0.001 0.80 
Serum estrone (pg/ml) 65 ± 5 32 ± 6 38 ± 8 0.005 0.56 
Serum DHEA (ng/ml) 4.8 ± 0.5 6.6 ± 0.6 7.2 ± 0.7 0.008 0.51 
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Variable 
Current 
Users 
Past     Users 
Non-User 
Controls 
P1 P2 
Serum 3α-androstanediol 
(ng/ml) 
2.2 ± 0.2 0.4 ± 0.2 0.6 ± 0.3 <0.001 0.57 
Serum 3β-androstanediol 
(ng/ml) 
0.35 ± 0.03 0.16 ± 0.04 0.11 ± 0.06 <0.001 0.49 
Serum AMH (pg/ml) 3862 ± 621 7562 ± 599 7052 ± 728 <0.001 0.59 
Serum inhibin B (pg/ml ) 97 ± 9 160 ± 10 173 ± 56 <0.001 0.40 
Serum total inhibin (pg/ml) 45 ± 4 85 ± 5 97 ± 6 <0.001 0.16 
Serum activin B (pg/ml) 88 ± 12 97 ± 14 76 ± 16   
Fat mass (kg) 15.7 ±1.2 19.8 ± 1.5 17.6 ± 1.7   
Lean mass (kg) 75.6 ± 1.7 64.8 ± 2.0 63.1 ± 2.3 <0.001 0.58  
Bone mass (kg) 3.4 ± 0.4 4.0 ± 0.5 3.2 ± 0.6   
Hip BMD (gm/cm2)  1.18 ± 0.02 1.13 ± 0.03 1.14 ± 0.03   
Hip z score 0.32 ± 0.31 0.24 ± 0.37 0.36 ± 0.44   
Spine BMD (gm/cm2) 1.34 ± 0.03 1.27 ± 0.03 1.31 ± 0.04   
Spine z score 0.51 ± 0.26 0.22 ± 0.31 0.44 ± 0.36   
 
All data as mean ± standard error of the mean 
1. P value for linear contrast for active androgen effect (ie current users vs non-user controls) 
listed when overall analysis of variance showed a significant effect 
2. P value for linear contrast for recovery from androgen effect (ie past users vs non-user 
controls) listed when overall analysis of variance showed a significant effect 
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Figure 1: Time for recovery sperm output following androgen abuse.  
Light green dots represent controls, dark green dots past users and red dots current users. 
The horizontal dotted blue line represents the mean value for the control group. Rate of 
recovery for androgen-suppressed variables was estimated as the time taken to reach the 
mean for controls. The vertical turquoise dotted line represents the X co-ordinate (time to 
recovery), where the regression line meets the mean for the controls (blue dotted line). 6 
men with vasectomy were excluded from the analysis. Sperm output recovered at 14.2 
months. X axis – number of days since last use of androgens, Y axis – Sperm output in millions 
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Figure 2: Time for recovery sperm density following androgen abuse. 
Light green dots represent controls, dark green dots past users and red dots current users. 
The horizontal dotted blue line represents the mean value for the control group. Rate of 
recovery for androgen-suppressed variables was estimated as the time taken to reach the 
mean for controls. The vertical turquoise dotted line represents the X co-ordinate (time to 
recovery), where the regression line meets the mean for the controls (blue dotted line). 6 
men with vasectomy were excluded from the analysis. X axis – number of days since last use 
of androgens, Y axis – Sperm density in millions/ml 
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Figure 3: Time for recovery serum FSH following androgen abuse 
Light green dots represent controls, dark green dots past users and red dots current users. 
The horizontal dotted blue line represents the mean value for the control group. Rate of 
recovery for androgen-suppressed variables was estimated as the time taken to reach the 
mean for controls. The vertical turquoise dotted line represents the X co-ordinate (time to 
recovery), where the regression line meets the mean for the controls (blue dotted line).  FSH 
recovered at 18.7 months. X axis – number of days since last use of androgens, Y axis – Serum 
FSH in IU/L  
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Figure 4: Time for recovery LH following androgen abuse 
Light green dots represent controls, dark green dots past users and red dots current users. 
The horizontal dotted blue line represents the mean value for the control group. Rate of 
recovery for androgen-suppressed variables was estimated as the time taken to reach the 
mean for controls. The vertical turquoise dotted line represents the X co-ordinate (time to 
recovery), where the regression line meets the mean for the controls (blue dotted line).  LH 
recovered at 9 months. X axis – number of days since last use of androgens, Y axis – Serum LH 
in IU/L 
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1.15. DISCUSSION 
 
This is one of the very few studies looking at duration of hypothalamic pituitary gonadal axis 
suppression and the perhaps the first study to demonstrate that the testicular suppression is 
completely reversible except for testicular volume and SHBG. A systematic review by Christou 
et al described a shorter duration for normalisation of LH and FSH levels at 13 -24 weeks 
compared to 36 weeks and 74.8 weeks in our study (Alen et al., 1985; Bonetti et al., 2008; 
Christou et al., 2017; Schurmeyer et al., 1984). 
Previous studies have showed deterioration in sperm output and quality during androgen 
abuse which were persistent at 8-30 weeks following cessation of use (Alen et al., 1985; 
Bonetti et al., 2008; Holma, 1977; T. Karila et al., 2004; Knuth et al., 1989; Schurmeyer et al., 
1984; Torres-Calleja et al., 2001). Holma et al reported that that fertility index, an index of 
sperm output, motility, morphology and acid phosphatase activity in the semen showed a 
pathological value 2 months following cessation of androgen use (Holma, 1977).      
Two third of users had a cyclical pattern of use, which allows time for recovery of the 
hypothalamic and pituitary suppression. Longer the gap between cycles, the recovery should 
be more pronounced. One third of the current and past users reported prior paternity 
(34.7%), of them 41% were current users and 26.8% were past users. 
In this study 44% of the current and past users has used hCG either alongside androgens or 
at the end of a cycle in what may be an attempt to mimic LH action to stimulate production 
and release of endogenous testosterone and spermatogenesis. Karila et al in their study of 18 
power athletes using massive doses of androgens along with hCG demonstrated that the 
spermatogenesis was maintained although there were morphological changes in the sperm 
and semen quality  despite gonadotropin suppression (T. Karila et al., 2004).                                                   
Gynaecomastia was observed in a quarter of the participants (26% across current and past 
users), which is a result of peripheral and possibly local aromatisation of testosterone to 
oestradiol. Gynaecomastia has been reported in several previous studies (Bonetti et al., 2008; 
Evans, 1997; Pope et al., 1994). Previous studies have reported testicular atrophy with 
androgen abuse (Alen et al., 1985; Bonetti et al., 2008; Schurmeyer et al., 1984) but found 
reversible unlike our study where the reduction testicular volume remained despite cessation 
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(median time from last use 300 days). The supposedly ‘recovery agents’ would only keep 
serum testosterone level high and prolong the pituitary suppression. 
1.15.1.STRENGTHS AND LIMITATIONS: 
 
The data collected in this study is robust including comprehensive medical history, 
examination, semen analysis and steroid hormone measurement by LC-MS across the three 
groups- current users, past users and healthy controls. Given the addictive nature of the 
steroids leading to continued use, it was hard to recruit past users. However, this was 
overcome by social media recruitment.  
The sample size is small owing to the secretive nature of drug abuse. There is a large diversity 
in the type, dose and duration of androgens used, self-administered supportive hormones 
(hCG, antioestrogens, aromatase inhibitors) and supplements which may contain hidden 
steroids. The benefit of such ‘recovery agents’ could be examined in future placebo controlled 
randomised clinical trials.  
 
1.16. CONCLUSION: 
 
We conclude that suppressed testicular function due to androgen abuse is mostly reversible 
(apart from persistent TV reduction). Recovery takes between 9 to 18 months or longer after 
ceasing androgen intake. Suppressed serum LH and FSH represent convenient, useful and 
underutilized markers of androgen abuse and recovery which are helpful in guiding clinicians 
managing such patients. 
 Androgen abuse is associated with distorted body image perception, disordered eating 
behaviour and high intensity energy expenditure exercises. The prolonged periods of 
hypogonadism affect libido, mood and loss of acquired muscle mass which leads to a 
continued use causing dependence. Apart from the reproductive health consequences, 
androgen abuse is associated with long term effects on general health. Androgen abuse is a 
public health issue and there needs to be more education available to the public, especially 
teenagers/high school students, trainers and health care providers to support during 
recovery. 
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2. CHAPTER: SPERM CRYOPRESERVATION PRIOR TO 
GONADOTOXIC TREATMENT: EXPERIENCE OF A SINGLE 
ACADEMIC CENTRE OVER 4 DECADES 
 
Citation: Shankara-Narayana, N., Di Pierro, I., Fennell, C., Ly, L. P., Bacha, F., Vrga, L., Savkovic, 
S., Turner, L., Jayadev, V., Conway, A.J., Handelsman, D. J. (2019). Sperm cryopreservation 
prior to gonadotoxic treatment: experience of a single academic centre over 4 decades. 
Human Reproduction, 34(5), 795-803.  
 
2.1. INTRODUCTION: 
 
Major improvement in survival from cancers over recent decades (Fidler et al., 2017; Gatta et 
al., 2009) has led comprehensive cancer care programs to focus on survivor experience of 
complications from effective oncology treatment (Edgar et al., 2009; Fossa et al., 2008). 
Prominent among these is at least transient fertility impairment as reproductive dysfunction 
is a virtually universal consequence of gonadotoxic (chemo- and/or radiotherapy) regimens 
or surgery leading to gamete loss such as orchidectomy. These cause spermatogenic damage 
resulting from temporary or permanent gamete loss causing male infertility (Meistrich, 2013). 
Following the proof in 1953 that human sperm freezing can preserve fertilizing capacity 
(Bunge et al., 1953), sperm banking was developed in the 1960s using donor sperm for 
untreatable male infertility (Sherman, 1973). By the 1970s, this was extended as prospective 
fertility insurance for men embarking on potentially sterilizing cancer treatments (C. M. 
Rothman, 1980; Saunders et al., 1978).  
The most frequent cancers affecting young men are testicular cancer and hematological 
diseases including lymphomas, leukaemia and bone marrow transplantation. However, many 
other cancers and non-cancer disease requiring gonadotoxic treatment may require sperm 
cryostorage to protect against lack of timely recovery of male fertility following iatrogenic 
spermatogenic damage.   
This study describes an effective sperm cryostorage program in New South Wales, operating 
over 4 decades from the late 1970s in a single academic centre with the same clinical and 
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laboratory staff providing comprehensive data in clinical, reproductive, semen analysis and 
hormonal data. We report the feasibility of sperm cryostorage especially at young age, 
regional access to the urban cryostorage facility, the impact on sperm output at the time of 
cryostorage of underlying reproductive, malignant and non-malignant disease as well as 
systemic symptoms.  
 
2.2. METHODS 
 
2.2.1. SPERM CRYOSTORAGE PROGRAM 
 
Since 1978 sperm cryostorage was offered to men referred to Andrology Department, 
Concord Repatriation General Hospital, Sydney, NSW (prior to 1999 as the Andrology Unit, 
Royal Prince Alfred Hospital) in large urban tertiary referral teaching hospitals of the 
University of Sydney Medical School. The sperm cryostorage program operated within the 
national health scheme (Medicare) as a NSW public hospital service provided without charge 
to eligible patients with a proven ongoing need for cryostorage due to impending iatrogenic 
gamete loss. Any sufficiently mature male adolescent or adult, without age limits, who could 
collect semen samples by masturbation was eligible for sperm cryostorage. Referrals came 
from medical or radiation oncologists, surgeons or other specialists for men who (a) had not 
completed their family and (b) were scheduled to undergo gonadotoxic treatment risking 
gamete loss. Cryostorage was not offered where gamete loss was not expected (eg 
vasectomy) or where impaired fertility could be rectified by other medical or surgical 
treatment (eg gonadotrophin deficiency, neurogenic erectile failure).  
 
The signed consent form included an obligation for annual follow-up review after completion 
of treatment to verify an ongoing need for cryostorage. Those wishing to allow post-mortem 
use of their sperm to induce pregnancy could nominate their current female conjugal partner. 
That nomination could be updated at follow-up visits by adding, deleting or changing the 
specified partner. All men underwent initial and follow-up review including a general and 
reproductive history (cryptorchidism or testicular pathology, marital and fertility status, 
smoking and alcohol use, recent fever or weight loss) and physical examination including 
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estimating testicular volume by orchidometry and androgenization. Fertility counselling was 
provided for their disease and its treatment including contraception advice and future use of 
stored sperm. The patients were also counselled about follow-up required to establish 
ongoing need for cryostorage without out-of-pocket cost or else disposal of samples by 
discarding as no longer required or after prolonged failure of follow-up or by transfer to a 
private facility  
 
Annual follow-up reviewed the need for ongoing cryostorage based on history of recent 
paternity, recovery of sperm output together with testicular examination, semen analysis and 
measurement of reproductive hormones (serum FSH, LH and testosterone). Where fertility or 
sperm output had returned and further gonadotoxic treatment was not anticipated, 
cryostored sperm samples were either discarded or transferred to a private cryostorage 
facility. Follow-up was organised by an experienced cryostorage nurse contacting the man, 
his family, treating doctors, general practitioner or treating specialists using phone, internet 
and mail as well as searching relevant databases including the death registry. If this failed to 
secure a follow-up visit, a case conference review considered the man’s disease, its treatment 
and likely recovery of fertility and may authorize a ‘sunset letter’ sent by registered post 
indicating an intention with 3 months’ notice to discard sperm. 
 
2.2.2. SEMEN ANALYSIS AND SPERM CRYOPRESERVATION 
 
Semen was produced by masturbation in a collecting room near the Clinical Andrology 
laboratory. An abstinence interval of 2-3 days was recommended but sperm was stored 
regardless of the recorded abstinence interval. Men were encouraged to provide three (and 
up to six) semen collections on alternate days prior to commencing gonadotoxic therapy with 
any viable sperm cryostored. Cryostorage was also undertaken after starting gonadotoxic 
treatment with affected men advised of hypothetical risks of mutational effects on sperm, 
issues that could be reviewed later prior to elective use of stored sperm. Neither electro-
ejaculation nor surgery (testicular biopsy or IVF-related sperm extraction procedures) were 
used to collect sperm. 
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Semen samples were processed after liquefaction according to the contemporaneous 
methods as specified by the WHO Laboratory Manual for the Examination and Processing of 
Human Semen, 1st to 5th editions. The semen analysis complied with all aspects of Björndahl's 
checklist (Björndahl et al., 2016) except for dilutions which were compliant with the WHO 
manual. Abstinence interval, semen volume, sperm concentration, morphology, motility and 
vitality were recorded. For cryostorage, semen was diluted 1:1 (v/v) with sperm freeze 
medium and 0.5ml aliquots were transferred in to plastic straws for freezing in graduated 
vapour phase nitrogen over 30 mins before transfer to larger vapour phase nitrogen tanks for 
storage at -1850C.  
 
 
2.3. STATISTICS 
 
Semen samples were analyzed for semen volume and sperm concentration from the first 
semen sample or a median value of these parameters where more than one sample was 
available. Total sperm output was calculated from the semen volume and sperm 
concentration. Sperm data were analysed after cube-root transformation to normalise 
distribution (Handelsman, 2002) with back-transformed results to the natural scale for clarity 
and as an estimate of the median. Correlations by rank and parametric methods gave near 
identical results for this large sample size. Data were analysed according to time in storage, 
diagnostic category, marital status, alcohol intake, smoking, prior fertility or infertility or 
known testicular pathology, cryptorchidism, history of recent fever or weight loss by survival 
analysis, analysis of variance and t-test as appropriate using SPSS 21 and NCSS v12 software. 
Differences between first and median sperm variables were analyzed without data 
transformation consistent with the Central Limit Theorem and confirmed by Box-Cox analysis. 
Within the state of New South Wales, the remoteness or regionality (relative to major cities) 
of a patient’s address was assessed based on postcodes using the Accessibility/Remoteness 
Index of Australia(Information and Research Branch, 2001) and expected prevalence of 
cancer in age-matched men was based on data from NSW Cancer Registry data. 
 
 
 54 
 
2.4. RESULTS 
 
2.4.1. ANTHROPOMETRIC AND DEMOGRAPHIC DATA 
 
This study analysed data from 2717 men comprising 2085 men with cancer, 234 men with 
non-cancer medical disease and 398 controls who were healthy volunteers for sperm 
donation (Table 4). Men seeking cryostorage (median 29 years, range 12.8-67 years) were 
similar in age to controls (median 30, range 18-58 years) with 136 (6.5%) under 18 years of 
age. There were small differences between some groups in height, weight, body mass index 
and body surface area (Table 4). Most (73%) men seeking cryostorage had unknown or 
untested fertility status and nearly half (48%) had no regular female conjugal partner.  
 
Residential postcodes were available for 1944 of the attendances with expected rates based 
on NSW Cancer Registry regional population data. Of them 1881 (96.8% observed versus 
92.6% expected) were from Metropolitan Sydney and inner regional NSW, 57 (observed 2.9% 
versus 6.8% expected) were from outer regional NSW and 6 (observed 0.3% versus expected 
0.6%) from remote NSW, suggesting only about half of the expected numbers of men from 
outer and remote areas compared with urban residents of New South Wales (NSW) attended 
cryostorage.  
 
Over 40 years requests for cryostorage increased progressively more than 10-fold with a 
consistent distribution between haematological, testicular and other cancers (Figure 6) 
whereas there was a 3-5 fold contemporaneous increase in all cancers, haematological and 
testicular cancers in this the state cancer registry (Figure 5). 
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Figure 5 - Shows attendance for new sperm cryostorage by year from 1978 to 2017 together 
with the incidence of new cancers  as shown in the NSW cancer registry over the same period. 
Blackline represents the number of request for cryostorage at Andrology department, 
Concord hospital, the coloured lines are the incidence recorded by NSW cancer registry for 
age matched men (dark blue representing all cancers, scaled down by 1000; pink line 
representing haematological cancers, scaled down by 100 and green line representing 
testicular cancer scaled down by 10). 
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Figure 6 - Shows attendance for new sperm cryostorage by year from 1978 to 2017 for all 
requests and a further breakdown according to the major cancer types (haematological, 
testis, other cancers) over the same period at Andrology department, Concord Hospital. 
Blackline represents the number of requests for cryostorage at Andrology department, the 
coloured lines represent the major cancer subtypes. Pink line representing new 
haematological cancers, green line representing testicular cancer and dark blue representing 
other cancers over the same period. 
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2.4.2. TIME TO DISPOSAL OF SAMPLES 
 
For all banked samples, the overall median time in cryostorage was 8.5 years (Table 3 and 
Figure 7). By 5 years about a quarter (26%) had been removed and ultimately 62.6% of 
cryostored samples were disposed of. Of the removed samples, 36% were discarded due to 
recovery of fertility or sperm production (natural paternity or normal sperm output), 26% 
were discarded due to death and 7% were transferred for use with the remainder lost to 
follow-up (Figure 7) The median time to transfer for use was 2.5 years while median time for 
disposal due to death was 3.5 years, for return of fertility was 6.5 years and for lost to follow-
up was 10.5 years. 
 
Table 3: Reasons for disposal of cryostored material and the median time 
Reasons to discontinue % Median time (years) 
Transferred 7 2.5 
Deceased 26 3.5 
No longer required 36 6.5 
Lost to F/U 31 10.5 
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Figure 7 – Fate of cryostored sperm: Kaplan-Meier plot of cumulative outcomes for disposal 
of cryostored sperm samples according to the reasons for disposal- patient died (deceased), 
sperm was no longer required (discontinued), patient was lost to follow up and transferred 
for use. 36% were discarded due to recovery of fertility or sperm production (natural paternity 
or normal sperm output), 26% were discarded due to death and 7% were transferred for use 
with the remainder 31% lost to follow-up. 
Inset- Kaplan-Meier plot of cumulative outcomes for disposal of cryostored sperm normalized 
for completed outcomes. The median time to transfer for use was 2.5 years while median 
time for disposal due to death was 3.5 years, for return of fertility was 6.5 years and for lost 
to follow-up was 10.5 years. 
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2.4.3. DISEASES 
 
Haematological malignancies accounted for nearly a third of the patients (Hodgkin’s 12%, 
non-Hodgkin’s lymphoma 10%, leukaemia 10%), followed by testicular cancers accounting for 
nearly a quarter (seminoma 14%, teratoma 10%) with other malignancies (17%) including 
sarcoma, gastrointestinal, glioma, head and neck, prostate, melanoma, lung and others 
(Figures 8 and 9). The non-cancer disease group (9.2%) was mostly comprised of patients with 
immunological, renal or genitourinary diseases and multiple sclerosis. 
 
2.4.4. SPERM OUTPUT 
 
Semen volume, sperm concentration and total sperm output were all significantly higher on 
the first compared with the median of all semen samples for that individual (by 0.15 ± 0.03 
[SEM] ml, 7 ± 0.8 million per ml, and 32 ± 3 million, respectively, all p <0.0001 by paired t-
test). Nevertheless, the differences were small (median difference of 0 for each variable) and 
subsequent analyses used the median semen variables.  
Sperm output for all cancers and non-cancer diseases was lower than healthy controls of 
similar age (Table 4). Testicular cancers had the lowest total sperm output, a finding that was 
nullified by accounting for unilateral orchidectomy of tumour-bearing testis prior to 
cryostorage (present in 613/680, 90%) when total sperm output was adjusted for total 
testicular volume (Figure 9).  
Lower sperm output was associated with a history of cryptorchidism (26 versus 90 million, 
p<0.001), of prior infertility (46 versus 89 million, p=0.005) or no prior fertility (85 versus 99 
million, p=0.02) and known testicular pathology (54 versus 91 million, p<0.0001), smoking (79 
versus 95 million, p<0.005) and living alone (single, divorced) compared with living with a 
partner (married, de facto) (89 versus 103 million, p=0.013), but not significantly with alcohol 
intake (p=0.55). Recent weight loss at the time of cryostorage was significantly associated 
with lower sperm output (78 versus 94 million, p=0.005) but not recent fever (p=0.11).  
Sperm output was correlated positively with total testicular volume (r= 0.44, p<0.0001) and 
negatively with serum FSH (r= -0.24, p<0.0001) and LH (r= -0.12, p<0.001) but not with serum 
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testosterone (-0.008, p=0.68). Serum FSH was increased in men with a single compared with 
two testes (median 6.35 versus 4.2 IU/L, p<0.0001). Sperm motility was significantly lower in 
cancer and non-cancer disease compared to the controls but there was no significant 
difference between the disease groups. 
 
 
 
Figure 8: Sperm output according to disease category. Sperm output expressed in cube root 
scale after back transformation. Sperm output was low in all disease categories compared to 
controls. 
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Figure 9: Sperm output corrected to testicular volume according to disease category. Sperm 
output expressed in cube root scale after back transformation. Sperm output was low in all 
disease categories compared to controls. Testicular cancers had the lowest total sperm 
output, a finding that was nullified by accounting for unilateral orchidectomy of tumour-
bearing testis prior to cryostorage (present in 613/680, 90%) when total sperm output was 
adjusted for total testicular volume. 
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Table 4: Summary of Anthropometric and Reproductive Health Characteristics 
 
Data shown as mean and standard deviation with median shown in brackets below sperm variables which were analysed after normalising cube-root 
transformation 
a indicates significant differences from healthy controls by one way ANOVA with Tukey-Kramer post-hoc test 
 
Healthy 
Controls 
Seminoma Teratoma Hodgkin's 
Lymphoma 
Non 
Hodgkin’s 
Lymphoma 
Leukaemia Sarcoma Other 
Cancer 
Non-cancer 
Disease  
N 398 361 319 319 270 315 177 323 234 
Age (y) 32 ± 9 31 ± 6 27 ± 6a 27 ± 7 a 32 ± 9 29 ±9.7 a 24 ± 7 a 35 ± 10 a 30 ± 9 
Height (cm) 177 ± 7 178 ± 7 179 ± 8 179 ± 8 178 ± 7 177 ± 8 179 ± 7 178 ± 8 177 ± 8 
Weight (kg) 76.3±12.6 83.3±16.0a 81.3±15.2a 79.5 ± 17.3 80.5 ± 17.6 78.0 ± 15.0 76.3 ± 16.3 81.7 ± 19.5a 82.3 ± 18.4a 
Body mass index (kg/m2) 23.9 ± 4.4 26.2 ± 4.6 a 25.5 ± 4.4 a 24.8 ± 5.2 25.4 ± 5.0 a 24.8 ± 4.4 23.8 ± 4.5 25.9 ± 5.6 a 26.0 ± 5.1 a 
Body surface area (m2) 1.94 ± 0.18 2.03 ±0.21 a 2.01 ±0.21a 1.99 ± 0.24 2.00 ± 0.23 1.96 ± 0.21 1.94 ± 0.23 2.01 ± 0.25a 2.01 ±0.24 a 
Semen Volume (ml) 3.3 ± 4.4 
(3.0) 
3.2 ± 2.2 
(3.0) 
3.2 ± 1.6 
(3.0) 
2.9 ± 1.5 a 
(2.8) 
3.1 ± 1.4 
(2.8) 
3.0 ± 1.9 a 
(2.6) 
2.9 ± 1.9 a 
(2.5) 
3.2 ± 1.6 
(3.0) 
2.9 ± 1.6 a 
(2.6) 
Sperm Density 
(million/ml) 
99 ± 59 
(87) 
31 ± 35 a 
(20) 
28 ± 37 a 
(15) 
54 ± 58 a 
(41) 
80 ± 95 a 
(56) 
76 ± 82 a 
(51) 
67 ± 61 a 
(48) 
70 ± 71 a 
(55) 
73 ± 70 a 
(56) 
Total sperm output 
(million)  
296 ± 241 
(248) 
95 ± 106 a 
(57) 
86 ± 123 a 
(42) 
154 ± 198 a 
(98) 
197 ± 210 a 
(142) 
212 ± 271 a 
(109) 
176 ± 195 a 
(103) 
219 ± 286 a 
(127) 
188 ± 212 a 
(123) 
Azoospermia (%) 0 3.7 6.6 3.6 1.6 6.1 1.2 1.7 3.8 
Sperm Motility (%) 65.3 ± 11.2 54.2 ± 16.9 51 ± 17 53.1 ± 17.1 53.1 ± 16 52.8 ± 16.5 50.7 ± 16.5 52.8 ± 16.5 52.4 ± 15.5 
Total testis volume (ml)  49 ± 7 23 ± 8 a 23 ± 8 a 42 ± 10 a 42 ± 11 a 40 ± 10 a 41 ± 11 a 42 ± 11 a 41 ± 12 a 
Serum FSH (IU/l) 4.0 ± 2.1 
(3.5) 
9.6 ± 8.3 a 
 (7.9) 
5.9 ± 7.0a 
       (4.7) 
5.4 ± 4.2 
(4.2) 
5.5 ± 4.1 a 
(4.5) 
5.5 ± 4.1 a 
(4.1) 
4.6 ± 3.6 
(3.8) 
5.9 ± 5.1 a 
(4.8) 
6.7 ± 8.5 a 
(5.0) 
Serum LH (IU/l) 5.5 ± 5.8 
(4.9) 
6.8 ± 5.5 
(5.9) 
8.3 ± 15.4 a 
(4.6) 
5.8 ± 3.2 
(5.2) 
5.3 ± 2.7 
(4.8) 
5.6 ± 3.3 
(5.0) 
5.0 ± 2.7 
(4.5) 
5.1 ± 2.7 
(4.6) 
7.0 ± 5.2 
(4.8) 
Serum Testosterone (nM) 22.0 ± 7.1 17.4 ± 7.2 a 20.1 ± 9.4 16.3 ± 7.1 a 15.0 ± 6.5 a 14.8 ± 8.7 a 13.9 ± 6.4 a 15 ± 7.1 a 13.6 ± 6.8 a 
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Table 5: Summary of large studies (>400 men) of cryostored sperm reported previously 
.Study Control Study 
Duration 
(years) 
Number Mean Age 
(years) 
Testis Blood Other Azoospermia 
(%) 
Discontinued 
Storage (%) 
Used 
(%) 
Kelleher et al. (2001) Y 22 930 28 323 (35) 308 (34) 270 (30) 3.3 21 7 
Ragni et al. (2003) N 15 776 28 367 (47) 353 (45) 56 (7) 11.6 18 5.2 
Magelssen et al. 
(2005) 
Y 20 422 28 422 (100) 0 0 0 -- 7 
van Casteren et al. 
(2010) 
N 24 764 27 292 (38) 361 (47) 111 (15) 9.7 -- -- 
Crha et al. (2009) N 21 619 26 270 (44) 197 (32) 152 (25) 9.7 -- 5.2 
Freour et al. (2012) N 10 1042 29 438 (41) 420 (41) 184 (18) 2.2 -- 7.9 
Bizet et al. (2012) N 15 1080 29 420 (39) 357 (33) 230 (21) 4.8 19 6.3 
Johnson et al. (2013) N 20 423 30 134 (32) 153 (36) 136 (32) 5 -- 10 
Chey Dearing et al. 
(2014) 
N 37 4362# 29 617 (36) 962 (57) 119 (7) -- -- 6 
Daudin et al. (2015)  N 34 4345 18 1042 (24) 2372(55) 912 (21) -- -- -- 
Muller et al. (2016)  N 20 898 29 393 (44) 308 (34) 197 (22) 3.0 34 10.7 
Depalo et al. (2016) N 16 721 29 393 (55) 261 (36) 67 (9) -- 1 2.6 
Jayasena et al. 
(2018) 
N 24 2906 31 989 (34) 
 
1134 (39) 783 (27) - -  
- 
Present study Y 40 2717 40 680 (29) 903 (39) 737 (32) 3.7 62.6 7 
 
# diagnosis only available in 1698 (39%) of patients 
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2.4.5. FEASIBILITY OF CRYOSTORAGE 
 
Most men (89%) could collect sperm for storage. Failure to cryostore resulting from azoospermia or 
near-azoospermia (7%), inability to collect semen (4%) or to attend (1%), the latter usually due to being 
too sick or conflict with timing of urgent treatment. Most men cryostored sperm prior to start of 
gonadotoxic treatment but a few already received chemotherapy (3.5%), radiotherapy (1.6%) or both 
(0.7%). Most men provided three ejaculates (52%) creating a median of 23 straws per man. Most 
underage (<18 years) adolescents completed cryostorage although overall they were slightly less likely 
to complete cryostorage (80%) and produce 3 ejaculate (46%) (Table 6). 
 
Table 6 Feasibility of cryostorage by age 
Sperm Cryostorage 
by Age (N, %) 
<18 years 
N=151 
>18 years 
N=2437  
Cryostored 121 (80.1) 2158 (88.6) 
Did not attend 2 (1.3) 19 (0.8) 
Did not freeze* 19 (12.6) 172 (7.1) 
Did not collect# 9 (6.0) 88 (3.6) 
Number of collections   
1 24 (18%) 229 (12%) 
2 28 (21%) 437 (20%) 
3 69 (51%) 1178 (54%) 
≥4 15 (11%) 294 (14%) 
* due to azoospermia or near-azoospermia.  
# due to being too sick or needing urgent treatment.  
Feasibility of cryostorage in adolescents (n=151) and adults (n=2437), describing the numbers that 
managed to collect and store and reasons for not storing. The table also describes the number of 
collections of samples between the age groups. 
 
2.5. DISCUSSION 
 
This study represents 4 decades of experience of sperm cryostorage by the same clinic and laboratory 
involving comprehensive clinical and reproductive data on 2319 men with cancer (n=2085) or non-
cancer (n=234) diseases together with 398 healthy age matched controls. Other studies of comparable 
size include a French study compiling experience of 23 centres over 34 years involving 4345 young males 
aged 11 to 20 years (Daudin et al., 2015) and a single centre British sperm bank study of semen analyses 
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with minimal clinical data collated over 37 years from 4362 men undertaking sperm cryostorage (Chey 
Dearing et al., 2014) (Table 5).   
The progressive increase in requests for sperm cryopreservation between 1978 and 2017 exceeds the 
state-wide 3-5 fold increases over the same period for new diagnosis of all, haematological, testicular or 
other cancers (Figure 5 and 6). This suggests the increasing demand for sperm cryostorage is most likely 
due by growing awareness among oncologists and oncology nurses of the availability of sperm 
cryostorage for male fertility preservation and its long established medio-legal significance in avoiding 
negligence claims (Brahams, 1992) rather than increases in underlying cancer incidence rates (C. Dearing 
et al., 2014). Nevertheless, we estimate less than half the target population of men with newly diagnosed 
cancers in reproductive age group are undertaking sperm cryostorage. This shortfall may be due to men 
having completed their desired family or attending other facilities but any residual extent of failure to 
offer cryostorage (Schover et al., 2002a, 2002b) cannot be estimated from this study. This aspect of 
cancer care remains suboptimal as sperm banking has positive psychological effects in both short-term 
coping with the diagnosis as well as long-term preparation for survival (Eiser et al., 2011; Hammarberg 
et al., 2017).  
The distribution of diseases, notably between testis and non-testis cancers, for which cryostorage is 
requested has remained stable over the decades observed. Yet there has been an increase in requests 
from men about to undergo bone marrow transplantation, a procedure that increased dramatically 
world-wide from <10,000 to over a million annually in less than the last 3 decades (Gratwohl et al., 2015) 
as well as a recent mild decrease over the last 5 years for men with testis cancer. The recent reduction 
in requests for cryostorage from men with testis cancer may reflect both the excellent prognosis for 
testis cancer treatment (5-year survival rate of 98% (Rockhold, 1993) ) with a good fertility prognosis 
(80% experiencing post-treatment recovery of sperm output within 5 years (Lampe et al., 1997)). This 
has led to more use of watchful waiting (i.e. surveillance without gonadotoxic treatment) as well 
platinum-based chemotherapy (Chovanec et al., 2017), which has relatively low toxicity with recoverable 
impact on spermatogenesis (Bujan et al., 2013; Howell et al., 2005; Suzuki et al., 2013). Nevertheless, 
gonadotoxicity is dose-dependent (Brydoy et al., 2012; Schrader et al., 2001) and as the ultimate extent 
of gonadotoxic treatment required is not predictable at first presentation of testis cancer, sperm 
cryostorage should remain the standard of care.  
Sperm cryostorage was feasible for virtually all cancers even in the presence of need for urgent 
treatment (e.g. superior vena caval syndrome from lymphoma). Sperm output for all cancers and non-
cancer diseases was lower, however, than healthy controls (Table 4). The healthy controls in this study 
were men screened as potential sperm donors who provided multiple semen samples comparable with 
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men seeking cryostorage (Handelsman, 1997). The median total sperm output (248 million/ejaculate) of 
the controls in this study was comparable with WHO reference ranges for unscreened men (196 
million/ejaculate) or recent fathers (255 million/ ejaculate) (Cooper et al., 2010). Testicular cancers had 
the lowest total sperm output consistent with previous reports (Lass et al., 1998; Rives et al., 2012; 
Williams et al., 2009); however this reduction was accounted for by excision of the tumour-bearing testis 
as the deficit in sperm output was corrected by adjustment for total testicular volume. Furthermore, 
patients with non-testis cancers also had impaired sperm output compared with age-matched healthy 
controls suggesting wider effects associated with a cancer diagnosis on sperm output suggesting that 
systemic factors rather than specific intra-testicular defects in spermatogenesis or testicular physiology 
explain the reduction of sperm output in testis or other cancers (Agarwal et al., 2014; van Casteren et 
al., 2010). These includes the impact of known pre-cancer factors that impair sperm production such as 
cryptorchidism and other testicular pathology, history of infertility, smoking (Hart et al., 2015) and 
recent weight loss but, surprisingly, not fever (Carlsen et al., 2003; Macleod et al., 1941; Sergerie et al., 
2007). Most studies of the effects of weight loss on sperm output are in men undergoing deliberate 
weight loss for obesity. Yet, obesity itself has deleterious effects on sperm output in some (Hammoud 
et al., 2008; Oliveira et al., 2017), but not all (MacDonald et al., 2010), studies. Bariatric surgery is 
reported to decrease (Sermondade et al., 2012), have no effect (Reis et al., 2012; Samavat et al., 2018) 
or increase (El Bardisi et al., 2016) sperm output whereas non-surgical weight loss for obesity may 
increase sperm output (Hakonsen et al., 2011). The potential role of radiological and other diagnostic 
investigations as well as other systemic effects associated with cancer (immune- or cytokine-mediated) 
should also be considered in future studies. We observed that the first sample was consistently higher 
than later, though differences were small, where most previous studies report solely the first sample. 
Analogous small differences in sperm quality between multiple semen samples have been described 
elsewhere (Jayasena et al., 2018). 
 
The cryostorage facility operates without age limits as sufficiently mature adolescents can often provide 
semen samples after spermarche, which occurs typically at age 12 with a testis volume of 8 ml (Ji et al., 
2000; Nielsen et al., 1986), so that cryostorage is virtually as feasible for psychologically mature 
adolescents as for adults. Analogously, older men into the 7th decade were able to cryostore sperm 
consistent with men’s lifelong natural fertility if they have younger female partners.  
  
In this study 7% of cryostored samples were transferred for use to induce a pregnancy at other private 
fertility clinics after a median time of 2.5 years in cryostorage. This proportion is the same as we reported 
previously (Kelleher et al., 2001) and similar to a  systematic review in 2016 including 30 studies and 
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11798 patients  showed an aggregated use rate of 8% (Ferrari et al., 2016).The relatively low rate of 
usage still represents a low cost as a form of fertility insurance which also has positive psychological 
impact both in the short-term of coping with the cancer diagnosis as well as longer-term planning for 
their longer-term survival. Although we reported pregnancy outcomes for use of cryostored sperm 
between 1978 and 2000 (Kelleher et al., 2001), no updated data was available due to more recent privacy 
restrictions on collecting data from external fertility clinics.  
The present study had a high rate of disposal of samples (62.6%) compared to other studies where the 
systemic review reported an aggregated discard rate of 16% (Table 5). This reflects the value of regular 
follow-up by an experienced cryostorage nurse which reduces the potentially open-ended accumulation 
of cryostored samples (requiring ever expanding bank capacity) thereby rendering the public service 
facility more cost-effective.  
Although this cryostorage service was provided under the national health scheme without cost or 
insurance coverage, access still proved limited by geography. Rural and remote areas of the state were 
markedly under-represented with only 50% as many patients compared to the numbers expected for 
urban-residing men. The deficit may have been underestimated as many men residing in non-urban 
areas often travel to Sydney to initiate oncology treatment when they had opportunity for sperm 
cryostorage. While theoretically possible that the deficit of remote-dwelling men may be due to 
attendance at other cryostorage facilities the paucity of such alternatives makes this implausible. This 
underlines the need for an accessible, integrated sperm cryostorage service as an inherent component 
of a comprehensive care plan for cancer and other serious diseases including men living in non-urban 
areas. 
The post-mortem use of cryostored sperm to induce a pregnancy is an increasingly discussed, 
controversial medico-legal issue. Within our state, men are required to provide written nomination of 
their conjugal female partner if they wish to allow use of their stored sperm to create a post-mortem 
pregnancy. Of 732 men cryostoring sperm who had partners, 630 (86%) chose to nominate a partner for 
potential post-mortem use of their sperm. Although the nomination can be varied at follow-up visits, 
this occurs rarely and then usually due to a change of partner. Unusual requests for post-mortem 
disposal of cryostored sperm without valid consent have included parents, as executors of the 
deceased’s estate, seeking to obtain the sperm for use with a surrogate; however, the deceased 
provided no written consent for an unspecified partner and commercial surrogacy remains illegal in this 
state. Another unusual request was from a nominated female partner to use her deceased partner’s 
stored sperm long after having formed a new conjugal relationship.  
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Sperm cryopreservation via semen collection by masturbation remains a standard of care for fertility 
preservation among men with cancer or other diseases requiring gonadotoxic treatment. An important 
additional consideration is the salvage option of testicular sperm extraction coupled with 
intracytoplasmic sperm injection which can produce paternity even after severe testicular injury (Hsiao 
et al., 2011; Zorn et al., 2006). Newly developing non-cytotoxic cancer therapies (eg tyrosine kinase 
inhibitors, immune checkpoint inhibitors) offer possibly less iatrogenic gonadal damage and infertility 
but data on reproductive effects remains sparse for both men and for pre-pubertal boys, for whom pre-
treatment sperm cryostorage will never be feasible. Other possibilities for preserving fertility in pre-
pubertal boys include testicular biopsy and cryostorage for future autologous re-implantation into the 
testis of spermatogonial stem cells or for in-vitro matured sperm for use in in-vitro fertilization. However, 
re-implantation of germinal stem cells must eliminate the risk of   inadvertent transmission of malignant 
cells. In-vitro spermatogenesis could theoretically be developed from autologous germinal stem cells 
biopsied from the testis or in-vitro re-programmed, induced pluripotent somatic cells to avoid testicular 
biopsy; however, all these techniques remain experimental with none achieved in humans at this time 
with the prospects still remote. In the interim, the safest storage of spermatogonial stem cells remain 
within the testis rather than as in-vitro cryostorage while the revivification techniques required remain 
undefined.  
 
We conclude that sperm cryopreservation is a well-established and feasible clinical procedure aiming to 
preserve male fertility prior to gonadotoxic treatment for cancer or other diseases. As a practical, low 
cost approach to insure fertility, sperm cryostorage is a readily integrated, best practice component of 
comprehensive cancer or other medical treatment regimens to overcome iatrogenic damage to 
spermatogenesis and male fertility for all post-pubertal males. Long recognized in oncology and the law 
that advising young male cancer patients on sperm cryostorage prior to cancer treatment is an essential 
component of adequate medical care (Oktay et al., 2018). Although utilization rates are low, such fertility 
insurance forms a positive psychological support preparing for the man’s future survival (Pacey et al., 
2011; Saito et al., 2005). Better access to extra-urban areas is required so that sperm cryopreservation 
becomes universally an integral part of comprehensive cancer treatment programs. This large study over 
4 decades shows that sperm cryostorage is feasible for virtually all men, including sufficiently mature 
adolescents, who can collect semen. Effective clinical follow-up assessing ongoing need for continuing 
cryostorage is essential to maintain efficiency of storage capacity and avoiding open-ended 
accumulation of cryostored samples. 
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3. CHAPTER: PAINFUL OVULATION IN A 46,XX SRY-VE ADULT MALE WITH 
SOX9 DUPLICATION: CASE REPORT & LITERATURE REVIEW 
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Ovulation in a 46,XX Sry-ve Adult Male due to SOX9 Duplication: Case Report and Literature Review’-   
Endocrinology, Diabetes & Metabolism Case Reports, 06 2017, EDM170045 
doi: 10.1530/EDM-17-0045 
 
3.1. BACKGROUND 
 
Disorders of Sexual Differntiation (DSDs) result from disruptions to the delicate balance of the molecular 
pathways in the male and female sex determining pathways. They can present at any age ranging from 
prenatal state, at birth (e.g., hypospadiasis, ambiguous genitalia etc.) to early adulthood (delayed 
puberty, infertility). They can be extremely challenging owing to the associated diagnostic and ethical 
dilemmas. DSDs are rare and need a systematic approach to establish diagnosis through a 
multidisciplinary approach. 
 
3.2. THE CASE 
   
A 17-year-old Caucasian male presented with a two-day history of a painful mass in left testis. There was 
no history of trauma, fever or weight loss. His pubertal development was normal. His medical history 
included right cryptorchidism with spontaneous descent at one year of age, Henoch-Schonlein purpura 
at four years, excision of a benign left extra adrenal ganglioneuroma at five years without recurrence, 
pyelonephritis at fourteen years and an upper lip capillary haemangioma.  
 
He was the only child to a non-consanguineous couple who had three previous miscarriages.  His father 
died aged 63 years from chronic lung disease secondary to asbestos exposure (Pedigree Chart, Figure 
10). Three first cousins had precocious puberty.  
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His height was 1.77m (mother 1.75m, father 1.68m), weight 68.8kg, with Tanner stage 4 pubertal 
development and small bilateral gynaecomastia, but no acne. By orchidometry, the left testis was 8mls, 
containing a tender solid 2cm mass and a large left hydrocele and the right testis was atrophic and 1ml.  
 
 
 
Figure 10: Pedigree chart 
 
 
3.2.1.  INVESTIGATIONS 
 
Scrotal ultrasound demonstrated an atrophic right (3ml) and a larger left testis containing a solid lesion 
2cm in diameter, suggestive of a neoplasm and a 22ml left hydrocele. CT scan of the chest and abdomen 
did not show evidence of metastatic disease or abnormal lymph nodes; the seminal vesicles and prostate 
were normal. 
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Table 7: Hormonal profile pre-operatively, post-operatively and on testosterone replacement 
therapy. 
 
He had elevated serum FSH (17.2 IU/L) and LH (11.7 IU/L), low serum testosterone of 5.1 nmol/L(table 7) and 
normal serum SHBG (24 nmol/L). Serum αFP and HCG were negative. Semen analysis showed azoospermia. The 
working diagnosis was a testicular tumour on a background of possible Klinefelter syndrome. 
3.2.2.  DIAGNOSIS, TREATMENT AND FOLLOW-UP 
 
Left partial orchidectomy was performed. Macroscopically the mass was a haematoma. Histopathology 
showed a haemorrhagic corpus luteal cyst within an ovo-testis (Figure 11 A to D). The gonad, including 
the ovarian tissue, was contained within a tunica albuginea. The testicular tissue contained Sertoli-cell-
only seminiferous tubules, interstitial Leydig cells, and some Sertoli cell nodules. The ovarian tissue 
comprised ovarian stroma, a few primordial follicles (the only germ cells in the ovo-testis), a hemorrhagic 
corpus luteum and several corpora albicans.  
Hormone 
Hormonal 
Panel 
Results Reference Range 
Pre-op. Post-op. Post Testosterone  Normal 
range 
Male 
 
Normal range 
Female 15 days 
pre op 
13 days 
pre op 
2 months 
post op 
6 months 
post T Rx 
14  
months 
post T Rx 
FSH 
(IU/L) 
13 17.2 38.2 3.3 0.8 1.0 -12  Follicular 3.5-12.5 
Mid-cycle 4.7-21.5 
Luteal 1.7- 7.7 
LH 
(IU/L) 
8 11.7 22.7 16 <0.1 0.6 – 12  Follicular 2.4- 12.6 
Mid-cycle 14-95 
Luteal 1-11.4 
Testosterone 
(nmol/L) 
4.5 5.1 8.7 9.6 9.7 11.5 – 32   <2.8 
SHBG 
(nmol/L) 
 24 
 
 
 
15-80   
NANDINI SHANKARA NARAYANA 72 
 
 
Figure 11: Ovo-testis histology from 17-year-old boy presenting with testicular pain. A: Seminiferous 
tubules (arrow), devoid of germ cells or spermatogenesis, with interstitial Leydig cells (arrow head). B: 
Sertoli cell nodule in testicular component (Leydig-rich background). C: Ovarian tissue with an involuting 
haemorrhagic corpus luteum (arrow) and a primordial follicle (dotted arrow). D: Ovarian tissue with an 
old corpus albicans (arrow), the adjacent ovarian stroma with a further primordial follicle. Image 
dimensions, A & B: 0.9 x 0.7mm, and C&D 2.2 x 1.7mm. 
 
Karyotype was 46,XX with a notably absent SRY signal on FISH analysis. The ovarian and testicular tissue 
both had confirmed 46,XX chromosomes without Y signal. Radiological bone age (wrist) was consistent 
with chronological age.  Post-operatively, both serum FSH (38.2 IU/L) and LH (22.7 IU/L) rose further 
with a serum total testosterone of 8.7 nmol/L. 
 
Repeat genetic testing on DNA extracted from blood, confirmed the absence of SRY and a 46,XX 
karyotype (Ohnesorg et al., 2011). This classified the diagnosis as 46,XX SRY negative (-ve) ovo-testicular 
DSD. Further analysis identified a duplication upstream of the SOX9 gene, which was confirmed by a 
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second independent method (MLPA - multiplex ligation dependent probe amplification)(Ohnesorg et al., 
2017).  
The proband’s mother did not carry the duplication, however there was no paternal family history of 
DSD or infertility. 
Within a multidisciplinary team, as the patient’s gender identity was unequivocally male, he was 
managed as a young man with hypogonadism requiring testosterone replacement and counselling 
regarding irreversible infertility associated with a missing Y chromosome. He was treated with injectable 
testosterone undecanoate (1000 mg, per 12 weeks) which achieved Tanner stage 5 virilisation with gain 
of muscle bulk and acne. His most recent trough serum total testosterone concentration was 9.6 nmol/L 
with suppressed serum LH (<0.1 IU/L) and FSH (0.8 IU/L), indicating adequate replacement therapy. 
 
3.3. DISCUSSION 
 
In mammals, the early gonad is bipotential and can differentiate into either a testis or an ovary. SRY is 
the master switch in testis determination (Kashimada et al., 2010) having evolved from the ancestral 
SOX3 (SRY type High Mobility Group box gene) gene. SRY (sex determining region on the Y chromosome) 
is specific to mammals (Sinclair et al., 1990). SRY upregulation of SOX9 induces differentiation of the 
bipotential gonad into a testis and, in its absence, the genital ridge develops by default into ovaries.  
The only known function of SRY is to upregulate the evolutionarily more conserved SOX9 (Jiang et al., 
2013), an autosomal (chromosome 17) gene.  SRY-induced SOX9 activation drives Sertoli cell 
differentiation and proliferation, a decisive step in testis development (Jiang et al., 2013; Sinclair et al., 
1990). SRY is sufficient but not necessary for testis development, as  increased SOX9 expression, is 
sufficient to induce testis formation, thus substituting for SRY function (Vidal et al., 2001). Ectopic 
expression of Sox9 in an XX gonad induces testis development in transgenic XX mice (Vidal et al., 2001) 
while SOX9 duplication can cause XX sex reversal in humans (B. Huang et al., 1999). Furthermore, 
experimentally replacing Sox9 for Sry, and Eif2s3x for Eif2s3y (spermatogonial proliferation factor) in 
mice produced phenotypic males with testes despite the absence of the Y chromosome. These two 
genes alone were sufficient to produce fertile haploid male gametes that could fertilise oocytes in vitro 
and produce offspring (Yamauchi et al., 2016). 
SOX9 is a pleiotropic gene with an array of gene dosage effects. Inactivation of both Sox9 alleles leads 
to the formation of ovaries in XY mice (Barrionuevo et al., 2006). In humans, SOX9 gene 
haploinsufficiency causes campomelic dysplasia (CD), an autosomal dominant skeletal dysplasia, as well 
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as male-to-female sex reversal in about 75 % of the 46,XY patients (Foster et al., 1994). SOX9 is also 
implicated in pancreatic development with pancreatic hypoplasia reported in patients with CD and in 
mouse models (Seymour, 2014). Sox9 regulates neural crest development and ectopic expression of 
Sox9 in the neural tube progenitors results in neural crest-like properties (Cheung et al., 2003). These 
links to neural crest development could explain the benign extra adrenal ganglioneuroma in this patient. 
Our 46,XX SRY-ve patient had a novel duplication in the regulatory region upstream of SOX9, leading to 
a male phenotype(Ohnesorg et al., 2017). He had at least one ovo-testis that produced sufficient 
testosterone to almost complete a phenotypically normal male puberty but not sufficient to suppress 
ovulation on more than one occasion, as shown by the apparent recent ovulation as indicated by a 
hemorrhagic corpus luteum as well as a corpus albicans, indicating prior ovulation. Given his male 
phenotype, no serum estradiol or progesterone concentrations were obtained pre-operatively nor did 
the hormonal levels (Table 7) confirm ovulation. It cannot be excluded that rather than true ovulation, 
the histological appearances of a corpus luteum and corpus albicans may have resulted from a collapsed, 
incompletely mature antral follicle without true LH surge-triggered ovulation. Apparent ovulation in 
phenotypic men has been reported previously in 46,XX, 46,XX/46,XY, 46,XX/47,XXY DSDs 
(Supplementary Table 1, summary of case reports), however, this is the only case of a 46,XX SRY-ve ovo-
testicular DSD from SOX9 duplication presented in Supplementary Table 1.  
The presence of the Y chromosome is associated with risk of malignancies in a dysgenic gonad. The 
patient’s 46,XX karyotype on all cell lines tested, suggests his risk of gonadoblastoma is low. However, 
based on a single case report of a Sertoli cell tumour in phenotypic male with 46 XX ovotesticular DSD 
(Gunasegaram et al., 1981), his follow-up will include regular scrotal ultrasound surveillance. 
His genetic diagnosis may have implications for the extended paternal family if the SOX9 duplication was 
inherited. The lack of paternal DNA precluded distinguishing between a de novo germline duplication in 
the patient or paternal transmission of the SOX9 duplication. The latter has been reported in a fertile 
46,XY father carrying a SOX9 or upstream enhancer duplication with transmission to a child with 46,XX 
karyotype resulting in female-to-male sex reversal (Benko et al., 2011; Cox, 2011; G.-J. Kim et al., 2015). 
As the paternal uncle and all his sons were fertile, there is no evidence to suggest this was paternally 
inherited. Previously reported SOX9 duplications are summarised in Supplementary Table 2, our case is 
unique in his presentation with a testicular mass from ovulation and with evidence of probable multiple 
ovulations. 
Consensus statement on management of intersex disorders of the Paediatric Endocrine Society and 
European Society for Paediatric Endocrinology at Chicago International Consensus Conference on 
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Intersex (Chicago consensus) of 2006(P. A. Lee et al., 2006) defined DSDs as congenital conditions in 
which development of chromosomal, gonadal, or anatomic sex is atypical. The proposed nomenclature 
emphasises on the knowledge of karyotype which is key in categorising the DSDs as (1) Sex Chromosome 
DSDs (variation in the number of sex chromosomes e.g. Turner’s syndrome 45, X; Klinefelter’s syndrome 
47, XXY; mixed gonadal dysgenesis etc., (2) 46, XY DSDs and (3) 46, XX DSDs as described in Table 
8(Hughes et al., 2006) . Table 8 also demonstrates categories of 46, XX DSDs that can cause virilisation 
or male phenotype in 46, XX individuals as presented in our present case. 
 
 
Table 8: Classification of DSDs, in particular 46XX DSDs that can result in virilisation or male phenotype 
DSD Category 
 
Examples 
 
Karyotype or Genes involved 
Sex 
Chromosome 
DSD  
Klinefelter’s syndrome 47,XXY and variants/ mosaics 
Turner’s syndrome 45,XO and variants/ mosaics 
Ovotesticular DSD 46,XX/46,XY chimerism 
46, XY DSD Disorders of androgen action (Androgen 
insensitivity syndrome) 
AR  
Disorders of androgen biosynthesis 
  
CYP11A1,HSD3B2 
CYP17A1,StAR, , HSD17B3, 
SRD5A2, POR 
Disorders of testicular development 
(Ovotesticular DSD, Testis regression) 
DHH, SRY, SF1,  WT1, SOX9 
Other syndromic associations of male genital 
development, isolated hypospadias, 
cryptorchidism 
CXorf6, INSL3, GREAT 
46, XX DSD Disorders of ovarian development (Ovotesticular 
DSD, Testicular DSD) 
SRY, RSPO1, dup SOX3, dup 
SOX9* 
Disorders of androgen excess - Fetal (Congenital 
Adrenal Hyperplasia), Feto placental (Aromatase 
deficiency) and 
Maternal (virilising tumours e.g. luteomas) 
HSD3B2, CYP21A2, CYP11B1, 
POR, 
CYP19 
Other syndromic associations (e.g. cloacal 
anomalies), Mullerian agenesis/ hypoplasia, 
Uterine abnormalities, Vaginal atresia (e.g. 
McKusick-Kaufman), Labial adhesions 
MKKS 
*Gene duplication detected in the current case of 46, XX karyotype in a young phenotypic male. 
 
Management of DSDs should integrate medical aspects of care with the psycho-social needs of the 
patient. Currently there are no recommendations for sex assignment in neonates who have DSD.  Any 
surgical procedure in children that leads to irreversible change must be considered with utmost 
NANDINI SHANKARA NARAYANA 76 
 
caution(Hughes et al., 2006). Ideally, the surgical procedure should also aim to preserve fertility in the 
most optimal way. In general, individuals with 46, XY DSD have an increased risk of malignancy may need 
prophylactic gonadectomy if indicated. Treatment is ideal in a multidisciplinary setting with 
considerations to genetic (implications to family and including reproductive recurrence risks), 
psychological aspects (sensitive individualised counselling including patient gender identity and 
preference), endocrinological (hormone replacement), surgical (cosmetic, prophylactic gonadectomy,) 
fertility preservation, reproductive opportunities and metabolic health (cardiovascular and bones). 
There are still uncharacterised genes causing DSD. Such DSDs are very rare and require a careful 
systematic, sensitive approach to diagnosis and management of the diagnostic and ethical challenges. 
Clinical assessment with karyotype (including SRY expression) and subsequent determination of the 
presence or absence of Müllerian structures are essential early investigations in any case of DSD. The 
sophisticated genetic diagnoses now feasible should be undertaken as the basis for genetic counselling 
of the extended family in any more complex cases. 
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4. CHAPTER: ACCURACY OF A DIRECT PROGESTERONE IMMUNOASSAY 
 
Citation: Shankara-Narayana, N., Zawada, S., Walters, K. A., Desai, R., Marren, A., & Handelsman, D. J. 
(2016). Accuracy of a Direct Progesterone Immunoassay. The Journal of Applied Laboratory Medicine: 
An AACC Publication, 1(3), 294-299. doi:10.1373/jalm.2016.020123 
  
 
4.1. INTRODUCTION 
 
Progesterone is a C21 steroid hormone secreted by the corpus luteum, following ovulation during the 
menstrual cycle. If pregnancy ensues, progesterone secretion is shifted to the placenta to provide 
essential support for implantation and maintenance of early pregnancy. Measurement of serum 
progesterone has an established diagnostic role in the mid-luteal phase to confirm recent ovulation and 
there is increasing use of serum progesterone during the late follicular phase to detect premature 
luteinisation during IVF hyperstimulation, reportedly associated with adverse pregnancy outcomes. In 
IVF, gonadotrophin releasing hormone (GnRH) analogues are used in controlled ovarian 
hyperstimulation to suppress pituitary gonadotropin secretion including preventing a premature 
luteinising hormone (LH) surge. Nevertheless during IVF hyperstimulation increases in serum 
progesterone during immediate pre-ovulatory (late follicular) phase are reported in 5-35% of IVF cycles 
(Elnashar, 2010), a finding termed premature luteinization.  
 
Although the pathophysiology of premature luteinization is poorly understood, it may impair 
endometrial receptivity (Fanchin et al., 1993; Smitz et al., 2007). Hypotheses to explain its origins include 
increased numbers of follicles recruited by hyperstimulation (Venetis et al., 2007), incompletely 
suppressed endogenous LH surge, excessive circulating LH-like activity from exogenous gonadotropins 
or aberrant LH receptor response to hyperstimulation (Elnashar, 2010; C.-C. Huang et al., 2012).   
 
However, the association between premature luteinization and adverse pregnancy outcomes in IVF 
hyperstimulation is debatable with some studies (Bosch et al., 2010; R. Huang et al., 2012; Ochsenkühn 
et al., 2012; B. Xu et al., 2012) but not all {(Givens et al., 1994; Martínez et al., 2004; Urman et al., 1999) 
including a meta-analysis(Venetis et al., 2007)} showing detrimental effects. Heterogeneity among these 
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studies may have arisen from various differences including the specific thresholds used to define 
increased serum progesterone as well as variation in the assay methodology as well as other systematic 
differences in IVF protocols used (Bosch et al., 2010; Venetis et al., 2007).   
 
The currently available method to measure serum progesterone is based on direct, non-extraction, 
immunoassays which are optimised to quantify high serum progesterone levels used to confirm 
ovulation. The performance of the direct progesterone immunoassays to the much smaller late follicular 
rise that defines premature luteinization has not been established. It is widely recognized that direct 
non-extraction immunoassays over-estimate concentrations of serum testosterone and estradiol 
compared with the gas or liquid chromatography, mass spectrometry-based reference methods 
especially at lower circulating concentrations (Handelsman et al., 2013; Rosner et al., 2007; Rosner 
et al., 2013) . This study therefore aimed to evaluate the accuracy of serum progesterone measurement 
by a direct (non-extracted) immunoassay against a liquid chromatography, mass spectrometry (LC-MS) 
method across the full range of serum progesterone concentrations. 
 
4.2. METHODS  
 
In a single-centre, observational study, serum samples were provided from 254 women undergoing IVF 
hyperstimulation in a single private IVF clinic. Blood samples taken routinely around the time of hCG 
administration had serum progesterone measured in both a direct progesterone immunoassay 
(Beckman Coulter Access) and by LC-MS.  
The progesterone immunoassay was performed according to the manufacturer’s directions with a limit 
of detection of 0.1 ng/ml (0.32 nM) and linearity between 0.1 – 40 ng/ml (0.32 – 127.2 nM). The assay 
was monitored for accuracy and reproducibility within (n=24) and between (n=603) assay using QC 
samples at low (nominal 3.5 nM, within-assay 3.5 nM, CV 11.5%; between assay 3.3 nM, CV 13.4%), 
medium (nominal 32.1 nM, within-assay 32.6 nM, CV 4.9%; between assay 32.7 nM, CV 7.8%) and high 
(nominal 83.1 nM, within-assay 83.1 nM, CV 4.2%; between assay 87.1 nM, CV 7.9%) range.  
The LC-MS measurement of serum progesterone was quantified using a previously described  (Harwood 
et al., 2009) and modified (Hsu et al., 2016) method for steroids employing atmospheric positive 
pressure ionization in positive mode. Progesterone was quantified by monitoring of transitions for 
progesterone (315.3 -> 97.1, Steraloids) and d9-progesterone (324.3->100.1, CDN Isotopes). The 
quadratic calibration curve was linear between 0.05 ng/ml and 128 ng/ml (0.16 – 407 nM) with a limit 
of detection of 0.02 ng/ml (0.06 nM) and limit of quantitation 0.05 ng/ml (0.16 nM). Quality control 
samples at low (0.8 ng/ml, 2.6 nM), medium (3.2 ng/ml, 10.2 nM) and high (16 ng/ml, 51 nM) levels in 
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each run. The accuracy of the progesterone measurements was 96.4 ± 1.9 (SEM)% (in triplicates over 11 
serial dilutions spanning the full dynamic range) compared with a Certified Reference Material 
preparation (Cerillant, Round Rock,Tx). Pooling quality control samples across the three levels, the 
accuracy was 109% (within) and 101% (between) run and coefficient of variation was 5% (within) and 
9% (between) run.  
Serum progesterone measurements were compared by Bland-Altman deviance plot and Passing-Bablok 
regression methods (MedCal version 16, Belgium). For quantitative analysis, left-censored 
(undetectable) results in LC-MS were assigned a value 0.05 ng/ml. For graphical purposes, only samples 
with LC-MS results above the quantitation limits are included. 
 
4.3. RESULTS 
 
Serum progesterone was detected in 252 (99%) samples by immunoassay and in 215 (85%) samples by 
LC-MS. The results compared by Bland-Altman deviance plot (figure 12) and Passing-Bablok regression 
(figure 13) are shown.   
The Bland-Altman analysis (figure 12, with the dashed line of identity and for 95% confidence limits and 
the mean difference in solid line) shows that immunoassay over-estimated serum progesterone in every 
sample (median 4.8 vs 1.5 nM; median difference 4.4 nM [interquartile range 3.5, 5.9 nM]). The upward 
bias of IA increased exponentially at low serum progesterone concentrations (immunoassay <5 nM or 
LC-MS<2 nM). 
In the Passing-Bablok regression (figure 13, with dashed line of identity and 95% confidence intervals for 
slope and solid line for regression) the slope was 1.0 (95%CI 0.9, 1.1) and intercept 3.2 nM (95%CI 3.1, 
3.3 nM).  
The median age of women was 38 years (range 20-49) but age was not correlated with either IA or LC-
MS result or their difference. 
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Figure 12. Bland–Altman deviance analysis plotting the difference between the immunoassay and LC-
MS assay for serum progesterone (in nmol/L) for all samples using only serum progesterone 
concentrations above limit of quantification.  
The main figure shows the difference plotted as a percentage deviation on the y axis and the LC-MS 
measurements on the x axis. The inset shows the same data plotted, with the y axis as the absolute 
difference between the immunoassay and LC-MS assay. The horizontal lines indicate the line of identity 
(dotted), the mean (solid line), and 95% CIs (dashed lines) of the deviations.  
The Bland-Altman analysis (the dashed line of identity and for 95% confidence limits and the mean 
difference in solid line) shows that immunoassay over-estimated serum progesterone in every sample 
(median 4.8 vs 1.5 nM; median difference 4.4 nM [interquartile range 3.5, 5.9 nM]). The upward bias of 
IA increased exponentially at low serum progesterone concentrations (immunoassay <5 nM or LC-MS<2 
nM). 
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Figure 13. Passing–Bablok regression of serum progesterone by immunoassay (y axis) against LC-MS 
assay (x axis) showing the regression (solid line) with the line of identity (dotted line) and 95% CIs for 
slope (dashed lines). In the Passing-Bablok regression (with dashed line of identity and 95% confidence 
intervals for slope and solid line for regression) the slope was 1.0 (95%CI 0.9, 1.1) and intercept 3.2 nM 
(95%CI 3.1, 3.3 nM).  
 
 
4.4. DISCUSSION  
 
Serum progesterone is routinely measured by direct immunoassay on multiplex platforms which are 
have rapid turnaround, are relatively inexpensive and easily integrated into chemical pathology 
laboratory assay profiles. The most widely used and best-established indication is for high mid-luteal 
measurement of serum progesterone to confirm recent ovulation. In addition, there is growing use to 
diagnose premature luteinization based on late follicular phase measurement of much lower levels of 
serum progesterone although this application has a paucity of supporting evidence at low serum 
progesterone concentrations. This study demonstrates that a widely used progesterone immunoassay 
consistently overestimates serum progesterone levels when compared with the reference method of 
LC-MS measurement, increasingly severe at lower serum progesterone concentrations. Despite the 
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consistent overestimation, the present study supports the use of direct progesterone immunoassay to 
confirm recent ovulation because of the reasonable agreement between the direct immunoassay and 
LC-MS reference methodology at higher serum progesterone concentrations (>5 nM by immunoassay, 
>2 nM by LC-MS). However, the increasing severe upward deviations of the immunoassay at lower serum 
progesterone concentrations (immunoassay <5 nM, LC-MS <2 nM) questions the reliability of using these 
lower serum progesterone measurements to define premature luteinization.  
 
These latter findings are relevant to the clinical practice in some IVF clinics to employ a threshold of 
serum progesterone to diagnose premature luteinization and to make decisions to defer or to proceed 
with embryo transfer in that cycle (Patton et al., 2014; Shapiro et al., 2010). Over-estimation of relatively 
small late follicular phase increases in serum progesterone has the potential to mistakenly defer embryo 
transfer due to inaccurately elevated measurements of serum progesterone. For accurate measurement 
of serum progesterone at such low threshold applications, LC-MS should be preferred for progesterone 
measurement due to its accuracy, at even these relatively low circulating progesterone concentrations 
(Leung et al., 2013). A limitation of our study is that we did not evaluate the IVF outcomes to correlate 
with the serum progesterone levels.  
 
We conclude that while supporting the utility of high serum progesterone immunoassay measurement 
(>5 nM) to verify recent ovulation, the inaccuracy of lower serum progesterone concentrations raises 
questions about the reliability of direct progesterone immunoassay to define premature luteinisation. 
This highlights the need for caution regarding clinical decision making for management of embryos in 
IVF cycles with apparently high late follicular phase serum progesterone concentrations based on an 
immunoassay that consistently overestimates low serum concentrations. 
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5.CHAPTER: RANDOMIZED, PLACEBO-CONTROLLED CLINICAL 
TRIAL OF TRANSDERMAL DHT GEL TO IMPROVE IVF OUTCOMES 
IN WOMEN WITH POOR OVARIAN RESPONSE AND LITERATURE 
REVIEW OF SAFETY OF TESTOSTERONE IN WOMEN 
 
5.1. INTRODUCTION 
 
There has been a recent interest in the positive role of androgens in female reproductive biology, sexual 
function and wellbeing. Androgens may have a positive role in early follicular development. It is now 
well established that polycystic ovaries are the commonest endocrine disorder in women of 
reproductive age. Polycystic ovaries are characterized by hyperandrogenism, polycystic ovarian 
morphology and oligomenorrohoea. At this stage it is unclear if hyperandrogenism is a cause or an effect 
of PCO. Polycystic Ovarian Syndrome, also known as Stein Leventhal Syndrome, was first described in 
1935 by Irving F. Stein, Sr., and Michael L. Leventhal, when they associated anovulation with the 
presence of ovarian cysts. The various androgen excess conditions in women include – PCOS, untreated 
Congenital Adrenal Hyperplasia, virilising adrenal/ovarian tumours and therapeutic use for the 
conditions listed below including female to male transsexuals. The best model to study the effects of 
androgens in females is obtained from studies in female to male transsexuals where the aim of the 
treatment is complete virilisation and histology specimen being available after sex reassignment surgery. 
Although the safety experience with using androgens in women is limited, nonetheless there are 
various conditions where it has been used. Long term use is usage is limited by virilising side effects. 
Most of the data regarding testosterone use in women comes from studies in menopausal women 
using testosterone to improve sexual function. Testosterone has been used in a large number of 
clinical trials in women in the treatment if various conditions - 
(A) Hypoactive sexual desire disorder (HSDD) to improve sexual function in menopausal    women  
(B) HIV   infected women to evaluate effects on body composition and bone health  
(C)Hypopituitarism, adrenal insufficiency or oophorectomy/ovarian insufficiency to determin cardiovas
cular risk, bone health and cognition 
(D) Premenopausal women with androgen deficiency  
(E) Anorexia nervosa to improve depression and cognition (F) IVF studies in women with poor ovarian r
esponse  
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(G) Other studies – breast cancer risk and cognition. 
 
This chapter describes the study protocol and literature review undertaken for the project ‘DHT use in 
women with poor IVF response’. Ethics approval was obtained for this project, however, could not be 
completed due to unavailability of the study drug in Australia. The study design is followed by literature 
review of safety of androgen use in women. 
 
5.2. BACKGROUND AND SIGNIFICANCE 
 
As women increasingly delay child-bearing, the proportion of older women seeking IVF treatment is 
rising in Australia(Macaldowie et al., 2014) and globally(Ishihara et al., 2015). Accordingly, the 
proportion of IVF treatment cycles resulting in suboptimal outcomes, due mainly to inadequate ovarian 
responses to FSH-based hyperstimulation, is also increasing and improved treatments are needed.  
 
Over 5 million babies have been born using assisted reproduction technologies (ART) in the 35 years 
since Louise Brown’s birth. In Australia, ~3% of babies born are now born through IVF wherein a live 
birth rate of 40% per cycle, which is considered high, falls markedly in older women(Ishihara et al., 2015; 
Macaldowie et al., 2014). Hence, as women increasingly delay childbearing, the demand for ART 
treatments is growing, and especially among older women with reduced ovarian responses. Despite the 
improved IVF techniques, suboptimal outcomes with low live birth rates per cycle remains a major 
challenge. The incidence of poor ovarian response is reported in 9-26% of IVF patients(Keay et al., 1997; 
Polyzos et al., 2011). Women with poor IVF outcomes relate mainly to inadequate ovarian response  and 
exhibit not only reduced live birth rates but also experience increased cycle cancellation rates and a 
need for larger doses of gonadotrophins, which increases both cost and ovarian hyperstimulation 
syndrome (OHSS) risk. 
 
Poor ovarian response (POR) to ovarian stimulation is defined by the first international consensus in the 
ESHRE Bologna criteria(Ferraretti et al., 2011). These require that at least two of the following three 
features must be present: (i) advanced maternal age(>40 years) or any other risk factor for POR; (ii) a 
previous POR(<3 oocytes on a conventional stimulation protocol); and (iii) an abnormal ovarian reserve 
test (ORT ie. antral follicle count <5-7 follicles (ultrasound) or serum AMH 0.5-1.1 ng/ml). Two episodes 
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of POR after maximal stimulation are sufficient to define a patient as a poor responder in the absence 
of advanced maternal age or abnormal ORT.   
 
Recent discovery and reinforced by findings from our lab suggest that a positive a physiological role of 
androgens acting via the androgen receptor (AR) in important in optimising female fertility (Cheng et al., 
2013; K. A. Walters, 2015; K. A. Walters et al., 2008; K. A. Walters et al., 2007; K. A. Walters et al., 2009; 
K. A. Walters, Middleton, et al., 2012; K A Walters et al., 2019; K. A. Walters et al., 2010a, 2010b). Over 
recent years some IVF clinics have adopted the unproven use of various off-label treatments that 
increase androgen exposure aiming to enhance poor ovarian responses in IVF (Balasch et al., 2006; 
Fabregues et al., 2009; Fouda et al., 2011; Goswami et al., 2004; C. H. Kim et al., 2011; Lossl et al., 2008; 
Wiser et al., 2010). These treatments include testosterone, the pro-androgen DHEA or an aromatase 
inhibitor (letrozole) which increases serum testosterone in women. However, each acts via additional 
pharmacological mechanisms (including via estrogen receptors (ER)) as well as the androgen receptor 
(AR), making it difficult to interpret the mechanism of action in previous or future clinical trials. Instead, 
we propose to use DHT treatment, a pure, non-aromatisable androgen, which acts solely via the AR. This 
would test definitely whether any potential beneficial effects (eg improved live birth/pregnancy rates, 
reduced FSH dose and duration, minimising OHSS risk and cost) are due to AR-mediated mechanisms. 
This new mechanism-based information would facilitate development of novel, effective fertility 
treatments for women with poor ovarian responses in IVF, as well as for subfertile women prior to 
seeking IVF treatment.  
 
5.2.1. THE ROLE OF AR MEDIATED ANDROGEN ACTION IN OVARIAN FOLLICLE 
DEVELOPMENT 
 
The evolutionary conservation of AR expression in all mammalian ovaries strongly suggests that AR-
mediated androgen actions influence ovarian follicle development. Androgens may have a role in early 
stages of follicular development (Nobert 2011). DHEA is the main precursor hormone for intrafollicular 
testosterone production. Ovarian thecal cells produce androgens under the influence of LH. Treatment 
with the androgens T or DHT increases preantral and small antral follicle numbers in primates(Vendola 
et al., 1998b), consistent with increased numbers of preantral and antral follicles in women with PCOS 
or other disorders such as congenital adrenal hyperplasia(Lucis et al., 1966a) or female-to-male 
transgender(Pache et al., 1993) characterized by hyperandrogenemia(Stubbs et al., 2007).  In concert, 
these observations support a role for androgens in stimulating early stages of follicle development, prior 
to the major impact of FSH on follicle maturation.  This enhancement by androgen action involves 
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multiple pathways including both ovarian and extra-ovarian (neuroendocrine) mechanisms leading to 
improved follicle maturation, health and recruitment as well as increased sensitivity to FSH 
stimulation(K. A. Walters et al., 2009). Nevertheless, despite the consistent evidence for a functional 
role of local AR-mediated androgen actions in follicle growth, previous pharmacological studies provide 
conflicting findings (reviewed in: (K. A. Walters, 2015; K. A. Walters et al., 2008; K. A. Walters, Allan, et 
al., 2012; K. A. Walters et al., 2010a)). This is mainly due to the use of aromatisable androgens (T, 
androstendione (A4), dehydroepiandrosterone (DHEA) that are converted into corresponding estradiol, 
which exerts estrogen receptor (ER)-mediated effects. Thus, the use of aromatizable androgens limit the 
ability of a sole pharmacological approach to define the specific AR or ER-mediated molecular 
mechanism(s). 
 
5.2.2. ANDROGEN TREATMENT TO IMPROVE OVARIAN FSH RESPONSE 
 
Population studies demonstrate a decrease in blood T, DHEA and A4 concentrations in women gradually 
between the ages of 20 and 45 years of age, without specific additional effects of the menopausal 
transition(Davison et al., 2005; Zumoff et al., 1995). This gradual decline in sex steroids over a woman’s 
reproductive life may contribute to, or reflect, the diminishing ability of the ageing ovary to respond to 
FSH-based stimulation for fertility treatments; how this relates to suboptimal age-related ovarian 
function remains to be clarified. Ovarian reserve declines steeply with age so older women undergoing 
IVF yield fewer oocytes even after maximal FSH stimulation (Broekmans et al., 2009).  
 
5.2.3. EVIDENCE FROM PRIMATE STUDIES: 
 
Vendola et al (1998) assessed the effects of short term high dose testosterone (4mg/kg/day for 3 days 
or 0.4mg/kg/day for 10days), low dose testosterone (0.02mg/kg/day for 5 days) or DHT 
(0.145mg/kg/day for 5 days) administration to rhesus monkeys(Vendola et al., 1998a). The histology of 
the ovaries showed a striking polycystic ovarian morphology with increased ovarian volume and antral 
follicles in comparison with the controls. Testosterone increased the number of Primary follicles by 
2.7-fold after 3 days and by 4.6- fold after 10 days of treatment. However, the number of large antral 
follicles did not change. There was also a more than two-fold increase in the capsular thickness. 
Thickness of the thecal layer and thecal cell proliferation marker Ki67 were also increased. There was 
no increased follicular atresia and granulosa cell apoptosis was significantly reduced. Also, AR gene 
expression positively correlated with granulosa cell proliferation and follicular growth and negatively 
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correlated with granulosa cell apoptosis and follicular atresia(Weil et al., 1998). These studies 
suggested that short term androgen treatment stimulated early stages ovarian follicular growth in 
primates. The same group also reported the positive and complementary synergistic effects of 
androgens and FSH in follicular growth in primates. Androgen treatment increased FSH receptor 
expression in granulosa cells.                                                                                                                                          
  
In recent years, following evidence that androgens may enhance follicle development, many IVF centres 
now use unproven androgen pre-treatment for (mainly older) women who have had poor ovarian 
response to FSH stimulation. One recent study suggests that one third of all IVF centres worldwide use 
DHEA supplementation in such women(Gleicher et al., 2011). Various clinical studies claiming that 
androgen pre-treatments improve poor ovarian response to IVF stimulation and pregnancy 
rates(Bercaire et al., 2018; Bosdou et al., 2012; Gleicher et al., 2011; Meldrum et al., 2013) are mostly 
from uncontrolled and/or underpowered studies so remain inconclusive. In any case, even better 
designed and more powerful clinical studies using similar designs will remain unable to identify the 
pathways and mechanisms involved. These pre-treatments so far used comprise: 
(i) DHEA, a pro-androgen with variable conversion to testosterone and estradiol so that the ultimate 
effects are mediated via an undefined mixture of both AR and ER mechanisms  
(ii) Testosterone where its actions are mediated by an unknown balance between AR and ER 
mechanisms 
(iii) Aromatase inhibitors that increase endogenous serum testosterone by blocking conversion to 
estradiol thereby enhancing AR but reducing ER effects.  
These multiple mechanisms invoked by these drugs limit the ability to interpret whether it is AR-
mediated androgen effects involved.  
 
By contrast, DHT is a unique natural pure (non-aromatisable) androgen which has effects mediated 
solely via AR without aromatisation to estradiol, thus avoiding the confounding of interpretation by 
involvement of ER mediated mechanisms.  
 
The potential benefits of androgens include better pregnancy and live birth rates as well as reduced 
cycle cancel rates, FSH dosage, OHSS risk and cost. This research has the potential to not only improve 
IVF treatment but also to provide new opportunities for non-IVF treatment for older women with 
declining fertility.   
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5.3. RESEARCH HYPOTHESIS 
 
DHT pre-treatment prior to an IVF cycle will improve the number of healthy, fertilisable oocytes 
retrieved. 
 
5.4. OBJECTIVE 
 
1. To undertake an investigator-initiated, randomized, placebo-controlled clinical trial to 
investigate the efficacy of transdermal DHT gel treatment prior to an IVF stimulation cycle in 
women with poor ovarian response. 
2. To do a literature review of – 
(i) Safety of androgen use in women  
(ii) Effects of hyperandrogenism on the female reproductive tract in all non-PCO 
hyperandrogenic states in women including- untreated congenital adrenal hyperplasia, 
female to male Transgenders and virilising tumours. 
 
5.5. RATIONALE 
 
Since DHT is a natural, pure, non-aromatisable androgen which has physiological effects mediated solely 
via AR, without any aromatisation to estradiol, it can uniquely evaluate AR-mediated effects while 
avoiding misinterpretation due to concurrent ER-mediated effects. Hence this study will determine 
whether there are beneficial effects on IVF outcomes of androgen pre-treatment prior to FSH 
stimulation and whether these are mediated via AR. 
 
 
5.6. PRACTICAL ISSUES/DIFFICULTIES ENCOUNTERED IN DESIGNING THE STUDY 
 
5.6.1. IS THIS A PHASE 1 TRIAL? 
 
One of the questions that arose whilst designing the trial was if this was a Phase 1 trial. DHT gel has been 
used in several trails in the past in men, hence it is not a phase 1 trial. Also, the previous studies that 
have used DHEA, testosterone or Aromatase Inhibitors would have resulted in some increase in serum 
DHT levels, therefore it has been indirectly tested. Moreover, DHT is an endogenous hormone already 
present in normal circulation in women. 
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5.6.2. HOW SAFE IS IT FOR USE IN WOMEN? 
 
The literature review is summarised in the discussion on the spectrum of androgen effects in women: 
ranging from small therapeutic doses for various indications to the extreme virilising effects seen in toxic 
doses as in female to male transsexuals, CAH and virilising tumours. Short term, low dose use was safe for 
use in women. 
 
5.6.3. ENTRY CRITERIA- MODIFIED BOLOGNA CRITERIA 
 
A modified Bologna criteria (Ferraretti et al., 2014; Ferraretti et al., 2011) stratified by age will be used 
to distinguish the effects of age itself from those of other criteria for POR as defined by the Bologna 
criteria, as age itself is a significant risk factor for POR. The other risk factors for POR are short menstrual 
cycle length, single ovary, ovarian cystectomy, chronic smoking, unexplained infertility, chemo- or 
radiotherapy, ovarian endometriosis or surgery, uterine artery embolization for leiomyoma, pelvic 
infection and other medical risk factors (Younis, 2012). 
Inclusion criteria 
• Age >18 years 
• Modified Bologna criteria stratified by age 
o For women ≥40 years, no additional inclusion criteria   
o For women <40 years, at least one additional inclusion criterion either  
▪ Previous IVF cycle with POR (≤ 3 oocytes with conventional stimulation)  
and/or 
▪ Impaired ovarian reserve (ultrasonic antral follicle count <7 follicles or serum AMH 
<1.1 ng/ml)  
5.6.4. STUDY ENDPOINTS 
 
Primary endpoint: 
Clinical pregnancy rate (intrauterine gestation with fetal heartbeat). 
The primary endpoint of the study will be the number of clinical pregnancies as we hypothesise 
that DHT improves the number and health of oocytes retrieved and their ability to be fertilised 
whereas the outcomes of pregnancy for fertilised oocytes is expected to be unchanged. 
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Secondary endpoints: 
1. Efficacy – Number of follicles on hCG day; Number of oocytes retrieved, Proportion of oocytes 
fertilised; Total number of embryos; Cycle cancellation rate; Total dose & duration of FSH; Sexual 
function (modified FSFI scale- see appendix) 
2. Mechanistic - Steroid profiles in the serum and follicular fluid and correlation of these with the 
standard IVF outcomes; evaluate mRNA expression for AR splice variants and noncoding RNA 
regulatory FSH receptor 
3. Safety - Miscarriage rate; adverse effects 
 
5.7. STUDY DESIGN 
 
This is an investigator-initiated, proof-of-concept study as a randomized, placebo-controlled, parallel 
group clinical trial of DHT (5mg vs placebo) gel used daily for 21 days immediately prior to an IVF 
hyperstimulation cycle with the goal of improving ovarian response in women with prior poor ovarian 
response to IVF.  
 
5.8. STUDY PROCEDURES 
 
5.8.1. RECRUITMENT, SCREENING AND CONSENT 
 
Patients attending a public hospital IVF clinic will be invited to participate subject to providing written 
informed consent and meeting eligibility criteria. Patient recruitment will be undertaken by the 
gynaecologist co-investigators, together with their fellow clinicians and clinic nurses. The trial has been 
approved by the relevant human ethics committee and registered with the ANZ clinical trials registry.  
 
5.8.2. ENROLMENT AND RANDOMISATION PROCEDURES 
 
Eligible, consenting participants will receive a consecutive, unique study enrolment number which will 
be documented in the participant’s medical record and all study documents. The participants will be 
randomized at the enrolment visit according to their unique study ID number to receive either DHT or 
placebo gel. All study staff and participants will remain blinded to treatment throughout the study. 
Randomization is according to a computer-generated random list, with a block size of 4 prepared by a 
person not directly involved with the study participants. The randomisation allocations will be provided 
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in sealed opaque envelopes marked with the study ID number on the outside to allow for concealed 
allocation in a 1:1 ratio to either the DHT or placebo treatment groups.  
 
5.8.2.1.First visit: Screening and enrolment  
 
• Scheduled for day 2 of the menstrual cycle prior to the IVF treatment. 
• Verify identity and date of birth 
• Obtained signed, informed consent & randomisation 
• Standardised reproductive and general medical history  
• Complete Brief Sexual Function Inventory questionnaire 
• Demographics and anthropometrics (age, height, weight, smoking, alcohol, drugs)  
• Baseline blood samples  
• Instruction for study  
o Daily gel application. To be applied to clean dry skin after a morning shower and spread 
thinly on abdomen or thighs and allowed to evaporate.  
o Dispense 21 days of supply of gel 
o Provide instruction and materials for home finger prick blood test 
 
5.8.2.2.Second visit: End of treatment (day 21) & start of IVF hyperstimulation 
 
• Scheduled for Day 23 of the menstrual cycle prior to IVF cycle  
• Coincides with schedule for patients to have their start-up IVF nurse interview 
• Return all syringes  
• Return of filter paper with dried blood sample 
• Blood sample for serum DHT and other variables 
• Complete Brief Sexual Function Inventory questionnaire 
5.8.2.3.Further visits 
 
IVF treatments will be according to the directions of the treating IVF clinician.  
Follicular fluid is collected after routine puncture of the follicles as required to collect the oocytes and 
stored rather than being discarded as usual. Samples will be collected at Fertility Unit and stored frozen 
at Research Institute until analysis. RT-PCR will be used to evaluate mRNA expression for AR splice 
variants and non-coding RNA regulatory FSH receptor 
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Withdrawal 
Participants will be free to withdraw from this study at any time without compromise of their IVF 
treatment.  
 
5.9. STUDY DURATION 
 
This project will require 4 years for completion. The clinical trial will commence in the Fertility Unit, RPA 
Hospital and may extend to additional centres as required. All methods, access to patients and human 
samples, and expertise exist in the laboratories and team. 
 
 
5.10. SAFETY 
 
5.10.1.STUDY RISK ASSESSMENT 
 
The study involves potential risks associated with study participation including use of the DHT gel in 
addition to those due to of IVF treatment. The additional risks beyond those of IVF treatment are 
considered and evaluated below.  
 
5.10.2.RISKS OF EXCESSIVE ANDROGEN ACTION  
 
Any androgen at sufficient dose and duration may cause androgenic side-effects such as acne, hirsutism, 
male-pattern alopecia, voice change or alternations in mood and behaviour in women. Androgen effects 
on skin, vocal cords or psychological functions requires sustained, supra-physiological exposure. Short-
term and/or lower dose effects are reversible on cessation of androgen exposure.  
 
5.10.3.EXPERIENCE WITH TRANSDERMAL TESTOSTERONE IN PLACEBO CONTROLLED 
RCTS  
 
Low dose, short term testosterone therapy in women is well tolerated. Testosterone has been used in a 
large number of clinical trials in women in the treatment of the various conditions – 
• (A) Hypoactive sexual desire disorder (HSDD) to improve sexual function in menopausal women 
(Barton et al., 2007; Braunstein et al., 2005; Buster et al., 2005; Chudakov et al., 2007; S. Davis et 
al., 2008; S. R. Davis et al., 2008; Davis et al., 2006; El-Hage et al., 2007; Fooladi et al., 2014; 
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Kingsberg et al., 2007; Nachtigall et al., 2011; Nathorst-Boos et al., 2006; Panay et al., 2010; 
Shifren et al., 2000; Shifren et al., 2006; Simon et al., 2005)  
• (B) HIV infected women to evaluate effects on body composition and bone health (Choi et al., 
2005; Dolan Looby et al., 2009a; Dolan et al., 2004; Herbst et al., 2006; K. Miller et al., 1998a) 
• (C) Hypopituitarism, adrenal insufficiency or oophorectomy/ovarian insufficiency to determine 
cardiovascular risk, bone health and cognition (G. M. Guerrieri et al., 2014; G. Huang et al., 2014; 
Popat et al., 2014) 
• (D) Premenopausal women with androgen deficiency (Goldstat et al., 2003) 
• (E) Anorexia nervosa to improve depression and cognition (K. K. Miller et al., 2005) 
• (F) IVF studies in women with poor ovarian response (Fabregues et al., 2009; C. H. Kim et al., 
2011; Massin et al., 2006) 
• (G) Other studies – breast cancer risk (Davis et al., 2009; Hofling et al., 2007) and cognition 
(Davison et al., 2011) 
Most of the data regarding testosterone use in women comes from studies in menopausal women to 
improve sexual function and these trials have used testosterone for a duration of 1-12months and a 
nominal daily delivery testosterone rate varying between 150mcg – 1250mcg/day. The literature review 
summarising various transdermal testosterone preparations in women along with the reported 
androgenic adverse effects is attached as an Appendix supplementary table 3. 
The incidence of androgenic adverse rates (hirsutism, acne, alopecia, deepening of voice) was not 
significantly different between the placebo group and the testosterone group in these studies except in 
Davis et al (2008, NEJM)(S. R. Davis et al., 2008) who reported increased hair growth in testosterone 
group over a treatment period of 1 year, Panay et al (2010,Climacteric)(Panay et al., 2010) reported 
slight increase in acne and hirsutism and Shifren et al (2006, Menopause)(Shifren et al., 2006) reported 
a small increase in depilation frequency at 24 weeks. The most frequent adverse event was a site 
reaction on the skin to the area application of the patch not seen in gel or cream preparation. This is well 
known side effects of the absorption enhancers used in patches rather than a drug effect. There were 
no differences in rates of withdrawal due to adverse effects between the testosterone and placebo 
groups.   
No adverse events whether androgenic or biochemical have been reported in the IVF studies.(Fabregues 
et al., 2009; C. H. Kim et al., 2011; Massin et al., 2006) The duration of testosterone treatment is 
significantly shorter in these studies ranging from 5-21 days, making it sufficiently safe for short-term 
use prior to controlled ovarian stimulation in women with poor ovarian response. 
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5.10.4.RATIONALE FOR DHT DOSE 
 
The study dose has been based on down-titration of DHT based on (a) best available current estimates 
of normal serum DHT levels in healthy women (~85 pg/ml(M. S. Rothman et al., 2011)) and men (~550 
pg/ml(Idan et al., 2010)), (b) reduction of dose based on steady-state levels achieved in men with the 
same DHT gel and (c) relative production rates of testosterone in men (~5mg/day) and women (~0.30 
mg/day).  
 
In concert these indicate that a 14-fold reduction of DHT dose from 70 mg/day for men to 5 mg/day for 
women is the most appropriate reference for a fixed dose, short-term exposure. The participants will be 
warned to report any new possible androgenic effects to their doctor for review and possible cessation 
of drug.  
 
Inappropriate androgen exposure may occur involving topical transfer of DHT gel to children or to other 
adults. Participants will be advised to apply gel after morning shower and warned to cover application 
site with clothing and avoiding direct skin contact with children.  
Another circumstance of potential inadvertent androgen exposure is the possibility of virilization of a 
female fetus. The study drug treatment stops (with return of all syringes) at the start of the IVF treatment 
cycle. DHT is cleared from the body within 24-36 hours from the last dermal application of gel. Virilisation 
of a female fetus from inappropriate androgen exposure can only occur when fetal organs are 
developing during the 1st trimester, which is several weeks after clearance of DHT from the maternal 
body. This makes virilization from study DHT medication highly unlikely.  
 
Previous studies using transdermal testosterone have not reported significant adverse androgenic 
effects for the 21-day period of study (see above). Similar studies of transdermal testosterone gel in IVF 
using 2-month exposure are currently underway.  
 
5.10.5. OTHER RISKS OF DHT GEL 
 
As a dermal gel, there is risk of a skin reaction from irritation or allergy at the gel administration site. 
Wide clinical experience with DHT or similar androgen-containing gels has not identified any allergic 
reactions and the rare irritation reactions are mild and reversible upon cessation of the gel application.  
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Other than androgen effects in inappropriate settings (eg children) or excessive androgenic effects, DHT 
has no other known adverse effects. 
 
 
5.10.6. GENERIC RISKS OF ADVERSE EFFECTS FROM PARTICIPATION IN A STUDY  
 
Generic risks of study participation include those of venesection-induced bruising or infection associated 
with blood sampling by venepuncture or finger-prick. In addition, there may be additional unknown risks.  
5.10.7. ADVERSE EVENT REPORTING 
 
At the day 21 visit, participants will be asked to if they have experienced any unusual, unexpected or 
unwanted effects (symptoms, signs, conditions or an observation) since they started treatment. Any 
reports of undesirable or unwelcome effects will be documented as adverse events (AE). The 
investigators will also judge whether the AE is definitely, likely, possible or unrelated to the study 
medication. 
Serious Adverse Event (SAE) Reporting 
The definition of SAE will be in accordance with ICH guidelines for GCP 1.5: “any untoward medical 
occurrence that results in the following: death, is life threatening, requires inpatient hospitalization or 
prolongation of existing hospitalization, persistent or significant disability /incapacity or congenital/birth 
defect, condition requiring unnecessary medical or surgical intervention”. All SAEs will be reported 
within 24hrs of the study coordinator or Principal Investigator being made aware of it and subsequently 
to the HREC as soon as possible. 
 
5.10.8.DATA SAFETY AND MONITORING BOARD (DSMB) 
 
An independent DSMB will be appointed to review all safety date from the study. The DSMB will include 
at least two with specialist expertise (endocrinology, gynaecology, pharmacology) and a biostatistician, 
each member having previous clinical trial experience. In consultation with the PI, the DSMB will develop 
its own charter, including the need (and if any the schedule) for an interim safety review. The DSMB will 
be provided with detailed, and if required unmasked, summaries of all safety measures including AEs for 
their review. 
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Early Termination of Study 
In the event of early termination, the PI will be responsible for informing participants, study treatment 
unblinding, correspondence to HREC and compiling a final study report. 
 
Unblinding 
The randomization code list will be held by a staff member not directly involved with the study 
participants to avoid any inadvertent unblinding. The PI can authorise unblinding if required for patient 
safety such as for adverse effects requiring treatment, accidental gel exposure of children from 
household or at request of the DSMB.  
 
 
5.11. STATISTICAL ANALYSIS 
 
5.11.1. DESIGN AND ANALYSIS CONSIDERATION 
The study is an investigator-initiated, randomised, placebo-controlled, parallel group clinical study. The 
primary and secondary endpoints will be analysed on an intention-to-treat basis for efficacy endpoints 
and for per protocol for safety endpoints using paired t-tests or mixed model analysis of variance to 
incorporate covariables based on known risk factors for poor IVF outcomes.  
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5.11.2. SAMPLE SIZE AND POWER 
 
Power calculation (PASS software, right) assuming two-sided α=0.05, β=0.2 (80% power) and a 
background pregnancy rate 
in women with POR of 
15%(Bosdou et al., 2012) 
indicates that 121 
women/group are required 
to reliably detect a 
significant benefit of DHT 
pre-treatment as defined as 
a doubling of the pregnancy 
rates to 30%.  
 
 
 
 
 
5.12. SAFETY OF ANDROGEN USE IN WOMEN; THE SPECTRUM OF EXCESSIVE 
ANDROGEN ACTION IN WOMEN - A REVIEW OF LITERATURE: THERAPEUTIC TO 
TOXIC DOSES 
 
5.12.1. THERAPEUTIC USE OF ANDROGENS IN WOMEN:  
 
Any androgen at sufficient dose and duration may cause androgenic side-effects such as acne, hirsutism, 
male-pattern alopecia, voice change or alternations in mood and behaviour in women. Androgen effects 
on skin, vocal cords or psychological functions requires sustained, supra-physiological exposure. Short-
term and/or lower dose effects are reversible on cessation of androgen exposure.  
 
A reappraisal of the Endocrine Society guidelines on Androgen treatment in women recommends against 
making a diagnosis of androgen deficiency in women due to lack of a well-recognised syndrome and 
paucity of data to relate the androgen levels with specific signs and symptoms.(Margaret E. Wierman et 
al., 2014). 
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Low dose, short term testosterone therapy in women is well tolerated. Testosterone has been used in a large 
number of clinical trials in women as summarised in the ‘safety’ section of the use of DHT in IVF study protocol 
(supplementary table 3).  
 
Further literature review was undertaken to explore the effects of androgen excess on the female 
reproductive organs in other Non PCOS virilising conditions in women – Untreated congenital adrenal 
hyperplasia, virilising tumours and female to male transsexuals.   
 
5.12.2. NON PCO CAUSES OF HYPERANDROGENISM IN WOMEN 
 
Following is a summary of the effects of hyperandrogenism in large/toxic doses (either from a 
pathological condition or iatrogenic use) on the female reproductive organs, especially the ovaries from 
non-PCO causes which include female to male transsexuals, untreated CAH and virilising tumours. 
 
5.12.2.1.  EFFECT OF ANDROGENS ON THE FEMALE REPRODUCTIVE SYSTEM IN FtoM TRANSSEXUALS 
 
According to the International Classification of Diseases 11 (ICD 11), people whose gender at birth is 
contrary to the one they identify with will be diagnosed with gender dysphoria (APA –DSM5). There has 
been an increased interest lately in the area of prenatal androgen exposure and the development of 
gender dysphorias and the possibility of pre-existing hyperandrogenism/PCOS in this cohort of subjects 
exhibiting sexual dimorphic behaviour.  
However, post androgen treatment, the best model to study the effects of androgens in female 
reproductive organs is obtained from studies in these female to male transsexuals where the aim of the 
treatment is complete virilisation and the histology specimen being available after sex reassignment 
surgery. The effects of androgens on the histology female reproductive organs in FTM TSx treated with 
testosterone are summarised below. None of these studies were randomised and a few studies did not 
have a control group.  
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5.12.2.1.1.  Untreated FtoM transsexuals and the prevalence of PCOS 
 
The prevalence of PCOS amongst untreated female to male transsexuals is controversial. In general 
population the prevalence of PCO is about 5-10% in women of reproductive age ((Franks, 1995; 
Futterweit, 1999; Knochenhauer et al., 1998)). Some authors found increased prevalence of PCO in FTM 
TSx at initial presentation prior to any androgen therapy (Balen et al., 1993; Futterweit, Weiss, et al., 
1986) (Baba et al., 2007) (Baba et al., 2011), whereas Amirikia et al(Amirikia et al., 1986) and Mueller et 
al (Mueller, Gooren, et al., 2008) did not find any difference in the prevalence between the FtM 
transsexuals and the general population. It is of note that only the recent papers have used Rotterdam 
or NIH criteria or a combination of both for the diagnosis of PCOS.  
This is relevant in the context of examining this cohort of people to study the effects androgen treatment 
on the ovaries whilst there could be already an underlying increased prevalence of PCOS in these 
individuals (Table 9).  
Positive association: 
1. Futterweit et al reported that PCO may be present in about 25% of FtoM Tx in a study of 40 
subjects (combination of (1) hirsutism and/or oligomenorrhoea with borderline or increased 
testosterone and/or LH/FSH ratio >2 and/or (2) ultrasound evidence of increased ovarian volume 
with multiple follicle cysts)(Futterweit, Weiss, et al., 1986). 
2. Balen et al reported 15 of the 16 subjects had ultrasound evidence of polycystic ovaries (10 or 
more cysts, 2-8mm diameter, arranged around a dense stroma or increased amount of stroma 
throughout) and nearly 50% of the subjects had PCOS(Balen et al., 1993). 
3. Baba et found a 58% prevalence of PCO in 69 untreated FtoM subjects (Rotterdam Criteria)(Baba 
et al., 2007). 
4. Vujovic et al, reported a prevalence of 14.4% in 76 FtoM Tx Serbians Vs 6-8% in general 
population, although they did not clarify if these subjects were treated with testosterone or 
not(Vujovic et al., 2009). 
5.  Baba et al again reported a prevalence of PCO of about 32% (by using Rotterdam Criteria) in the 
untreated FtoM Tx group in a group of 128 subjects as opposed to a background prevalence of 
3-5% in the general Japanese population(Baba et al., 2011). 
 
Negative association: 
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1. Amirikia et al did not find any evidence of PCO prior to exogenous testosterone administration 
in their 10 FtM Transsexuals (Amirikia et al., 1986).  
2. Mueller et al did not find any significant difference between the untreated FtoM Tx and controls 
using both the Rotterdam and NIH criteria for PCOS. (61 FtM Tx and 94 contols) (Mueller, Gooren, 
et al., 2008). 
 
 
Table 9: Prevalence of PCO in untreated FTM Tx in population studies 
 
No Paper TSx N= Prevalence of 
PCOS 
POSITIVE ASSOCIATION 
1 Futterweit, Weiss, et al. (1986) 40 25% 
2 Balen et al. (1993) 16 50% 
3 Baba et al. (2007) 69 58% 
4 Vujovic et al. (2009) 76 14.4% 
5 Baba et al. (2011) 128 32% 
NEGATIVE ASSOCIATION 
6 Amirikia et al. (1986) 10 0 
7 Mueller, Gooren, et al. (2008) 61 No difference 
 
 
5.12.2.1.2. Testosterone dose and duration 
Testosterone was mostly administered as an Intramuscular Injection in supraphysiological doses. The 
following forms of testosterone were used: Testosterone enanthate 200mg – 400mg IM, Depo 
Testosterone 200-400mg IM, Methandriol PO/IM 30mg to 60mg, Sustanon 250mg IM, 120-160mg/d 
Andriol oral, DHT Gel 125mg/d, Depo Testoviron 100mg and Testoviron 100mg. 
The duration of testosterone use in these studies varied between one to eight years. 
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5.12.2.1.3.  Virilising effects: 
 
The known androgenic effects of Testosterone in women include acne, hirsutism, alopecia, voice 
deepening, breast atrophy and clitoromegaly.  
The most prominent effects of high dose Testosterone were on the skin and clitoris((L. J. Gooren et al., 
2008; Louis J. Gooren et al., 2008; Traish et al., 2010)). Potential for clitoral growth is highest in the 
younger women but limited in adults (Traish et al., 2010).  
In majority of the people voice deepening occurs after 6-12 weeks of androgen administration(L. J. 
Gooren et al., 2008). The pattern of hair growth is similar to that of pubertal boys – facial hair followed 
by pubic hair, and after prolonged therapy on chin, neck, legs, arms and chest(Giltay et al., 2000). 
Cessation of menstruation takes several months (Meyer et al., 1986). 
 
5.12.2.1.3.1.Effects on the ovary 
8 studies were reviewed to summarise the effects of testosterone on ovarian histology in testosterone 
treated FtoM transsexuals (101upplementary table 4a and 4b). The ovarian morphology is similar to that 
of PCO in FtoM transsexuals treated with androgens. The total ovarian volume was increased in FtoM 
Transsexuals in most of the studies. The cortex was thickened and collagenised. There was significant 
increase in the collagenisation of the tunica albugenia compared to the controls. The stroma was 
hyperplastic and contained clusters of luteinised cells. Some authors reported the presence of primordial 
follicles ((N. Miller et al., 1986; Pache et al., 1991; Spinder et al., 1989)) and Ikeda et al(Ikeda et al., 2013) 
reported that there was no difference between the TSx and control groups.  Healthy antral follicles by 
reported by Pache (62 Vs 57) and Ikeda reported no difference between the groups (Pache et al., 1991), 
(Ikeda et al., 2013). There was a significant increase in the cystic atretic and atretic follicles in most 
studies. Pache (Pache et al., 1991)and Chada (Chadha et al., 1994) reported hyperplastic theca interna 
and most papers reported presence of luteinised cells in the theca interna ((Chadha et al., 1994; 
Futterweit & Deligdisch, 1986; Pache et al., 1991; Spinder et al., 1989) . There was a significant increase 
in multicystic ovaries on histology. For further details are on supplementary tables 4a and 4b. 
Long term androgen therapy causes primordial follicle depletion and affects the developmental capacity 
of the follicles (Van Den Broecke et al., 2001)(Van den Broecke 2001). 
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5.12.2.1.3.2. Effects on the endometrium 
Testosterone acts on the endometrium directly through androgen receptors or indirectly through 
estradiol after aromatization (Simpson, 2002). Aromatase activity has not been found in normal 
endometrium but described in benign and malignant endometrial pathology (Watanabe et al., 1995). 
 5 studies are summarised below describing the effects of androgens on the endometrium obtained from 
hysterectomy specimens in FtM transsexuals undergoing sexual reassignment surgery (supplementary 
table 5). In general, the endometrium was thin, inactive and atrophic. None of the FtM had a secretory 
endometrium as opposed to 33% in controls (Chadha et al., 1994; Futterweit & Deligdisch, 1986). Miller 
et al (N. Miller et al., 1986) noted a striking 81% inactive endometrium and atrophic endometrium in 
19%. The inactive endometrium was similar to atrophic menopausal endometrium(Perrone et al., 2009). 
Expression of Ki-67, a marker of cell proliferation was evaluated by Perrone et al 2009, by 
immunohistochemistry and found that Ki-67 expression in the glands and stroma was significantly lower 
in FtM transsexuals than in premenopausal women and similar in FtM transsexuals and menopausal 
women. 
Endometrial polyps were present in 4-18.5% (Grynberg et al., 2010; Perrone et al., 2009). One patient 
with atypical hyperplasia had a small focus of adenocarcinoma (Grynberg et al., 2010) and one tubal 
metaplasia was reported by Chadha et al (Chadha et al., 1994). 
5.12.2.1.3.3. Effects on the uterus 
There were minimal or no changes noted in the myometrium in the 4 reviewed studies, only one study 
had a control group. Leiomyomata were quoted between 16-21%. Adenomyosis was reported in about 
4.5% (Grynberg et al., 2010). Summary reported on supplementary table 6. 
5.12.2.1.3.4. Effects on the cervix and vagina 
Only a couple of studies described changes in the cervix from androgen exposure and one study 
described effects on the vaginal epithelium in FtM Tx (supplementary table 7 and 8). The ectocevical 
mucosa was found to be atrophic in 75% (N. Miller et al., 1986), but the endocervix was not described 
in the same group of patients. However, Grynberg et al (Grynberg et al., 2010) noted simple hyperplasia 
of the endocervical mucosa in 21% of the FtM Tx and no changes in the exocervix. There was 1 FtM Tx 
with squamous CIN (N. Miller et al., 1986) and 1CIN1 (Grynberg et al., 2010). 
Vaginal epithelium was thin and Ki-67 expression was almost absent (supplementary table 8) as 
described by Baldassarre et al (Baldassarre et al., 2013). 
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5.12.2.1.3.5. Effects on the breast tissue 
Mastectomy specimen from sexual reassignment surgery provide unique opportunity to study the 
effects of testosterone on the breast tissue in FtM tanssexuals. The histological changes in these subjects 
was described in 5 studies (Supplementory Table 9).   
 The changes seen in breast tissue due to androgen exposure are similar to that in postmenopausal 
women consistent with mammary involution. These include marked reduction in glandular tissue, 
lobular atrophy and increase in fibrous connective tissue. Four studies (Futterweit et al., 1988; Grynberg 
et al., 2010; Sapino et al., 1990; Slagter et al., 2006) demonstrated a variable degree of epithelial 
involution, hyalinosis of the stroma especially the intralobular and extralobular stroma and lobular 
atrophy.  Slagter et al(Slagter et al., 2006) reported only small amounts of fat tissue comparable to that 
of post-menopausal women. On the contrary, Burgess et al (Burgess et al., 1993) reported that long term 
androgen therapy did not have any significant effects on the histology of the breast in their 29 FtM Tx 
and 10 controls. The only observed statistically significant difference in this study was the presence of 
micro calcification in the some of the Tx subjects, the cause of which was unclear. Otherwise, in most of 
the studies the more detailed encountered histological changes were atrophy and loss of epithelial 
lining, shrinkage of the acini and ducts, involution of lobulo- alveolar structure, lobular atrophy and a 
dense hyalinised fibrous stroma. Some of the effects of androgen exposure on the breast tissue and the 
variability seen in these effects are possibly due to a combination of the direct effects of testosterone 
and that of oestrogens formed by the peripheral aromatisation of the high dose exogenously 
administered testosterone. 
Grynberg et al (Grynberg et al., 2010) reported about 30% prevalence of fibrocystic disease, whilst 
Slagter et al(Slagter et al., 2006) reported none. Grynberg et al also found about 2% adenofibromata. 
The reported focal ductal epithelial hyperplasia and focal apocrine metaplasia were very low in 
comparison to the control group and the general population (Slagter et al., 2006). 
 
5.12.2.1.4.Gynaecological malignancies  
5.12.2.1.4.1. Ovarian Cancer 
There have been three reported cases of ovarian cancer in FtMTx (Dizon et al., 2006; Hage et al., 2000). 
One of them was papillary serous cystadenoma, the second was a multicystous serous papillary 
borderline ovarian tumour and the third one being cystic endometroid adenocarcinoma. Only the 
second case (Hage et al., 2000) had multiple cystic follicles resulting from high androgen exposure in the 
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non-involved ovary. The third reported case (Dizon et al., 2006) had AR staining of the histopathology 
sample which turned out to be positive, suggesting a possible endocrine mechanism to ovarian 
carcinogenesis. The previous notion that polycystic ovaries predispose to ovarian cancer is now no 
longer supported, however it is of note that with long term androgen treatment in FTM Tx, there is an 
upregulation of AR in the ovaries and the uterus (Chadha et al., 1994). The preclinical data also suggested 
a growth stimulating effect of testosterone and a possible effect in tumour progression(Gibson et al., 
2014). Therefore, it may be worthwhile to consider bilateral salpingo oophorectomy along with 
hysterectomy in sexual reassignment surgery. 
  
5.12.2.1.4.2. Other gynaecological malignancies: 
There has been one reported case of uterine cancer and one case of invasive cervical cancer (Urban et 
al.). Long term androgen therapy leads to amenorrhoea resulting in endometrial atrophy. The cervical 
mucosa also undergoes atrophic changes. Exogenously administered testosterone is aromatised to 
Oestradiol and the endometrium is exposed to unopposed action of Oestrogens, increasing the risk of 
endometrial carcinoma. With aromatisation to oestradiol, the plasma levels remain in a range to cause 
biological effects (Mueller & Gooren, 2008; Spinder et al., 1989). This action remains unopposed by 
progesterone.  
Androgen receptors have been demonstrated in cultured endometrial epithelium in in vitro studies 
(Tuckerman et al., 2000). The presence of aromatase activity in endometrial cancer and benign 
endometrial tissue support a possible role of androgens playing role in malignant transformation 
through aromatisation in the endometrial tissue (H W M Jongen et al., 2005). Therefore, it may be a 
consideration to add progesterone in FTM Tx with intact uterus. 
There has been one reported case of cervical carcinoma in situ (Driák et al., 2005) and one case of vaginal 
carcinoma, 18 years post sexual reassignment surgery (Schenck et al., 2010). Former gender specific 
diseases should be given consideration in this cohort of patients.  Schenck et al recommended routine 
preoperative HPV screening in sexual reassignment surgery (Schenck et al., 2010). 
5.12.2.1.4.3. Breast Cancer: 
Androgens cause marked reduction in the glandular tissue of the breast and increase the fibrous 
connective tissue. The effects on the breast tissue are possibly through partial aromatisation to 
Oestradiol in peripheral tissues and activation of androgen receptors (AR) in mammary tissue leading to 
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cellular growth and proliferation (Burcombe et al., 2003; Gooren et al., 2013; Nikolic et al., 2012).  Nipple 
areola complex preservation at subcutaneous mastectomy does come with the potential risk of 
malignancy in the remaining ductal tissue. The association of testosterone with breast cancer is 
debatable and the Endocrine Society guidelines on the use of androgen therapy in women stated that 
the clinical trials to date did not have the sufficient size or duration to ascertain whether observed 
associations were causal (M. E. Wierman et al., 2014). 
Fewer than 20 cases of breast cancer reported so far in FTM Tx. Apart from a handful of case reports, 
two large retrospective cohort studies and one systematic review has been published (Brown et al., 
2015; Gooren et al., 2013; Hartley et al., 2018; Stone et al., 2018).  
Burcombe et al reported a case of a ductal carcinoma in a  FTM Tx 10 years post bilateral subcutaneous 
mastectomy with nipple reimplantation (Burcombe et al., 2003). The tumour was an ER and PR. BRCA 
status was not reported. This patient was later continued on transdermal DHT therapy. Similarly, there 
was another reported case of invasive ductal carcinoma (ER and PR negative, HER2 positive), one year 
post bilateral nipple sparing mastectomy (Nikolic et al., 2012). Histopathology in this case was positive 
for androgen receptors in only 2% of the tumour cells. BRCA was not tested in this case. The continuation 
of androgen therapy was not reported. 
Two other reported cases by Shao et al were also invasive ductal carcinomas (Shao et al., 2011). Of them, 
the first case was ER and HER2 positive, PR and BRCA negative and post-surgery and chemotherapy he 
was restarted on low dose testosterone cream to maintain masculinity; the second case was ER and 
HER2 positive and BRCA negative and again after surgery and chemotherapy patient was resumed on 
low dose testosterone therapy. 
Barghouthi et al reported a case of a 28-year-old transgender male with invasive ductal carcinoma. ER 
and PR negative, HER2 positive. Genetic testing was negative for AR, BRCA1 and BRCA2, but had a variant 
of undetermined significance (VUS). This patient declined further testosterone and received neo 
adjuvant chemotherapy (Barghouthi et al., 2018) 
Gooren et al, in their large observational study to examine the incidence of breast cancer in Dutch 
transsexual population found one case of tubular adenocarcinoma (ER and PR positive) in 795 FTM Txs 
receiving testosterone, accounting to 15,974 total years of exposure(Gooren et al., 2013). Duration of 
testosterone was between 18 months to 13 years. The estimated incidence rate in these individuals was 
5.9 per 100,000 person-years (1 case in 17, 025 person-years of follow up) with 95% confidence interval 
of 0.5 to 27.4 per 100,000 years, lower than expected for female breast cancer but within expected 
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norms for male breast cancer. This study concluded that testosterone treatment does not increase the 
risk of breast cancer in these individuals.  
A systematic review by Stone et al reported 17 cases of breast cancer FtM patients, with a median age 
of 44.5 years at diagnosis. They reported 8 cases on invasive ductal carcinoma, 2 cases of tubular 
carcinomas and 7 unrecorded type.  14 patients had ER/PR status reported, 12 were ER positive, 9 were 
PR positive and all were BRCA negative. Only 1 patient had a positive family history (Stone et al., 2018)  
Some breast cancer which are ER and PR negative but AR positive suggest AR positivity as a possible risk 
factor (Shao et al., 2011). The relation of testosterone to HER2 over expression is unknown (Hartley et 
al., 2018; Shao et al., 2011). Currently there are no guidelines regarding continuation of testosterone in 
these transmen after breast cancer. Some case reports suggest recommencing testosterone at a smaller 
dose or as a topical preparation with or without aromatase inhibitors to prevent peripheral conversion 
of testosterone to oestradiol (Burcombe et al., 2003; Gooren et al., 2013; Hartley et al., 2018; Shao et 
al., 2011). DHT (as non aromatisable) or nandrolone may be options to consider in this scenario. 
 
5.12.2.2. CAH AND EFFECTS OF ANDROGEN EXCESS ON THE FEMALE OVARIES 
 
CAH is an autosomal recessive inherited disorder of adrenal steroidogenesis, usually resulting from 
deficiency of the enzyme 21 hydroxylase in the adrenal cortex. The loss of negative feedback of cortisol 
leads to increased pituitary ACTH secretion resulting in adrenocortical hyperplasia.  The enzyme 
deficiencies lead to accumulation of cortisol precursors above the level of the block and shunt them to 
alternate steroid pathways. The severity and phenotype are determined by the level of deficiency.  In 
the ‘classic CAH’, the deficiency is severe and leads to cortisol insufficiency, manifesting as ‘salt wasting’ 
or ‘simple virilising’ forms. Newborn babies with salt wasting CAH have unprovoked hypotensive crisis 
from aldosterone deficiency, whilst the excess androgens results in ambiguous genitalia or 
virilisation/male genital phenotype in a female foetus. The less severe ‘nonclassic CAH’ is characterised 
by normal cortisol levels and hyperandrogenism resulting in a PCO like phenotype characterised by acne, 
hirsutism, irregular menses and fertility issues. 
Association between CAH and Polycystic Ovaries was recognised by Broster in 1938 (Hague et al., 1990), 
who treated some of his patients with adrenogenital syndrome by unilateral adrenalectomy: at 
laparotomy he noted that a number of patients had cystic ovaries. 
Four observational studies have been summarised to compare ovarian size, presence of multiple cysts, 
follicle numbers on imaging and hormone profiles of CAH patients with that of controls (supplementary 
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tables 10a and 10b). Hague et al used relatives of women with known CAH as the control group (Hague 
et al., 1990). 2 studies did not have any controls (Fleischman et al., 2007; Stikkelbroeck et al., 2004). The 
enzyme deficiency in most of the patients was 21 hydroxylase, which is the commonest cause. Pall et al 
reported the observations only in nonclassic CAH patients, comparing them with normal controls and in 
PCO groups (Pall et al., 2010). Hague et al and Pall et al found significantly higher proportion of patients 
with multicystic ovaries than the background prevalence whilst Stikkelbroeck et al only found a 
prevalence of 15.4% and interestingly Fleischman et al found none. The mean ovarian volume and the 
mean number of follicles were higher in the NCCAH group than the normal controls but not as high in 
the PCO group as observed by Pall et al. 
The ovarian histology was only reported in one study, from one patient. They reported presence of 
multicystic ovaries, hyperthecosis and multiple follicular cyst (Lucis et al., 1966b). The endometrium and 
myometrium were normal. 
5.12.2.2.1.CAH and Ovarian cysts in neonates and children: 
There have been 4 cases of large ovarian cysts in neonates/children with CAH (Guran et al., 2012; Jin et 
al., 2011; Shankar et al., 2010; Topaloglu et al., 1997). All the four were 46XX karyotype and three were 
born with ambiguous genitalia (table 11). The presentation was anywhere between the time of birth to 
Day 8 in the neonates born with ambiguous genitalia. Two of the three with ambiguous genitalia had 21 
hydroxylase deficiency (Guran et al., 2012; Shankar et al., 2010) and one had 11 β hydroxylase deficiency 
(Topaloglu et al., 1997). Jin et al reported a 14 year old girl with Congenital Lipoid Adrenal Hyperplasia 
(CLAH) with StAR gene mutation presenting with a large 12x12x2cm ovarian cyst(Jin et al., 2011). 
The proposed mechanism for the ovarian cyst formation is the adrenal androgen excess disrupting the 
cyclicity of the gonadotrophin release or direct action on the ovary (Shankar et al., 2010). The 
nonclassical CAH as opposed to salt losing CAH is particularly more associated with ovarian cysts because 
of the long period of non-treatment (Shankar et al., 2010) before diagnosis. 
 
5.12.3. MATERNAL VIRILISING TUMOURS 
 
Maternal virilisation during pregnancy has been reported in literature in multiple case scenarios, 
luteomas being the most common cause. There are under 200 reported cases reported in English 
literature. Pregnancy luteomas are rare benign tumours of the ovary, mostly incidentally diagnosed on 
ultrasound or surgery and regress spontaneously after deliver. They were first described in 1963 by Dr. 
Sternberg. They can cause varying degree virilisation in the mother and or the foetus depending on the 
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level of hyperandrogenemia. Large tumours can cause mass effect, obstructive symptoms and may 
present as torsion. About one third of these luteomas are hormonally active, among them, 10~50% 
mothers have clinical signs of hyperandrogenism and 60~70% female infants exhibit some degree of 
virilization (J R Choi et al., 2000; Cronjé, 1984; Y. C. Wang et al., 2005b). Placental aromatase is protective 
preventing maternal androgens from reaching the foetal circulation. Luteomas form from the 
proliferation of luteinised cells under the influence of β-hCG during pregnancy and can produce of 
androgens resulting in maternal and foetal virilisation. 
 
Literature review of conditions causing hyperandrogenemia during pregnancy along with clinical signs 
and symptoms and hormones levels are where full text articles were available is summarised in tables 
12a, 12b and 12c. Changes in ovarian morphology, clinical signs and symptoms under the influence of 
hyperandrogenemia in pregnancy is a valuable model to study the effects of androgens in pregnant 
women albeit the proposed study drug DHT is administered only prior to conception. 
 
5.13. CONCLUSION 
 
The above literature review describes the range of androgenic effects in women from the use of a small 
therapeutic dose of testosterone as used in IVF/HSSD where the side effects are nil or minimal to the 
extreme masculinising effects seen in virilising tumours and in transsexuals. The striking similarity in all 
these scenarios is the multicystic ovarian morphology in hyperandrogenaemia either due to therapeutic 
use or pathological cause, which reinfornces the hypothesis of the role of AR in human ovarian 
folliculogenesis and hence scope for therapeutic use of androgens in women with poor ovarian 
response. 
 
Small dose, short term testosterone is safe in women. There is a positive role for androgens in women 
with poor ovarian response undergoing IVF. In these women, DHT effects would be unique as DHT is a 
non-aromatisable androgen, giving AR only mediated results. This remains to be explored clinically when 
the drug becomes available in Australia.   
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6. CONCLUSION 
 
Andrology clinical practice and research in the current day involves encounter of wide range of 
pathologies requiring a solid understanding of the molecular, genetic, hormonal and clinical aspects for 
efficient management and tailored patient care. This is true in a primary care setting, tertiary care or in 
a multidisciplinary team.  
The first chapter dealt with androgen abuse -reversibility and time course required for the recovery of 
reproductive functions. It is hard to perform a prospective study of this nature. The 3 groups of 
participants- current users, past users (last use >3 months) and non-user controls provided some robust 
hormonal data. This study showed that suppressed testicular function due to androgen abuse is mostly 
reversible (apart from persistent testicular volume reduction) with recovery taking between 9 to 18 
months or longer after ceasing androgen intake. Suppressed serum LH and FSH represent convenient, 
useful and underutilized markers of androgen abuse and recovery.  
Following on the theme of male fertility, the second chapter dealt with fertility preservation in men 
undergoing gonadotoxic treatment or at risk of gamete loss from surgery. This large study of 2717 men 
spanning over 4 decades in a single academic centre showed that sperm cryostorage was feasible for 
virtually all men, including sufficiently mature adolescents, who could collect semen to insure future 
paternity as well as making positive psychological preparation for the patient’s survival. Disposal of 
cryostored material when no longer required was efficient with regular follow-up. Sperm 
cryopreservation should be an integral part of comprehensive treatment plan in men receiving 
gonadotoxic treatment but remains underutilised, with under representation of regional and remote 
rural NSW. 
Leading on from fertility preservation and pre-freeze semen and sperm parameters in men undergoing 
gonadotoxic treatment, third chapter further described the fine molecular and genetic mechanisms of 
sexual differentiation and development based on case of 46XX DSD. In mammals, the early gonad is 
bipotent and can differentiate into either a testis or an ovary. SRY is the master switch in testis 
determination, responsible for differentiation of the bipotent gonad into testis. SRY activates SOX9 gene, 
SOX9 as a transcription factor is the second major gene involved in male sex determination. SOX9 drives 
the proliferation of Sertoli cells and activates AMH/MIS repressing the ovary. SOX9 is sufficient to induce 
testis formation and can substitute for SRY function. Assessing karyotype and then determination of the 
presence or absence of Mullerian structures are necessary serial investigations in any case of DSD, 
except for mixed gonadal dysgenesis identified by karyotype alone. Treatment is ideal in a 
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multidisciplinary setting with considerations to genetic (implications to family and reproductive 
recurrence risk), psychological aspects (sensitive individualized counselling including patient gender 
identity and preference), endocrinological (hormone replacement), surgical (cosmetic, prophylactic 
gonadectomy) fertility preservation and reproductive opportunities and metabolic health 
(cardiovascular and bones). 
Further focussing on laboratory investigations lading on from genetic tests, the fourth chapter described 
comparison of progesterone levels compared by immunoassay (IM) Vs LC-MS. Virtually all serum 
progesterone measurements in clinical and IVF practice use direct, non-extraction immunoassays often 
in multiplex, high throughput platform assays optimised for high, post-ovulatory, mid-luteal phase 
serum progesterone concentrations. This study showed that immunoassay over-estimated serum 
progesterone in almost every sample with an increasingly high variability and deviation at lower 
concentrations (IA <5nM, equivalent to LC-MS <2nM). IA consistently overestimated serum 
progesterone levels so that low measurements (IA<5 nM) were too inaccurate to be used quantitatively. 
The utility of higher serum progesterone measurements by IA and serum progesterone and other 
steroids measured by multiplex LC-MS profiling in predicting IVF pregnancy outcomes warrants further 
investigation. There is a need for caution in clinical diagnosis of premature luteinization based on 
increased late follicular phase serum progesterone measurements using direct progesterone 
immunoassay that consistently overestimates low serum progesterone concentrations. 
Carrying the link from IVF related investigation, the final chapter described a study design/protocol for 
use of DHT on women with poor ovarian response. Recent research has proven a physiological role of 
androgens acting via the androgen receptor (AR) in optimising female fertility. There have been various 
off-label treatments that increase androgen exposure aiming to enhance poor ovarian responses in IVF 
to increase serum testosterone in women. However, it is not clear if these are estrogen receptors(ER) 
mediated effects or ER and androgen receptor (AR) mediated. This study proposed to use DHT 
treatment, a pure, non-aromatisable androgen, which acts solely via the AR.  Literature review on safety 
of androgen use in women showed that short duration, low dose testosterone use in women prior to 
ovarian stimulation is safe. The study received ethics approval but could not commence due to 
unavailability of DHT in Australia. 
 
Finally, the above work shows the expansion of horizon in current Andrology clinical practice and 
research requiring a broad-based knowledge and understanding of the intricate genetics, laboratory 
investigations, clinical and community medicine. Future research will be based on through 
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understanding of these expanding new arenas as we prepare for latest challenges in patient centred, 
tailored care and preventive medicine.  
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8. APPENDIX (SUPPLEMENTARY TABLES) 
 
Supplementary Table 1: Clinical characteristics, histopathology of the gonad removed and hormonal profile, semen analysis and karyotype of phenotypic 
men with evidence of ovulation 
 
Paper  Parvin (1982) 
Perez-Palacios 
et al. (1981) 
Ceci et al. 
(2015) 
Kanaka-
Gantenbein et al. 
(2007) 
Gallegos et al. (1976)   
 
Our case Case 1 Case 2 Case 3 
Age at 
presentation 
32 yr 16 yr 22 yr 13 yr 15 yr 13 yr 11 yr 
 
18 yr 
Presenting 
symptom 
Pain in R testis 
Bl gynaeco 
mastia  
Pain in R 
testis 
L scrotal pain 
following injury 
Familial, siblings 
Pain and mass in L 
testis 
Duration 1 week NR 2 days NR NR 2 days 
Phenotype Male Male Male Male Male Male Male Male 
H/o crypt 
orchidism 
+ + - - - - - + 
Fertility + NA NR NR NA NA NA Azoospermic 
Relevant 
past history 
Testicular pain 
age 24yrs 
Thelarche at 14 
year 
L 
hypospadias, 
b/l 
mammoplast
y  
L inguinal hernia 
at 6 months of age 
Hypospadias, 
Bl 
gynaecomasti
a 
Hypospadias, 
Bl 
gynaecomastia 
Hypospadias 
 
  
Benign extra 
adrenal 
ganglioneuroma, lip 
capillary 
haemangioma, 
Henoch-Schonlein 
purpura 
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Paper  Parvin (1982) 
Perez-Palacios 
et al. (1981) 
Ceci et al. 
(2015) 
Kanaka-
Gantenbein et al. 
(2007) 
Gallegos et al. (1976)  
 
Our case Case 1 Case 2 Case 3 
Examination 
Small, hard, 
tender R testis 
over pubic 
tubercle,  
Normal Lf testis 
Bl 
gynaecomastia
, 
5.5cm penis, 
2.5 ml R testis 
and absent Lf 
testis 
Atrophic R 
testis and 
rubbery hard 
large left 
testis 
Acne, 
Gynaecomastia, 
pubic hair stage 5, 
normal penis, 
tender Lf scrotum, 
R testis 5-6ml 
Scrotal 
gonads 
Scrotal gonads 
Scrotal 
gonads 
Tanner stage 4 
puberty, small Bl 
gynaecomastia, L 
testis 8mls with a 
tender solid 2cm 
mass, large Lf 
hydrocele, R testis 
atrophic 1ml 
 
Primordial 
follicles 
+ + + + + + + + 
Corpus  
luteum 
- hemorrhagic +  hemorrhagic NR NR NR + 
Corpus 
albicans 
+ - + NR NR NR NR + 
Paper  
Parvin Parvin 
(1982) 
Perez-Palacios 
et al  Perez-
Palacios et al. 
(1981) 
Ceci et al Ceci 
et al. (2015) 
Kanaka-
Gantenbein 
et al Kanaka-
Gantenbein et al. 
(2007) 
Gallegos et al Gallegos et al. (1976) 
Our case 
Case 1 Case 2 Case 3 
Fallopian 
tube 
+ + + + - - - - 
uterus - 
+ Endometrial 
bleed 
+ + - - - - 
Ovotestis + + + - + + + + 
Testicular 
tissue 
- + 
Rudimentary 
epididymis 
+ in contralateral 
gonad 
+ + + + 
Leydig cells - + - -   + + 
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Paper  Parvin (1982) 
Perez-Palacios 
et al. (1981) 
Ceci et al. 
(2015) 
Kanaka-
Gantenbein et al. 
(2007) 
Gallegos et al. (1976)  
 
Our case 
Case 1 Case 2 Case 3 
Sertoli cells - + - + + +  + 
Semini 
ferous 
tubules 
- + - + + + + + 
Spermato 
genesis 
- Spermatogia - Spermatogia - - - - 
FSH (IU/L) 7.6 5.5 26.3 20*    13 
LH (IU/L) 7.4 11 9.8 8.2*    8 
T (nmol/L) 24.5 2.4 15.5 9.1*    4.5 
E2 (pmol/L) NR 180 135 36.7 *    - 
P4 (nmol/L) NR 1.2 NR NR    - 
Semen 
analysis 
15 x 106 
sperm/ml 
60% motile 
 
NA 
NR NR NA NA NA Azoospermia 
Karyotype 
Peripheral 
blood 
46,XX/ 46,XY 
Chimera 
(81%, 19%) 
46,XX/ 
47XXY 
(72%, 28%) 
46,XX/ 
46,XY 
Chimera 
(11%, 89%) 
46,XX/ 
47,XXY 
(70%, 30%) 
46,XX, no Y 
detected 
46,XX, no Y 
detected 
46,XX, no Y 
detected 
46, XX, SRY -ve 
Karyotype 
gonadal 
tissue 
_ 
46,XX/ 
47XXY 
_ 
46,XX/ 
47XXY 
46,XX/ 
47XXY 
46,XX/ 
47XXY 
46,XX/ 
47XXY 
46, XX, SRY -ve 
 
*  2 weeks post gonadectomy, R right, L left, Bl bilateral, NA not applicable, NR not reported, T testosterone, E2 estradiol, P4 progesterone 
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Supplementary Table 2: Summary of case reports with SOX9/upstream duplication 
 
No Paper N= Age at 
presentation 
Presenting 
complaint 
Histology Genetics Comments 
1 B. Huang 
et al. 
(1999) 
1 Infant Ambiguous 
genitalia 
Not performed SOX9 duplication - 
2 Kojima et 
al. (2008) 
 
5 Infant Ambiguous 
genitalia 
Bl Wolffian structures + 
Germinal aplasia, Sertoli 
and Leydig cells+ 
No ovarian 
tissue/uterus/tubes 
SOX9 upregulation and DAX1 
duplication 
Sporadic cases 
3 Cox (2011) 
  
3 Adult Infertile 
 
 
 
Leydig, Sertoli cells + 
Atrophies seminiferous 
tubules 
No spermatogenesis 
~178 kb duplication 600kb 
upstream of SOX9 
3 members (2 brothers and paternal 
uncle) from a family including a 46, XY 
father who carried the duplication 
4 Annalisa 
Vetro et al. 
(2011) 
2 Adult Infertile Germinal cell aplasia 96kb triplication 500kb 
upstream of SOX9 
 
Brothers 
5 Benko et al. 
(2011) 
 
 
4 Birth Ambiguous 
genitalia 
Case1: ovotestis and 
fallopian tubes 
Case 1: ~605-695 kb 
duplication 353kb upstream 
of SOX9 
All 3 were sporadic cases 
 
Case 2: L ovary, fallopian 
tubes, rudimentary vagina 
and uterus 
Case 2: ~148 kb duplication -
595 to -447kb upstream of 
SOX9 
Case 2: duplication paternally 
inherited. Duplication shared by two 
46,XY brothers and not the sister. 
Case 3: ovotestis, 
primordial follicles, 
seminiferous tubules, 
Sertoli cells,  
fallopian tube + 
Case 3 and 4: ~762-780kb 
duplication ~508kb upstream 
of SOX9 
Case 3 and 4: Brothers inherited 
duplication from 46,XY father and 
46,XY grandfather. 
 140 
 
No Paper N= Age at 
presentation 
Presenting 
complaint 
Histology Genetics Comments 
6 Xiao et al. 
(2013) 
1 Adult Infertile Not reported ~74kb duplication ~510-
584kb upstream of SOX9 
- 
7 G. M. Lee et 
al. (2014)
  
1 4 years Small testis duplication upstream of 
SOX9 
SOX9 duplication - 
 
 
 
1. 8 G.-J. Kim et 
al. (2015) 
3 Case1:  
25 years 
Azoospermia Not reported 143kb duplication ~516-
659kb upstream of SOX9 
- 
Case 2: 
At birth 
Ambiguous 
genitalia 
L ovary, fallopian tubes+, R 
ovotestis primitive 
seminiferous tubules 
Case 2: ~444kb duplication 
~259-703kb upstream of 
SOX9 
Paternally inherited 
Case 3: 
At birth 
Ambiguous 
genitalia 
R ovary, L dysgenic testis/ 
ovotestis 
Vagina, rudimentary 
uterus + 
Case 3: 480kb duplication 
264-744kb upstream of SOX9 
- 
1. 9 Hyon et al. 
(2015) 
 
3 Adult Infertile Case 1 and 2: atrophic 
seminiferous tubules  
containing only Sertoli cells 
suggestive of testicular 
dysgenesis, Leydig cell 
hyperplasia 
No spermatogenesis 
Case 1: 83kb duplication 
~694kb upstream of SOX9 
Case 1 and 2 were brothers 
Case 2: 83kb duplication 
~694kb upstream of SOX9 
Case 3: 140kb duplication 
~694kb upstream of SOX9 
10 A. Vetro et 
al. (2015) 
 
2 Case 1: Adult 
 
Infertile N/A Duplication upstream of 
SOX9 
- 
Case 2: Infant 
 
Ambiguous 
genitalia 
Ovotestis, numerous 
oocytes, pre-pubertal 
seminiferous tubules 
Duplication upstream of 
SOX9 
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No Paper N= Age at 
presentation 
Presenting 
complaint 
Histology Genetics Comments 
11 Our Case 1 Adult Mass in L testis Ovotestis, hemorrhagic 
corpus luteum and 
corpus albicans, 
primordial follicles, 
sertoli cell nodules, 
seminiferous tubules 
with no 
spermatogenesis 
Duplication upstream of 
SOX9 
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Supplementary Table 3. Summary of adverse events of Androgens in women in various studies using transdermal testosterone for therapeutic use grouped 
by duration of use for indications as described 
 
No Study I N= Designated 
daily dose 
Form Estimated 
daily 
delivery 
Duration  
Androgenic Adverse Events 
Site 
Reaction 
Acne Hirsutism Facial 
Depilation 
Voice 
Deepening 
Alopecia 
 
DURATION OF TREATMENT UPTO 4 WEEKS 
1 Fabregu
es et al. 
(2009) 
F C 31 
 
Nil Patch 1200 mcg 5 days - - - - - - 
T 31 
 
12.2mg 
2 K. K. 
Miller et 
al. (2005) 
E C 9 Placebo Patch Placebo 3 weeks NS - - - - - 
T 24 
 
4.2 / 8.4 mg 150 / 300 
mcg 
3 C. H. Kim 
et al. 
(2011) 
F C 55 
 
Nil Gel 1250 mcg 21 days 0 0 0 0 0 0 
T 55 
 
12.5 mg 
4 Massin et 
al. (2006) 
 
F C 25 
 
Placebo Gel 1000 mcg 15-20 
days 
0 0 0 0 0 0 
T 24 10 mg 
5 Chudako
v et al. 
(2007) 
A C 5 Placebo Gel Placebo 1 month - - - - - - 
T 5 50mg prn 5000 mcg 
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No Study I N= Designated 
daily dose 
Form Estimated 
daily 
delivery 
Duration  
Androgenic Adverse Events 
Site 
Reaction 
Acne Hirsutism Facial 
Depilation 
Voice 
Deepening 
Alopecia 
6 Barton et 
al. (2007) 
A C 75 
 
Placebo Cream Placebo 4 weeks NS NS NS NS NS 
 
 
 
NS 
T 75 
 
10.4 mg 1000 mcg 
 
DURATION OF TREATMENT 5 TO 12 WEEKS 
7 Fooladi 
et al. 
(2014) 
A C 16 
 
Placebo Patch Placebo 12 weeks 0 0 0 0 0 
 
- 
T 20 
 
3.94 mg 300mcg 
8  Shifren 
et al. 
(2000) 
A C 75 
 
Placebo 
 
Patch Placebo 12 weeks 0.01% NS NS NS - - 
T 75 4.1 mg 150 mcg 
 
0 NS NS NS - - 
75 8.2 mg 300 mcg 0 NS NS Slight 
increase 
- - 
9 K. Miller 
et al. 
(1998b) 
B C 17 Placebo 
 
Patch Placebo 12 weeks NS - NS NS - - 
T 18 4.1 mg 
 
150 mcg 
 
18 8.2 mg 
 
300 mcg 
10 Nathorst-
Boos et 
al. (2006) 
A C 30 
 
Placebo Gel Placebo 3 months - NS NS NS - - 
T 30 
 
10 mg 1000 mcg 
11 El-Hage 
et al. 
(2007) 
A C 18 
 
Placebo Cream Placebo 3 months - 0 NS - - - 
T 18 
 
10 mg 1000 mcg 
12 Goldstat 
et al. 
(2003) 
 
 
A C 
 
13 
 
Placebo Cream Placebo 12 weeks 0 0 NS NS 0 - 
T 18 10 mg 1000 mcg 
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No Study I N= Designated 
daily dose 
Form Estimated 
daily 
delivery 
Duration  
Androgenic Adverse Events 
Site 
Reaction 
Acne Hirsutism Facial 
Depilation 
Voice 
Deepening 
Alopecia 
 
DURATION OF TREATMENT 13 TO 24 WEEKS 
 
13 Nachtigal
l et al. 
(2011) 
 
A C 545 
 
Placebo 
 
 
Patch Placebo 6 Months, 
4yrs open 
label, 
Results at 
1yr 
21.6% 9.2% 17.3% - 4% 6.3% 
T 549 8.4 mg 300 mcg 
14 Panay et 
al. (2010) 
A C 
 
142 Placebo Patch Placebo 6 months 29.6% 1.4% 12% - 2.8% 6.3% 
T 
 
130 8.4 mg 300 mcg NS 4.6% 18.5% - NS NS 
15 Hofling et 
al. (2007) 
G C 49 
 
Placebo Patch Placebo 6 months - - - - - - 
T 50 
 
8.4 mg 300 mcg 
16 Kingsber
g et al. 
(2007) 
 
A C 68 
 
Placebo Patch Placebo 6 months - - - - - - 
T 64 8.4 mg 
 
300 mcg 
17 Davis et 
al. (2006) 
 
 
A C 39 
 
Placebo Patch Placebo 24 weeks NS NS NS NS NS NS 
 
T 37 4.1 mg 300 mcg 
18 Shifren 
et al. 
(2006) 
 
 
A C 273 Placebo Patch Placebo 
 
24 weeks NS NS NS NS NS NS 
T 276 8.4 mg 300 mcg 
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No Study I N= Designated 
daily dose 
Form Estimated 
daily 
delivery 
Duration  
Androgenic Adverse Events 
Site 
Reaction 
Acne Hirsutism Facial 
Depilation 
Voice 
Deepening 
Alopecia 
19 Herbst et 
al. 
(2006) 
 
 
 
B C 19 
 
Placebo Patch Placebo 
 
Site 
Reaction 
Acne Hirs
utis
m 
Facial 
Depilation 
Voice 
Deepening 
Alopecia --- 
T 19 
 
8.2 mg 300 µg 
20 Braunste
in et al. 
(2005) 
A C 119 
 
Placebo Patch Placebo 24 weeks 
 
31% 13% 2% - 
 
- 
 
- 
 
T 107 
 
4.1 mg 150 mcg NS NS NS 
110 
 
8.2 mg 300 mcg 
111 
 
12.3 mg 450 mcg 
21 Simon et 
al. (2005) 
 
 
 
 
A C 279 
 
Placebo Patch Placebo 
 
24 weeks NS NS NS NS NS NS 
T 283 8.4 mg 300 mcg 
22 Choi et 
al. (2005) 
 
 
 
B C 26 
 
Placebo 
 
 
Patch Placebo 
 
24 weeks 0 4% NS - - - 
T 26 
 
8.2 mg 300 mcg 
23 Buster et 
al. (2005) 
 
 
A C 266 
 
Placebo Patch Placebo 
 
24 weeks NS NS NS NS NS NS 
T 266 
 
8.4 mg 300 mcg 
24 Dolan et 
al. (2004) 
B C 28 
 
Placebo Patch Placebo 
 
6 months - - NS - - - 
T 29 
 
4.1 mg 150 mcg 
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No Study I N= Designated 
daily dose 
Form Estimated 
daily 
delivery 
Duration  
Androgenic Adverse Events 
Site 
Reaction 
Acne Hirsutism Facial 
Depilation 
Voice 
Deepening 
Alopecia 
25 S. Davis 
et al. 
(2008) 
D C 64 Placebo Spray Placebo 16 weeks NS 4.7% 0 
 
- NS 
 
- 
 
T 66 60 mcL 200mcg 
 
7.6% 4.5% 
 
64 90 mcL 300mcg 
 
9.4% 9.4% 
 
67 180 mcL 600mcg 
 
9% 11.9% 
 
DURATION OF TREATMENT 25 TO 52 WEEKS 
 
26 Gioia M. 
Guerrieri 
et al. 
(2014) 
 
 
C C 61 
 
Placebo Patch Placebo 12 months NS 
 
3.3% NS NS - - 
T 67 
 
4.1 mg 150mcg 7.5% 
27 Davis et 
al. (2009) 
G C 79 
 
Placebo Patch Placebo 52 weeks - - - - - - 
T 70 
 
4.2 mg 150 mcg 
 
28 S. R. 
Davis et 
al. (2008) 
A  277 Placebo 
 
Patch Placebo 52 weeks - 
 
 
5.1% 10.5% - 7.2% 7.9% 
267 4.2 mg 
 
150 mcg NS NS NS NS 
270 8.4 mg 
 
300 mcg 19.9% 
29 K. K. 
Miller et 
al. (2006)  
C C 27 
 
Placebo Patch Placebo 
 
12 months NS NS NS NS NS NS 
T 24 
 
8.4 mg 
 
300 mcg 33% 
30 Davison 
et al. 
(2011) 
G C 30 
 
Nil Spray - 
 
26 weeks - - - - - - 
T 9 
 
90 mcL 300 mcg 
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No Study I N= Designated 
daily dose 
Form Estimated 
daily 
delivery 
Duration  
Androgenic Adverse Events 
Site 
Reaction 
Acne Hirsutism Facial 
Depilation 
Voice 
Deepening 
Alopecia 
 
DURATION OF TREATMENT BEYOND 52 WEEKS 
 
31 Popat et 
al. (2014) 
C C 72 
 
Placebo 
 
Patch Placebo 
 
3 years - - - - - - 
T 73 
 
4.1 mg 150 mcg 
32 Dolan 
Looby et 
al. 
(2009b) 
B C 12 
 
Placebo Patch Placebo 
 
18 months NS NS NS NS NS NS 
T 13 
 
8.4 mcg 300 mcg 
 
I= Indication 
• (A) Hypoactive Sexual Desire Disorder to improve sexual function in menopausal women(Barton et al., 2007; Braunstein et al., 2005; Buster et al., 
2005; Chudakov et al., 2007; S. Davis et al., 2008; S. R. Davis et al., 2008; Davis et al., 2006; El-Hage et al., 2007; Fooladi et al., 2014; Kingsberg et 
al., 2007; Nachtigall et al., 2011; Nathorst-Boos et al., 2006; Panay et al., 2010; Shifren et al., 2000; Shifren et al., 2006; Simon et al., 2005) 
• (B) HIV infected women to evaluate effects on body composition and bone health(K. Miller et al., 1998b) (Choi et al., 2005; Dolan Looby et al., 2009b; 
Dolan et al., 2004; Herbst et al., 2006) 
• (C) Hypopituitarism, adrenal insufficiency or oophorectomy/ovarian insufficiency to determine cardiovascular risk, bone health and cognition(Gioia M. 
Guerrieri et al., 2014) (G. Huang et al., 2014; Popat et al., 2014) 
• (D) Premenopausal women with androgen deficiency(Goldstat et al., 2003) 
• (E) Anorexia nervosa to improve depression and cognition(K. K. Miller et al., 2005) 
• (F) IVF studies in women with poor ovarian response(Fabregues et al., 2009; C. H. Kim et al., 2011; Massin et al., 2006) 
• (G) Other studies – breast Ca risk(Davis et al., 2009; Hofling et al., 2007), Cognition(Davison et al., 2011) 
 
- = Not reported 
C= Control group 
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T= Testosterone group 
 
 
This literature review included only transdermal testosterone studies and excluded studies of testosterone by oral /sublingual administration (Barrett-Connor et 
al., 1999; Basaria et al., 2002; Chiuve et al., 2004; de Paula et al., 2007; Adrian S. Dobs et al., 2002; Flöter et al., 2005; Lenharo Penteado et al., 2008; Lobo 
et al., 2003; Moller et al., 2013; Penotti et al., 2001; Poels et al., 2013; Raisz et al., 1996; Warnock et al., 2005; Watts et al., 1995; Zang et al., 2006),  Intra 
muscular injection or subdermal implant (G. Huang et al., 2014)(Anders et al., 2005; Burger et al., 1987; Davis et al., 1995; Davis et al., 2000; Dow et al., 1983; 
"Management of persistent menopausal symptoms with oestradiol-testosterone implants: clinical, biochemical and hormonal results : Jean Hailes and Henry 
Burger - Melbourne, Australia," 1984; Barbara B. Sherwin et al., 1985; B. B. Sherwin et al., 1985) or where results were not available(White et al., 2012) 
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Supplementary Table 4a: Summary of testosterone preparations, doses, duration and ovarian histology in female to male transsexuals 
 
No Paper Dose of T Duration 
of T 
N= Primordial 
follicles/ 
x100 
power 
field 
Healthy 
Antral 
follicles 
Cystic atretic 
follicles 
Atretic 
follicles 
Theca interna   Multicystic 
ovaries on 
histology 
Tx C Tx 
% 
C % Tx  
no 
C  
no 
Tx 
no 
C 
no 
Hyper 
Plastic 
Luteinised Tx % 
 
C% 
Tx % C % 
1 N. Miller 
et al. 
(1986) 
T enanthate 200mg 
1/12ly – 400mg 
1/52ly IM, Depo T 
200-400mg 1/52ly 
IM, 
Methandriol 
PO/IM 30mg 
1/52ly to 60mg/d  
1-8 years 32 - + NR NR NR NR NR 
 
NR 
2 Futterwe
it and 
Deligdisc
h (1986) 
T enanthate IM 
400mg 3-4/52ly 
 19 12+ NR NR NR NR NR NR NR N
R 
N
R 
37 26 68 0 
3 Amirikia 
et al. 
(1986) 
T enanthate 200mg 
2/52ly – 
14month 
– 7 years 
10 6& 9.9 18 NR NR 2 1.8 2.6 4.3 - - NR NR 
4 Spinder 
et al. 
(1989) 
 17 ± 6 
months 
26 9# + NR NR NR NR NR N
R 
N
R 
69 
 
0 69 
 
11 
5 Pache et 
al. (1991) 
250mg sustanon 
IM 2/52ly, 120-
160mg/d andriol 
oral, DHT Gel 
125mg/d 
21 
months 
17 13^ + 62 57 9 ± 5 4 ± 2 17 
±  
11 
5 ± 
4 
+  + NR NR NR 
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TSx= transsexual 
C= control 
 NR= not reported 
+ = controls had pelvic surgery for non-endocrine reasons 
& = controls – 2 groups – 3 PCO and 3 normal 
# = Controls- Eugonadal FtoM TSx 
^ = Controls – women with regular menses undergoing oophorectomy for non-endocrine reasons 
*= Controls – 1 ovary from autopsy, 4 premenopausal and 7 postmenopausal women 
~ = Controls – women with gynaecological malignancies 
* = Control group – 30 menopausal women undergoing hysterectomy and 13 pre-menopausal women undergoing hysteroscopy for infertility 
No Paper Dose of T Duration 
of T 
N= Primordial 
follicles/ 
x100 
power 
field 
Healthy 
Antral 
follicles 
Cystic atretic 
follicles 
Atretic 
follicles 
Theca interna   Multicystic 
ovaries on 
histology 
Tx C Tx 
% 
C % Tx  
no 
C  
no 
Tx 
no 
C 
no 
Hyper 
Plastic 
Luteinised Tx % 
 
C% 
Tx% C% 
6 Chadha 
et al. 
(1994) 
250mg sustanon 
IM 2/52ly, 120-
160mg/d andriol 
oral, DHT Gel 
125mg/d 
21 
months 
13 12* NR NR ↑ NR ↑ NR + N
R 
+ NR NR NR 
7 Grynberg 
et al. 
(2010) 
- 43 ± 7 
months  
112 - NR NR NR ↑ NR NR N
R 
N
R 
NR NR 79.5% NR 
8 Ikeda et 
al. (2013) 
T enanthate IM 
2/52ly 
38 
months 
11 10~ No                                                                                           
difference 
No 
difference 
NR ↑ NR N
R 
N
R 
NR NR NR N
R 
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Supplementary Table 4b: Summary of testosterone effects on ovarian histology in testosterone treated female to male transsexuals 
 
 
 
 
 
 
No Paper Ovary volume in mls Cortex in 
mm 
Tunica albugenia in mm Stroma Corpora 
lutea 
Corpora 
albicantia 
Tx C Tx C Total Collagenis
ation % 
Hyperplastic 
 
Luteinised 
 cells 
Tx % C % 
 
Tx % 
 
C % 
Tx C Tx  C  
 
Tx % C % Tx % C % 
1 Miller 1986 NR NR NR NR NR NR NR NR NR NR NR NR + NR + NR 
2 Futterweit 1986 ↑ 5/19 - NR NR NR NR 68 NR 84 17 26 0 16 58 26 83 
3 Amirikia 1986 7.9 5.9 Nr NR 0.64  0.17  NR NR NR NR NR NR NR NR NR NR 
4 Spinder 1989 NR NR NR NR NR NR 96 33 81 0 27 22 15 33 100 100 
5 Pache 1991                                                                                              7.6 2.7 Thickened   
collagenised 
NR NR NR NR + NR + NR NR NR NR NR 
 
0.8 
 
0.2 
6 Chadha 1994 ↑ NR Thickened   
collagenised 
NR NR NR NR + NR + NR NR NR NR NR 
7 Grynberg 2010 ↑ 44% NR NR NR NR NR NR NR + NR NR NR NR NR NR NR 
R L 
11 10 
8 Ikeda 2013 NR NR NR NR 0.32  0.15  0.3  0.1  72 0 91 30 0 70 27 30 
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Supplementary Table 5: Endometrial histology in testosterone treated FtoM TSx 
No Paper Duration 
of T 
N= Thin 
 E 
Inactive  
E 
Proliferative  
E 
Secretory 
E 
Atrophic 
E 
E 
hyperplasia 
Non 
functional 
polyps 
Adeno 
Ca 
Additional 
Comments TSx C 
1 Miller 
1986 
1-8 years 32 36*  81%   19%     
2 Futterweit 
1986 
 19 12  Tx 37% Tx 63% 0      
C 17% C 50% 33.3% 
3 Amirikia  
1986 
14month 
– 7 years 
10 6  10% 80%  10%     
4 Chadha 
1994 
21 
months 
  12  +  0 15%    1 tubal 
metaplasia 
5 Perrone 
2009# 
33.6 ± 21 
months 
27 43* + +     18.5%  Ki 67 in 
glands and 
stroma ↓ 
6 Grynberg  
2010 
43 ± 7 
months  
112 -   48%  45% 7% 4% 1/112 1 patient 
with had a 
small focus 
of adenoCa 
*  Controls from routine surgery and autopsy material   E=Endometrium 
# Form of testosterone -Depo Testoviron 100mg every 7-10 days, testosterone preparations for other studies summarised in table (on ovarian histology) 
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Supplementary Table 6: Myometrial histology in testosterone treated FtoM TSx  
No Paper Myometrium Leiyomyoma Adenomyosis 
1 Miller 
1986 
Min change 16%  
2 Futterweit 
1986 
 21%  
3 Chadha 
1994 
No change   
4 Grynberg  
2010 
Min change 17% 4.5% 
  
 
 
 
Supplementary Table 7: Cervical histology in testosterone treated FtoM TSx 
No Paper Ectocervical 
mucosa 
Endocervical 
mucosa 
Cervical 
dysplasia 
Exocervix 
1 Miller 1986 atrophy 75%  Squamous 
CIN 
 
2 Grynberg  
2010 
 Hyperplasia in 
21% 
CIN1 1/112 No change 
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Supplementary Table 8: Vaginal histology in testosterone treated FtoM TSx   
No Paper Dose of T Duration N= Vaginal epithelium Ki 67 expression 
Tx C 
1 Baldassarre et al. 
(2013) 
Testoviron 100mg  
Every 7-10days 
At least 1 year 
before hysterectomy 
16 32* Thinner Almost absent 
*= controls- 2 groups- 16 premenopausal and 16 postmenopausal women 
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Supplementary Table 9: Breast histology on mastectomy specimens in FToM TSx  
 
 
No 
Paper  
T dose 
T 
duration 
N= Glandular 
tissue 
Fibrous 
connective 
tissue 
Lobular 
atrophy 
Fibro 
cystic 
lesion 
Adeno 
fibromas 
Atypical 
hyper 
plasia 
Ca in 
situ 
Intra ductal 
papilloma/ 
papillomatosis 
Additional 
information 
TSx C 
1 Sapino et 
al. (1990) 
 
 T 
propionate 
250mg IM 
2/52ly 
2-3 
years 
2  Reduced Increased       1 apocrine 
metaplasia 
2 Futterweit 
et al. 
(1988) 
T 
enanthate 
or T 
cypionate 
400mg IM 
3-4/52ly 
13.8 ± 
9.8 
months 
12 1* 
 
 
Reduced Increased 
 
Severe 
25% 
Moderate 
33% 
Mild 42% 
  None    
3 Burgess et 
al. (1993) 
Testoral 
90mg/d or 
sustanol 
250mg 
1/12ly 
Atleast 
18 
months 
29 10         presence of 
micro 
calcification 
4 Slagter et 
al. (2006) 
Sustanon 
250 2/52ly 
18-24 
months 
23 10 Reduced Increased Increased None     2 focal ductal 
epithelial 
hyperplasia 3 
focal 
apocrine 
metaplasia 
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No 
Paper  
T dose 
T 
duration 
N= Glandular 
tissue 
Fibrous 
connective 
tissue 
Lobular 
atrophy 
Fibro 
cystic 
lesion 
Adeno 
fibromas 
Atypical 
hyper 
plasia 
Ca in 
situ 
Intra ductal 
papilloma/ 
papillomatosis 
Additional 
5 Grynberg 
et al. 
(2010) 
- 43 ± 7 
months  
112 - Reduced 
93% 
Proliferation 
93% 
Severe 
7% 
Mild 86% 
Stromal 
changes 
7% 
30% 2% None None None  
*= control, mastectomy specimen form remaining normal breast tissue of a 35 yr lady with breast Ca  
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Supplementary Table 10a: Observational studies in women with CAH reporting on ovarian morphology 
 
No Paper Type of study N= Enzyme 
deficiency, 
n= 
Type of CAH Multicystic Ovaries Ovarian Volume 
(mean cc) 
No of Follicles 
(Mean) 
CAH C* PCOS 21 
OHD 
11 
OHD 
SWb SVc NCCAHd CAH C PCOS CAH C PCOS CAH C PCOS 
1 Hague et al. 
(1990) 
Observational 36 31a  34 2 47% 20% 32% 83% 67%  No difference    
2 Stikkelbroeck 
et al. (2004) 
Observational 13 -  11  77%  23% 15.4%    64%    
3 Fleischman 
et al. (2007) 
Cross 
sectional 
10 -       0   Normal Normal 
4 Pall et al. 
(2010) 
Prospective  
Observational 
23 27 106 23 -   100% 24% 4% 79.5% 6.1 ± 
4.5 
5.2 ± 
2.3 
10.2 ± 
4.4 
8.1 ± 
3.5 
6 ± 
2.8 
11.7 ± 
2.8 
a = relatives of CAH pts ,  b= Salt wasting,  c = Simple Virilising, d = Non classic CAH 
*= Controls 
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Supplementary Table 10b: Observational studies in women with CAH reporting on 17 OHP and androgen levels 
 
 
No Paper 17 OHP 
Mean nmo/l 
A4 
Mean nmo/l 
T  
Mean  
1 Hague 
1990 
79.9 ± 43 7.8 ± 2.9 3.2 ± 1 nmol/l 
2 Stikkelbroeck 
2004 
- - - 
3 Fleischman 
2007 
25.88   3.3 7.7 pmol/l 
4 Pall 2010 14.9 ± 24 
ng/ml  
4.71 ± 2.54 
ng/ml 
3.53 ± 2.12 pg/ml 
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Supplementary Table 11: Paediatric Case reports with ovarian cysts in CAH patients 
 
No Paper Enzyme  
deficiency 
Ambiguous 
genitalia 
Age at presentation 
with abdo symptoms 
Ovarian Cyst 
 U/l  or B/l 
Cyst size Histology 
1 Topaloglu et 
al. (1997) 
11 βOHD + At birth B/l RO 6x6x5.5cm 
LO 
0.4x0.4x0.4cm 
Benign H’agic follicular cyst with multiple foci 
of calicification in the cyst wall 
2 Shankar et 
al. (2010) 
21 OHD + Day 8 B/l 7x5cm RO – 2 cysts, 1 with  H’agic fluid and clots 
LO- solitary cyst, clear fluid 
3 Jin et al. 
(2011) 
StAR gene 
mutation- 
CLAH* 
- 14 years  12x12x2cm Multiple H’agic corpora lutea 
4 Guran et al. 
(2012) 
21 OHD + At birth U/l 10x8x7cm LO – follicular cyst 
* = CLAH – congenital lipoid adrenal hyperplasia, U/L unilateral, B/L bilateral, RO right ovary, LO left ovary  
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Supplementary Table 12a: Summary of case reports of maternal virilising tumours with tumour type, history and diagnosis  
 
No Paper Tumour type B/ 
M* 
U/l 
Or B/l# 
Primary Age Parity Symptom 
duration 
 
Gestational 
age at 
presentation 
Diagnosis 
 
1 Deknuydt et al. (2018) 
Case 1 
Luteoma B U/l NA 36 4 Every 
pregnanc
y 
NR Intra operative 
2 Deknuydt et al. (2018) 
Case 2 
 Luteoma B U/l NA 37 2  Both 
pregnanci
es 
NR NR 
3 Rathore et al. (2017) Luteoma B U/l NA 28 3 8 weeks - Imaging 
4 Brar et al. (2017) Luteoma B U/l NA 30 NR 8 weeks NA Imaging 
5 Verma et al. (2016) Luteoma B U/l NA 33 Primi - Term Intra operative 
6 Rapisarda et al. (2016) Luteoma B U/l NA 25 Primi 5 weeks 28 Imaging 
7 Y. Wang et al. (2015) Luteoma B U/l NA 26 0 1 day 15 weeks Imaging 
8 Wadzinski et al. (2014) Luteoma B B/l NA 40 1 NR 16 weeks Retrospective 
9 Oz et al. (2014) Steroid cell 
tumour NOS 
M U/l  24 Primi 39 wks 39 wks - 
10 Dasari et al. (2013) Luteoma B B/l  26 Primi 2 wks 8 wks - 
11 Papantoniou et al. (2012) Kruckenberg M B/l Gastric Ca   2 weeks 30 wks Intra operative 
12 Amoah et al. (2011) Hyper reaction 
luteinalis 
B B/l  23 Primi 24 wks 10 wks  - 
13 Masarie et al. (2010) Luteoma B U/l  28 Primi 33 wks 33 wks Imaging 
14 Kanova et al. (2011) Luteoma B U/l  31 NR 36 wks NR - 
15 Bolat et al. (2011) Mucinous 
Cystadenoma 
B U/l  34 G2P1 36 20 - 
16 Graham et al. (2010) Benign 
Brenner 
tumour 
B U/l  37 NR 18 24 - 
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No Paper Tumour type B/ 
M* 
U/l 
Or B/l# 
Primary Age Parity Symptom 
duration 
 
Gestational 
age at 
presentation 
Diagnosis 
 
17 Chen 2009 Recurrent 
Luteoma 
B B/l  31 G3P2A1 N/A Conception – 
Artificial 
insemination 
- 
18 Ugaki et al. (2009) Luteoma B U/l  33 Primi NR 35 wks Intra operative 
19 Ozdegirmenci 
2007 
Kruckenberg M B/l Gastric Ca 22 Primi 8 wks 28 wks - 
20 Pather et al. (2007) Borderline 
Mucinous 
Cystadenoma 
 U/l  28 Primi 28 wks 12 wks Imaging 
21 Dahl et al. (2008) Luteoma B B/l  32 G2P0 NR 32 wks - 
22 Y. C. Wang et al. (2005a) Luteoma B B/l  28 Primi 2 wks 35 wks - 
23 Vulink et al. (2004) Benign ovarian 
steroid cell 
tumour NOS 
B U/l  37 Primi 20 wks 12 wks - 
24 Powell et al. (2002) Metastatic 
endocervical 
adenoca 
M U/l  34 G4P3 NR 34 wks - 
25 Mazza et al. (2002) Luteoma B B/l  34 Primi 12 wks 5 wks - 
26 Arima et al. (2000) Yolk sac 
tumour 
M U/l  22 NR NR 28 wks - 
27 Warmann 2000 Luteoma B NR  28 NR 20 wks NR - 
28 J. R. Choi et al. (2000) Luteoma B B/L  33 G2P1 NR 28 wks - 
29 Rodriguez 1998 Luteoma B U/l  20 G2P2 NR 2 wks post 
partum 
- 
30 Manganiello et al. (1995) Luteoma B B/l  26 Primi 24 wks 6 wks - 
 162 
 
No Paper Tumour type B/ 
M* 
U/l 
Or B/l# 
Primary Age Parity Symptom 
duration 
 
Gestational 
age at 
presentation 
Diagnosis 
 
31 Illingworth 1992 Luteoma B B/l  18 NR 16 wks 8 wks - 
32 Fung et al. (1991) Kruckenberg M B/l Unknown 36 G5P4 6 wks 23 wks - 
33 Ismail et al. (1990) Sclerosing 
stromal 
tumour 
?B B/l  29 Primi 7 wks 10 wks - 
34 Okadome 1989 Hyperreactio 
luteinalis 
B U/L  29 Primi 24 wks 24 wks Imaging 
35 Kirk et al. (1990) Adrenocortical 
tumour 
B U/l  42 G5P2  
A3 
 15 yrs N/A Retrospective - child 15 
yrs 
36  Silva et al. (1988) Kruckenberg M U/l Gastric 30  G3P2 NR 26 wks  - 
37 van de Kamp et al. (1984) Adrenal 
tumour 
B   34 G2P2 17 yrs N/A Retrospective - child 14 
months 
38 Fuller et al. (1983) Adrenal 
adenoma 
B   33 G4P2A2 7 yrs Post partum Retrospective – child 
with ambiguous 
genitalia 
39 Cohen et al. (1982) Luteoma B   27 Primi 16 wks 36 wks Retrospective – child 
with ambiguous 
genitalia 
40 (Forest et al., 1978) Kruckenberg M B/l Gastric 30  24 wks NR - 
41 Bell (1977) Kruckenberg M U/l NR 38 G7P5A1 6 wks 31 wks Retrospective – child 
with ambiguous 
genitalia 
42 Polansky et al. (1975) Luteoma B B/l  23  11 wks 40 wks  
43 Haymond et al. (1973) Ovarian 
stromal cell 
tumour 
B U/l  24 Primi 20 wks NR - 
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No Paper Tumour type B/ 
M* 
U/l 
Or B/l# 
Primary Age Parity Symptom 
duration 
 
Gestational 
age at 
presentation 
Diagnosis 
 
44 Verhoeven et al. (1973) Mucinous 
Cystadenoma 
B U/l  30 G1P0 12 wks 36 wks - 
45 Murset et al. (1970) Adrenal 
adenoma 
B U/l  36 P1 19 yrs N/A Retrospective – child 7 
yrs with cryptorchidism 
46  Shuster et al. (1968) Luteoma B B/L  25 G2P0 2 yrs 20 wks - 
47 Connor et al. (1968) Kruckenberg M NR Gastric 38 NR 12 wks NR - 
48 O'Malley et al. (1967) Luteoma B U/l  21  8 wks 36 wks - 
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Supplementary Table 12b: Summary of case reports of maternal virilising tumours with signs and symptoms 
 
No Paper SIGNS AND SYMPTOMS 
Hirsutism Acne Voice 
deepening 
Alopecia Breast  
Atrophy 
Clitoro 
megaly 
Lactation  
Failure/ 
delay 
 ♀ foetus 
virilised 
Menstrual 
cycle 
Obstructive 
Uropathy 
Acute 
abd 
1 Deknuydt 
2018 Case 1 
+ - + - - + NR - - - - 
2 Deknuydt 
2018 Case 2 
+ - - - - + NR - - - - 
3 Rathore 2017 - - - - - - NR - Amenorrhoe
a 
- + 
4 Brar 2017 - - - - - - NR - Amenorrhoe
a 
- - 
5 Verma 2016 - - - - - - NR - NA - - 
6 Rapisarda 
2016 
+ + + - - + NR - NA + - 
7 Wang 2015 - - - - - - - - NA + + 
8 Wadzinski 
2014 
+ + + - - + NR + NA - - 
9 Murat Oz 
2014 
+ +    +  Male Irr  - 
10 S.Dasari 2013 + NR NR NR NR NR NA +   + 
11 Papantoniou 
2011 
+ - - - - + NR - NR  - 
12 Amoah 2011 +  + NR NR      + 
13 Masarie 2010 + NR NR NR NR NR     - 
14 Kanova 2011 + + +    + Male    
15 Bolat 2010 + - - NR NR - NR male NR - + 
  
 165 
 
No Paper SIGNS AND SYMPTOMS 
Hirsutism Acne Voice 
deepening 
Alopecia Breast  
Atrophy 
Clitoro 
megaly 
Lactation  
Failure/ 
delay 
 ♀ foetus 
virilised 
Menstrual 
cycle 
Obstructive 
Uropathy 
Acute 
abd 
16 Graham  
2010 
+ + + NR + NR NR Male NR - - 
17 Chen  2009 NR NR + NR NR NR NR Gender 
pre 
selection 
male 
NR - - 
18 Ugaki  2009 + NR + + NR NR NR + NR NR NR 
19 Ozdegirmenci 
2007 
+ + + NR NR + NR + NR NR - 
20 Pather 2006 + + NR NR NR NR - Male NR - - 
21 Dahl 2008 + NR + + NR + + Male - - - 
22 Kao 2005 
Wang 2005 
+ NR + NR NR NR NR + NR NR NR 
23 Vulink 2003 + NR + NR NR        + NR Male Regular NR NR 
24 Powell 2002 + + + NR NR NR NR Male NR NR NR 
25 Mazza 2002 + NR + NR NR + NR + Regular NR NR 
26 Arima 2000 NR NR + NR NR + NR - NR NR NR 
27 Warmann 
2000 
NR NR + NR NR NR NR + NR NR NR 
28 C hoi  
2000 
+ NR NR NR NR NR NR - NR NR NR 
28 Rodriguez 
1998 
- + - - NR NR NR Male NR NR NR 
30 Manganiello 
1995 
+ + + - NR NR NR - Regular NR NR 
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No 
 
Paper SIGNS AND SYMPTOMS 
Hirsutism Acne Voice 
deepening 
Alopecia Breast  
Atrophy 
Clitoro 
megaly 
Lactation  
Failure/ 
delay 
 ♀ foetus 
virilised 
Menstrual 
cycle 
Obstructive 
Uropathy 
Acute 
abd 
31 Illingworth 
1992 
+ NR + + NR + NR - NR NR NR 
32 Fung 1990 + + + + + + N/A - Regular NR NR 
33 Ismail 1989 + + + NR NR NR         - Male NR - - 
34 Okadome 
1989 
+ + + NR NR + NR - Iregular NR + 
35 Kirk 1989 + NR NR NR NR + NR + Regular NR NR 
36 Silva 1988 + + NR NR NR NR NR + NR NR NR 
37 Kamp 1984 + NR + NR NR NR NR + regular NR NR 
38 Fuller 1982 +  + NR NR + NR + Regular NR NR 
39 Cohen 1982 + + + + NR + NR + Irregular NR NR 
40 Forest 1977 + + + NR NR + + + Regular NR NR 
41 Bell 1977 + + NR NR NR NR NR + NR NR NR 
42 Polansky 1974 +     + - Male Irregular NR NR 
43 Haymond 
1973 
+ NR + NR + NR NR + NR NR NR 
44 Verhoeven 
1973 
+ + + NR NR + N/A Male Regular NR + 
45 Zachmann 
1970 
+ + + + + + + + Regular NR NR 
46  Shuster 1968 + NR NR NR NR + NR Male Irregular NR NR 
47 Connor 1968 + + NR NR NR NR NR + Regular NR NR 
48 O’Malley 1966 + NR + NR NR + NR + NR NR NR 
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Supplementary table 12c: Summary of case reports of maternal virilising tumours with steroid hormone levels and pregnancy outcomes 
No 
 
Paper Hormone levels  Pregnancy outcome 
T DHT DHEA DHEAS A4 P4 Cortisol 17  
OH P 
ACTH β HCG SHBG 
1 Deknuydt 
2018 
Case 1 
19 ng/ml          27.7 
nmol/L 
- 
2 Deknuydt 
2018 
Case 2 
10.8 
ng/ml 
         315 
nmol/l 
- 
3 Rathore 
2017 
NR NR NR NR NR NR NR NR NR 6364 
IU/l 
NR NA 
4 Brar 
2017 
NR NR NR NR NR NR NR NR NR 990 IU/l NR NA 
5 Verma 2016 NR NR NR NR NR NR NR NR NR  NR uneventful 
6 Rapisarda 
2016 
6270 
ng/dl 
NR NR 646 
ug/dl 
200 
ng/dl 
NR NR NR NR NR 690 
nmol/l 
 
7 Wang 2015 52 
nmol/L 
NR NR NR NR NR NR NR NR NR NR C section at 37 weeks 
8 Wadzinski 
2014 
1981 
ng/dl 
NR 38 ug/dl NR NR NR NR NR NR NR NR C section at 33 weeks 
9 Murat Oz 
2014 
112  
nmol/L 
NR NR 17.6 
μmol/L 
412 
nmol/L 
NR NR NR  
NR 
NR NR Healthy boy LCSC at 
39 wks 
10 S.Dasari   
2013 
51.46 
nmol/L 
NR NR NR NR NR NR NR NR 73857 
IU/L 
NR Miscarriage at 17wks 
2 to cervical 
incompetence 
11 Papantoniou 
2011 
>17 
nmol/L 
NR NR >27 
μmol/L 
>34 
nmol/L 
NR 1129.6 
nmol/L 
63.6 
nmol/l 
19 
ng/ml 
NR NR PROM 34wks 
Female baby 
12 Amoah 
2011 
31.9 
nmol/L 
NR 3 nmol/L NR 35 
nmol/L 
NR NR NR N 184129 
IU/L 
(12/40) 
>180 
nmol/L 
Healthy girl at 38 wks 
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No 
 
Paper Hormone levels  Pregnancy outcome 
T DHT DHEA DHEAS A4 P4 Cortisol 17  
OH P 
ACTH β HCG SHBG 
13 Masarie  
2010 
 
867 
ng/dL 
NR NR NR NR NR NR NR NR NR NR Healthy girl at 37 wks  
14 Kanova 
2011 
26 
nmol/L 
NR NR 3.5 
μmol/L 
8.26 
nmol/L 
NR 823 
nmol/L 
NR NR NR 306 
nmol/L 
Spontaneous vaginal 
delivery boy 
15 Bolat 
2010 
NR NR NR NR NR NR NR NR NR NR NR LSCS IUGR boy 
16 Graham  
2010 
130 
nmol/L 
NR NR 20.3 
μmol/L 
>35 
nmol/L 
NR 784 
nmol/l 
890 
nmol/L 
normal NR NR LSCS 33wks healthy 
boy 
17 Chen  
2009 
12400 
ng/dL 
NR NR NR NR NR NR NR NR NR NR LCCS at 35 wks, 
healthy baby boy 
Previous 2 virilised 
female babies 
18 Ugaki  
2009 
6.11 
ng/L 
NR NR NR NR NR NR NR NR NR NR LSCS at 35 wks girl 
19 Ozdegirmenci 
2007 
15 ng/ml NR NR NR 99 
ng/mL 
NR NR NR NR NR NR PROM 32 wks girl 
20 Pather 
2006 
54 
nmol/L 
NR NR 11.2 
nmol/L 
121 
nmol/L 
NR NR NR NR NR NR LSCs at 33 wks healthy 
boy 
21 Dahl 
2008 
2696 
ng/dL 
NR NR 95 
μg/dL 
NR NR NR NR NR NR NR LSCS at 38 wk healthy 
boy 
22 Kao 2005 
Wang 2005 
11539 
ng/dL 
NR NR NR NR NR NR NR NR NR NR Vaginal delivery 
36wks healthy girl 
23 Vulink 2003 105 
nmol/L 
NR NR 21.8 
μmol/L 
496 
nmol/L 
NR NR NR NR NR >180 
nmol/L 
Still birth at 23 wks 
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No 
 
Paper Hormone levels Pregnancy outcome 
T DHT DHEA DHEAS A4 P4 Cortisol 17  
OH P 
ACTH β HCG SHBG 
24 Powell 2002 5830 
mg/dL 
NR 43.2 ng/ 
mL 
NR NR NR NR NR NR NR NR LSCS healthy boy 
25 Mazza 2002 2000 
ng/dL 
NR NR NR 6500 
ng/dl 
NR NR NR NR NR NR LSCS 39wks  
26 Arima 2000 3570 
ng/dL 
NR NR NR NR NR NR NR NR NR NR LSCS at 32 wks 
27 Warmann 
2000 
Elevated NR NR NR NR NR NR NR NR NR NR Full term girl with CAH 
28 C hoi 2000 54 ng/dl  NR NR NR NR NR NR NR NR NR NR Vaginal delivery at 29 
wks 
29 Rodriguez 
1998 
NR NR NR NR NR NR NR NR NR NR NR   
30 Manganiello 
1995 
927 
ng/ml 
NR NR 1 
μg/ml 
NR NR NR NR NR NR NR Vaginal delivery at 39 
wks 
31 Illingworth 
1992 
25.7 
nmol/L 
NR NR NR NR NR NR NR NR NR NR LSCS at 31 wks 
32 Fung 1990 40 mol/L NR NR 8.6 
mol/L 
>26 
mol/L 
NR 961 
mol/L 
NR NR NR NR Still birth at 23 wks 
33 Ismail 1989 92.4 
nmol/l 
NR NR NR NR NR NR NR NR NR NR Vaginal birth at 27 wks  
34 Okadome 
1989 
4730 
ng/dl 
3.43 
ng/
ml 
NR 2110 
ng/ml 
34.1 
ng/ml 
21.7 
pg/m
l 
NR - NR - - Vaginal delivery at 39 
wks healthy girl 
35 Kirk 1989 4.5 
nmol/L 
NR NR 2.7 
nmol/L 
11 
nmol/L 
8.7 
nmol
/L 
NR NR NR NR NR NR 
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No 
 
Paper Hormone levels  Pregnancy outcome 
T DHT DHEA DHEAS A4 P4 Cortisol 17  
OH P 
ACTH β HCG SHBG 
36 Silva 1988 5400 
ng/dl 
544 
ng/d
l 
18.6 
ng/ml 
3.7 
μg/ml 
265 
ng/ml 
NR NR NR NR 8470 
mIU/ml 
 LSCS at 28 wks, baby 
died at 3 days 
37 Kamp 1984 5.8 
nmol/L 
1.2 
nmol
/l 
NR 27.5 
μmol/l 
6.8 
nmol/L 
NR NR 1.3 
nmol/l 
NR NR 44.5 
nmol/L 
NR 
38 Fuller 1982 6.6 
nmol/l 
 
NR NR 36 
μmol/l 
14 
nmol/l 
NR NR NR <35 
ng/l 
NR NR Term delivery girl 
39 Cohen 1982 2000 
ng/dl 
NR NR NR NR NR NR NR NR NR NR LSCS term, girl 
40 Forest 1977 4181 
ng/dl 
NR NR NR 8876 
ng/dl 
1075 
ng/dl 
NR 9736 
ng/dl 
NR NR NR Vaginal delivery at 
term, girl 
41 Bell 1977 NR NR NR NR NR NR NR NR NR NR NR Vaginal delivery at 31 
wks. girl 
42 Polansky 1974 30.67 
ng/ml 
NR NR NR NR NR NR NR NR NR NR LSCS at 40 wks, 
healthy boy 
43 Haymond 
1973 
NR NR NR NR NR NR NR NR NR NR NR Vaginal delivery at 36 
wks 
44  Verhoeven 
1973 
24 ng/dl NR NR NR NR NR NR NR NR NR NR Laparotomy at term, 
healthy boy 
45 Zachmann 
1970 
NR NR NR NR NR NR NR NR NR NR NR  
46 Shuster 1968 NR NR NR NR NR NR NR NR NR NR NR  
47 Connor 1968 NR NR NR NR NR NR NR NR NR NR NR  
48 O’Malley 
1966 
NR NR NR NR NR NR NR NR NR NR NR  
* Benign/Malignant    # Unilateral/Bilateral     NA not applicable       NR not reported 
